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ABSTRACT  
Congenital myopathy and muscular dystrophy are two groups of inherited muscle diseases 
characterised by muscle weakness, and sub-classified by hallmark pathological features within 
a skeletal muscle biopsy. In order to understand the pathogenesis of inherited muscle disorders, 
and develop or apply therapies based on mechanistic insight, one must elucidate deep 
knowledge of the associated gene, genetic variant and the function of the encoded protein.  
This thesis focuses on three aspects of gene discovery in the inherited myopathies: (1) 
Identification of a novel variant and phenotype for a known disease gene; (2) understanding 
the functional role of a recently identified disease gene in skeletal muscle biology and disease; 
and (3) discovering a novel disease gene for congenital myopathy.  
We identified the first recessive variant within ACTA1 (encoding α-skeletal actin) as the genetic 
cause of congenital muscular dystrophy with rigid spine. This case uniquely describes recessive 
ACTA1 variants where α-skeletal actin protein is expressed. The unique clinical and 
histological presentation expands the spectrum of ACTA1 disease, and will help guide clinical 
care and future genetic diagnoses.   
Our team identified LMOD3 (leiomodin-3) as a novel disease gene for severe nemaline 
myopathy (NM). KLHL40 (encoding kelch-like family member 40) is another disease gene for 
severe NM. A recent study suggests mouse Klhl40 protects mouse Lmod3 protein from 
proteasome-mediated degradation, with the mechanistic basis of KLHL40-NM resulting from 
secondary loss of LMOD3. We investigated the regulation of human LMODs by human 
KLHL40, and unexpectedly found evidence that disputes the central paradigm that KLHL40 
protects LMOD3 from proteasome-mediated degradation.  
vi 
 
We identified PYROXD1 as a new genetic cause of early-onset congenital myopathy. We 
provide the first characterisation of PYROXD1 as a nuclear-cytoplasmic oxidoreductase and 
our discovery highlights oxidative distress as a core mechanistic pathway in the myopathies. 
We derived a mouse model of Pyroxd1 deficiency, determining that global loss of mouse 
Pyroxd1 is embryonic lethal. We subsequently developed a mouse model with skeletal muscle 
knock-out of Pyroxd1 – as a means to elucidate the role of PYROXD1 in biology and disease.  
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Chapter 1 - General Introduction 
1.1 Skeletal muscle  
Skeletal muscle consists of bundles of multinucleated muscle cells (myofibres) (Engel & 
Franzini-Armstrong, 2004; Frontera & Ochala, 2015). Within the myofibre are tightly packed 
myofibrils which are made up of repeating sarcomeres, the contractile unit of skeletal muscle. 
Sarcomeres are bordered by the Z-band, appearing as electron dense lines on electron 
microscopy. The thin filaments are anchored in the Z-band and extend into the centre of the 
sarcomere, the M-band. The thin filaments are predominately made up of filamentous actin, 
tropomyosin and the troponin complex. The M-band anchors the thick filament, which 
interdigitate the thin filaments. The thick filaments are predominantly made up of myosin and 
are electron dense, appearing as dark areas on electron microscopy (A-band). The thin 
filaments are less electron dense and areas only of thin filaments appear as lighter areas on 
electron microscopy (I-band). This contrast gives a straited appearance to skeletal muscle 
(Figure 1.1).  
Muscle contraction occurs when myosin heads within the thick filament bind to actin within 
the thin filament and pull the thin filament towards the centre of the sarcomere. This shortens 
the sarcomere and the synchronised shortening of sarcomeres contracts the muscle and 
generates force (Engel & Franzini-Armstrong, 2004). This is termed the sliding filament theory 
and was proposed simultaneously by Huxley & Niedergerke (1954) and Huxley & Hanson 
(1954). In a relaxed sarcomere, tropomyosin masks the myosin-binding sites on actin, 
preventing muscle contraction. The positioning of tropomyosin is regulated by the troponin 
complex (Engel & Franzini-Armstrong, 2004). 
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A muscle contracts in response to an action potential carried by the motor neuron to the 
myofibre (Engel & Franzini-Armstrong, 2004; Frontera & Ochala, 2015). The action potential 
depolarises the myofibre through the T-tubule network, triggering calcium release from the 
sarcoplasmic reticulum into the cytosol of the myofibril. The released calcium binds troponin 
C within the troponin complex. Binding of calcium to troponin C shifts tropomyosin, 
unmasking the myosin binding site on actin and allowing the sarcomere to contract (Engel & 
Franzini-Armstrong, 2004). 
 
 
Figure 1.1: Sarcomere structure. Electron microscopy and aligned schematic of a single 
sarcomere and a section of the thin filament: Z-band (Z), M-band (M), I-band (I) and A-band 
(A). Reproduced from Sanoudou and Beggs (2001) 
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1.2 Inherited myopathies and project aims 
Variants within genes encoding proteins responsible for skeletal muscle structure and function 
are associated with muscle disease (www.musclegenetable.fr). Identifying the genetic basis of 
muscle disease is the first step to elucidating the disease mechanism and to develop, or apply, 
mechanistic-based treatments. This thesis is divided into three projects which stem from the 
gene discovery programme of the Institute for Neuroscience and Muscle Research (INMR). 
Our goal is to provide a genetic diagnosis for our patients, and use this knowledge to guide 
clinical care and research into disease mechanism. Detailed descriptions of the sarcomeric 
components and the muscle disease of research focus are included in the introductions within 
the following chapters.  
Chapter two will focus on the first missense recessive variant within ACTA1, encoding α-
skeletal actin, as the genetic cause of congenital muscular dystrophy with rigid spine. The aim 
of this part of my PhD was to perform histological and molecular characterisation of patient 
skeletal muscle to determine if the identified variant within ACTA1 was pathogenic. 
Chapter three will focus on two disease genes for nemaline myopathy: LMOD3, encoding 
leiomodin-3, and KLHL40, encoding kelch-like family member 40. The aim of this part of my 
PhD was to deepen our understanding of nemaline myopathy pathogenesis, by further 
understanding the LMOD family as regulators of thin filament length, and the link between 
KLHL40 and LMOD3 in humans.  
Chapter four will focus on variants within the oxidoreductase PYROXD1 as a new genetic cause 
of congenital myopathy. The aim of this part of my PhD was: (1) To provide the first 
characterisation of PYROXD1 and PYROXD1-myopathy; and (2) generate two mouse models 
to further our understanding of PYROXD1 in fundamental biology and disease. 
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Chapter 2 - ACTA1: A novel missense variant expands the clinical 
and histological spectrum of ACTA1 variants and congenital 
muscular dystrophy 
Prologue 
As part of the gene discovery program of the INMR, targeted next-generation sequencing 
identified a novel variant in alpha-skeletal actin (ACTA1) that expands the phenotypic and 
histological spectrum associated with ACTA1 variants and congenital muscular dystrophy. This 
finding has been published as a short report. I am second author on this publication which is 
presented as Part A of this chapter. 
My role in this research study also involved the molecular characterisation of the ACTA1 
Val154Leu variant. These experiments and lines of investigation were necessary for, but not 
included in, our short report and are presented in Part B of this chapter. 
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2.1 Introduction 
2.1.1 α-skeletal actin 
Mammalian actins 
Alpha skeletal actin is encoded by ACTA1, one of six mammalian actin genes, and is the major 
actin isoform in skeletal muscle. Actin is highly conserved between species and amino acid 
conservation is greater than 90% between actin isoforms (Sheterline, Clayton, & Sparrow, 
1998). Despite this large amount of sequence homology, each actin isoform is expressed in 
specific cell types and carries out distinct functional roles. The two non-muscle actins are 
cytoplasmic β-actin (ACTB) and cytoplasmic γ-actin (ACTG1). Cytoplasmic β- and γ-actin are 
important components of the cytoskeleton and are involved in many processes including cell 
movement, vesicle transport and cell division (Sheterline et al., 1998). There are four muscle 
specific actin isoforms that are major constituents of the sarcomere, and are essential for muscle 
contraction: Smooth muscle expresses two actins - smooth muscle α-actin (ACTA2) and smooth 
muscle γ-actin (ACTAG2); and striated muscle expresses two actins - cardiac actin (ACTC) and 
α-skeletal actin (ACTA1). 
Cardiac actin is the major actin expressed in cardiac muscle and extraocular muscle. In skeletal 
muscle, cardiac actin is the predominant foetal actin isoform. It is highly expressed in utero 
and down regulated shortly after birth to be replaced by α-skeletal actin, the dominant actin in 
adult skeletal muscle (Ilkovski, Clement, Sewry, North, & Cooper, 2005). Due to the high 
conservation between isoforms and species, each residue within α-skeletal actin is considered 
functionally important. The Exome Variant Server (http://evs.gs.washington.edu/EVS/) 
documents only four missense changes within ACTA1 in healthy individuals – c.334C>T 
p.Leu112Phe; c.662C>A p.Arg208Ser; c.745G>A p.Val249Iso; c.1095C>G p.Asn365Glu.  
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Monomeric α-skeletal actin 
The nascent polypeptide chain of α-skeletal actin consists of 377 residues. Cleavage of the first 
two residues – methionine and cysteine, and methylation of the third – aspartic acid, are 
required to produce the mature, correctly folded polypeptide (Sheterline et al., 1998). G-actin 
is the monomeric form of actin consisting of two domains, named the ‘large’ and ‘small’ 
domains. These domains are further divided into 4 subdomains (Figure 2.1). Two clefts are 
situated between the domains – the hydrophobic pocket and the ATP-binding pocket (Kabsch, 
Mannherz, Suck, Pai, & Holmes, 1990). ATP and a metal ion (Ca2+ or Mg2+) bind within the 
ATP-binding pocket (Sheterline et al., 1998). The two domains of actin are linked by two 
polypeptide chains called the hinge region (Kabsch et al., 1990). The hinge region allows 
substantial movement of the two domains relative to each other, allowing molecules to bind 
within the two clefts (Sheterline et al., 1998).  
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Figure 2.1: Monomeric α-skeletal actin. G-actin showing the four subdomains, ATP-binding 
pocket, hydrophobic pocket and the two polypeptide chains making up the hinge region (red 
arrows). Molecular modelling of α-skeletal actin was carried out in DeepView/Swiss-Pdb 
Viewer (v 4.1.0) http://www.expasy.org/spdbv/(4) from the crystal structure solved by Kabsch 
et al. (1990).  
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Filamentous α-skeletal actin 
Functional α-skeletal actin is a filamentous structure (F-actin) formed by polymerisation of 
monomeric actin (G-actin). The formation of F-actin is a two-step process – nucleation 
followed by polymerisation. Nucleation is the formation of an unstable trimer of ATP-bound 
G-actin monomers termed the ‘nucleus’ (Kasai, Asakura, & Oosawa, 1962). Polymerisation is 
the subsequent addition of ATP-bound G-actin monomers to the nucleus. ATP bound to the G-
actin is hydrolysed to ADP + Pi which stabilises the monomeric subunits (Sheterline et al., 
1998). Addition of G-actin monomers in non-muscle cells occurs more rapidly at the plus end 
(barbed end) of the actin filament and there is very little, if any, monomeric addition at the 
minus end (pointed end) (Pollard, 1986). 
Subdomains 1 and 3 are orientated towards the plus end (barbed end, towards the Z-band) and 
subdomains 2 and 4 are orientated towards the minus ends (pointed end, towards the M-band). 
Subdomains 1 and 2 are orientated towards the outer edge of F-actin. Residues on the surface 
of subdomains 1 and 2 are able to interact with a variety of proteins. Subdomains 3 and 4 are 
orientated towards the inner-edge of F-actin. Residues on the surface of subdomains 3 and 4 
are able to interact with neighbouring actin monomers (Engel & Franzini-Armstrong, 2004).  
Sarcomere thin filament 
 α-Skeletal actin is the major component of the sarcomere thin filament. Sarcomere contraction 
occurs when myosin heads on the thick filament bind to actin and pull the thin filament towards 
the centre of the sarcomere, the M-band (A. F. Huxley & Niedergerke, 1954; H. Huxley & 
Hanson, 1954). Aligned thin filaments are required for efficient muscle contraction and 
regulation of a consistent thin filament length is paramount for efficient muscle contraction and 
force generation. Therefore, actin filament turnover dynamics are slow and tightly regulated 
(R. S. Littlefield & Fowler, 2008a). In contrast to skeletal muscle, non-muscle actin is highly 
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dynamic to allow adaptation to the cells changing environmental demands. Actin turnover 
requires a constant exchange between actin bound in thin filaments and soluble monomeric G-
actin molecules.  
 
Within the sarcomere thin filament, the plus end (barbed end) of the actin filament is bound to 
the Z-band by α-actinin and capped by CapZ. The minus end (pointed end) is orientated 
towards the M-band and is capped by tropomodulin. In contrast to non-muscle actin filaments, 
in sarcomeric thin filaments, monomers are added to both the barbed and pointed-ends (Kouchi, 
Takahashi, & Shimada, 1993; R. Littlefield, Almenar-Queralt, & Fowler, 2001). In striated 
muscle, regulation of the thin filament occurs predominantly at the pointed ends and involves 
a number of factors (reviewed in R. S. Littlefield & Fowler, 2008b).  
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2.1.2 Skeletal α-actin disease  
Establishing ACTA1 as a disease gene 
The existence of variants within ACTA1 as a genetic cause of muscle disease was first 
suggested in 1995 (Laing, 1995; Laing et al., 1995). In 1997 Goebel et al reported three 
congenital myopathy patients with actin aggregates within their skeletal muscle biopsy (Goebel 
et al., 1997). ACTA1 variants were identified within these patients in 1999 (Nowak et al.), 
establishing ACTA1 as a disease gene for congenital myopathy. Over 200 disease-causing 
variants within ACTA1 have now been identified 
(https://databases.lovd.nl/shared/variants/ACTA1/unique).  
Clinical presentation 
Variants within ACTA1 are a common genetic cause of congenital myopathy (Laing et al., 
2009; Nowak et al., 1999). Patients typically present with a severe congenital myopathy 
phenotype. Severe congenital myopathy patients often die within the first year of life and others 
require assisted ventilation (Laing et al., 2009; Sparrow et al., 2003). However ACTA1 disease 
phenotypes lie on a spectrum ranging in severity, inclusive of milder cases where the individual 
lives into adulthood (Agrawal et al., 2004; Saito et al., 2011; Schroder, Durling, & Laing, 
2004).  
Common congenital myopathy subtypes and pathological hallmarks  
Five sub-classes of congenital myopathy have been associated with variants within ACTA1, 
with overlapping pathological features on skeletal muscle histology (Figure 2.2): (1) Nemaline 
myopathy is the most common congenital myopathy associated with ACTA1 variants. 
Nemaline bodies are the identifying histological feature on muscle biopsy. Nemaline bodies 
are protein inclusions, often containing thin filament and Z-band proteins such as actin, α 
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actinin-2 and nebulin (Dubowitz & Sewry, 2007); (2) Intranuclear rod myopathy – rods are 
present within the myonuclei (Nowak et al., 1999); (3) Actin filament aggregate myopathy - 
abnormal aggregates of actin can be seen in sarcomeres of a muscle biopsy (Nowak et al., 
1999); (4) Congenital fibre type disproportion - characterised by smaller type one fibres 
(Clarke, 2011); and (5) Core-rod myopathies - characterised by areas of sarcomeric 
disorganisation that lack mitochondria, as well as nemaline rods (Kaindl et al., 2004).  
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Figure 2.2: Overlapping skeletal muscle histological presentations caused by ACTA1 
variants. Upper panel - Electron microscopy images of nemaline bodies (left, white arrow); 
rods within the nucleus (middle, white arrow); and actin aggregates (right, white arrow). Lower 
panel – ATPase pH 10.4 stain showing small slow fibres in disproportion to fast fibres (left, 
pale – slow fibres, dark – fast fibres); and NADH stain showing core-like areas (right, black 
arrows) (Laing et al., 2009) 
  
13 
 
Molecular genetics of ACTA1 variants 
Most ACTA1 mutations are de novo dominant (~ 90% of cases) (Laing et al., 2009). Whilst 
there is little correlation between histological abnormalities, presumed functional consequence 
of the mutation and the clinical severity, the amount of mutant protein expressed correlates 
with age of onset (Ilkovski et al., 2004).  
Recessive mutations make up ~ 10% of cases and typically occur in consanguineous families 
(Laing et al., 2009). To date, all recessive mutations have been functional null mutations (Costa 
et al., 2004; Laing et al., 2009; Nowak, Ravenscroft, & Laing, 2013; Nowak et al., 2007). The 
disease is caused by the absence of skeletal α-actin expression. Functional null mutations in 
skeletal actin are usually neonatally lethal. In patients that survive infancy, there is persistence 
of cardiac actin expression after birth in skeletal muscle which allows muscle function (Nowak 
et al., 2007). The more α-cardiac actin that is expressed, the milder the disease severity. Overall, 
there is little correlation between the histology and clinical severity, nor histology and the 
ACTA1 mutation (type or function) (Feng & Marston, 2009). 
Mapping of ACTA1 variants  
Mapping of ACTA1 variants on monomeric actin using molecular modelling programs allows 
hypotheses to be developed on how these mutations affect functionality of the thin filament. 
ACTA1 mutations can be grouped into six categories by predicted functional outcomes: N-
terminal processing, post-translational folding, polymerisation, interaction with the Z-band 
protein α-actinin and interaction with nebulin & structure of the contractile apparatus (Feng & 
Marston, 2009). 
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2.1.3 Aims of this project 
Targeted parallel sequencing identified a novel homozygous missense variant in ACTA1 within 
a muscular dystrophy patient with rigid spine. Our aim was to determine if the novel variant 
identified within ACTA1 was pathogenic. 
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2.2 Part A: PAPER - Recessive ACTA1 variant causes congenital 
muscular dystrophy with rigid spine 
  
SHORT REPORT
Recessive ACTA1 variant causes congenital muscular
dystrophy with rigid spine
Gina L O’Grady1,2, Heather A Best1,2, Emily C Oates1,2, Simranpreet Kaur1, Amanda Charlton3,
Susan Brammah4, Jaya Punetha5, Akanchha Kesari5, Kathryn N North1,2,6,7, Biljana Ilkovski1,2,
Eric P Hoffman5 and Nigel F Clarke*,1,2
Variants in ACTA1, which encodes a-skeletal actin, cause several congenital myopathies, most commonly nemaline myopathy.
Autosomal recessive variants comprise approximately 10% of ACTA1 myopathy. All recessive variants reported to date have
resulted in loss of skeletal a-actin expression from muscle and severe weakness from birth. Targeted next-generation sequencing
in two brothers with congenital muscular dystrophy with rigid spine revealed homozygous missense variants in ACTA1. Skeletal
a-actin expression was preserved in these patients. This report expands the clinical and histological phenotype of ACTA1
disease to include congenital muscular dystrophy with rigid spine and dystrophic features on muscle biopsy. This represents
a new class of recessive ACTA1 variants, which do not abolish protein expression.
European Journal of Human Genetics (2015) 23, 883–886; doi:10.1038/ejhg.2014.169; published online 3 September 2014
INTRODUCTION
Variants in the skeletal muscle a-actin gene (ACTA1) are a common
cause of congenital myopathy with over 200 different variants now
reported.1 By far, the most frequent histological pattern associated is
autosomal dominant nemaline myopathy; less common patterns
include actin-accumulation myopathy, intranuclear rod myopathy
and congenital fiber-type disproportion.1 Approximately 10% of
ACTA1-myopathy patients have autosomal recessive disease, and
until now all such patients have had nemaline myopathy and a
severe congenital phenotype associated with loss of a-skeletal actin
expression.1 We report a novel homozygous recessive missense variant
(c.460G4C, P.(Val154Leu)) in two brothers with infantile-onset
congenital muscular dystrophy with rigid spine, thus expanding the
histological and clinical phenotypes associated with ACTA1 variants
and establishing a new class of ACTA1 variants – recessive variants
associated with expression of mutant actin and mild-to-moderate
disease severity.
PATIENTS AND METHODS
Patients
We enrolled a large cohort of patients with limb-girdle weakness who
lacked a genetic diagnosis in a whole-exome sequencing study,
conducted with approval from the Human Research Ethics Commit-
tee of the Sydney Children’s Hospitals Network (10/CHW/45).
Genetic analysis
DNA was extracted from blood leukocytes of Patient 1 using standard
techniques. A QIAGEN (Melbourne, VIC, Australia) QIAamp DNA
FFPE Tissue kit was used to extract DNA from formalin-fixed
paraffin-embedded skeletal muscle of Patient 2.
Targeted next-generation sequencing of 45 neuromuscular disease
genes was performed by emulsion PCR (RainDance, Billerica, MA,
USA) of 1840 amplimers followed by sequence analysis (Illumina
HiScan SQ). Data interpretation were performed using NextGene
software. Confirmatory Sanger sequencing was carried out by the
Australian Genome Research Facility, Sydney. The sequence was
aligned on Sequencer 4.9 (Ann Arbor, MI, USA) with the reference
sequence from NCBI, NM_001100.3. The variant is submitted to the
Leiden Muscular Dystrophy ACTA1 Mutation Database (www.LOVD.
nl/ACTA1 (database ID ACTA1_00245)). Molecular modeling of the
a-skeletal actin monomer was performed using DeepView/Swiss-Pdb
Viewer (v 4.1.0, Basel, Switzerland), http://www.expasy.org/spdbv/2
from the crystal structure solved by Kabsch et al.3
Muscle biopsy analysis
Muscle histology slides were stained using standard procedures.
Frozen muscle biopsy sections were stained with antibodies to
a-skeletal actin, cardiac actin and neonatal myosin. Western blot
analysis was performed using antibodies to a-skeletal actin and
cardiac actin. Glyceraldehyde 3-phosphate dehydrogenase was used
as a loading control. See Supplementary methods for further details.
RESULTS
Clinical features
A Sri Lankan couple with possible distant consanguinity had two
affected sons and four healthy children. The affected boys’ prenatal
and perinatal periods were uncomplicated and both walked at around
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1 year of age. Neck weakness was noted in infancy in Patient 1 and by
age 2 years, both were unable to run and fell frequently. Patient 1 had
mild, stable, generalized weakness during childhood that progressed
slowly from late teenage years. A mild thoracic kyphoscoliosis
developed in adolescence. In early adulthood he developed mild
dysphagia and mild restrictive lung disease. At age 25 years, forced
vital lung capacity measured 44% of predicted. Nocturnal ventilation
was not required. At age 34 years, he walked short distances and had a
rigid spine (Figure 1a), generalized muscle wasting and a body mass
index of 15. There was mild facial weakness, restricted jaw opening,
scapular winging and generalized weakness in all limbs, worse in
proximal muscles.
At age 5 years, Patient 2 was ambulant but used a wheelchair for
longer distances. He had generalized weakness, more severe in
proximal limb muscles with a positive Gowers’ sign. He suffered
recurrent pneumonia and died during one episode at age 6 years.
Neither boy had ptosis, ophthalmoplegia, nor limb contractures.
Creatine kinase measures varied between 222and 1930U/l. The
electromyogram was myopathic in both siblings. Nerve conduction
studies and echocardiograms were normal. Muscle MRI in Patient 1
at 34 years showed widespread muscle atrophy and fat infiltration
(Figure 1b and c). At the mid thigh there was relative sparing of the
vastus lateralis, vastus medialis, gracilis and sartorius muscles, while
the posterior compartment and rectus femoris were more severely
affected. In the lower leg there was mild to moderate generalized fatty
infiltration, especially of soleus.
Genetic analysis
A missense variant (c.460G4C, p.(Val154Leu)) in ACTA1 was
identified in Patient 1. Sanger sequencing confirmed that both
brothers were homozygous for the variant, with both parents
heterozygous for the change. All unaffected siblings were either
heterozygous or homozygous for the normal allele. A previously
unreported, heterozygous missense variant in SEPN1 (NM_020451.2:
c.1162A4G, p.(Ser388Gly) (Leiden Muscular Dystrophy SEPN1
Mutation Database (www.LOVD.nl/SEPN1 (database ID SEPN1_
00115)) was also identified in Patient 1 but a second SEPN1 variant
was not found with Sanger sequencing or on a custom screen for exon
deletions or duplications. No variants were found in other genes
previously associated with a rigid spine phenotype (CAPN3, COL6A1,
COL6A2, COL6A3 or LMNA).
Molecular modeling showed that the Val154Leu variant alters a
residue in subdomain 3 situated near the ATP-binding pocket and the
hinge region (Figure 2h). The hinge region is responsible for relative
movement of the domains in respect to each other, allowing
molecules, including ATP, to bind in the clefts. As flexibility of the
relative domains is essential for polymerization of the actin filament,
the Val154Leu variant may influence polymerization by influencing
the hinge region. The relative movement of the two domains may be
changed such that ATP binds less efficiently.
Muscle biopsy analysis
A quadriceps muscle biopsy of Patient 1 at age 17 years 7 months
showed increased fiber size variation, numerous internalized nuclei,
fiber splitting, occasional degenerating and regenerating fibers
(Figure 2b). Thirty-four percent of myofibers had at least one internal
or central nucleus and 13% had two or more. The nicotinamide
adenine dinucleotide tetrazolium reductase (NADH), cytochrome
oxidase (COX) and succinic dehydrogenase (SDH) stains showed
central lucencies and a ‘moth-eaten appearance’, suggestive of cores
(Figure 2d). Similar findings, with prominent fatty infiltration, were
present in a quadriceps biopsy from Patient 2 at age 5 years.
In both patients, electron microscopy (EM) showed smeared and
accumulated Z-band material that typically spanned 1–2 sarco-
meres in length, but extended across up to half the width of the
fiber. The degree of accumulated Z-band material is unusual for
minicores (Figure 2a). A single more typical minicore, lacking the
accumulated Z-band material, was seen in the biopsy from Patient
Figure 1 Clinical and radiological features associated with ACTA1 variant Val154Leu. (a) Patient 1 at age 34 years demonstrating maximum forward flexion
of the spine and neck. (b and c) Patient 1 muscle MRI of the left mid thigh (b) showing prominent fat infiltration in the rectus femoris and muscles of the
posterior compartment (arrows), and left lower leg (c) showing particular involvement of the soleus (arrow).
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2. Occasional small nemaline rods were present (Figure 2c). These
were too small and infrequent to be seen on light microscopy on
Gomori trichrome, or with staining for cardiac and a-skeletal
actin, or a-actinin.
Immunohistochemical staining for neonatal myosin on Patient 1
muscle showed 1% positive fibers (Figure 2e), consistent with the
presence of occasional regenerating fibers. Cardiac a-actin was present
in 20% of myofibers of variable size and fiber type, and with variable
staining intensity (Figure 2i and j). Staining for a-skeletal actin
showed normal levels of expression in all myofibers, indicating that
mutant p.(Val154Leu) actin is expressed and is the predominant actin
isoform in most myofibers (Figure 2f and g).
Western blot analysis of Patient 1 muscle showed normal levels of
a-skeletal actin (Figure 2k). Cardiac actin was markedly upregulated
compared with normal controls (Figure 2l).
DISCUSSION
The ACTA1 gene is highly conserved throughout evolution and
polymorphisms that alter the protein sequence are extremely rare in
the general population, indicating that most changes to the actin
Figure 2 Histological features associated with ACTA1 variant Val154Leu. (a) Electron microscopy of Patient 1’s quadriceps muscle biopsy shows
accumulated Z-band material. (b) Hematoxylin and eosin staining of Patient 1 quadriceps muscle shows multiple internalized nuclei (i), a regenerating fiber
(ii) and a likely split fiber (iii). (c) Electron microscopy of Patient 1’s quadriceps muscle biopsy shows streaming and accumulation (i) of Z-band material.
Occasional small rods are also present (arrows). (d) COX SDH staining of Patient 1 quadriceps muscle biopsy demonstrating central lucencies and ‘moth-
eaten’ areas suggestive of cores. (e) One percent of myofibers in Patient 1 was positive for neonatal myosin, supporting the presence of occasional
regenerating fibers. (f) Immunohistochemistry for skeletal a-actin shows normal expression in all myofibers in muscle from Patient 1 at 17 years of age
compared with adult control (g). (h) Molecular modeling of a-skeletal actin monomer in DeepView/Swiss-Pdb Viewer (v 4.1.0, http://www.expasy.org/spdbv/)
from the crystal structure solved by Kabsch et al.3 Valine154 is shown in yellow space fill, on actin depicted as a black ribbon structure. The two
polypeptide chains making up the hinge region are shown in blue. (i) Immunohistochemistry of Patient 1 muscle demonstrates the presence of cardiac
a-skeletal actin in 20% of myofibers of variable size and staining intensity, compared with adult control skeletal muscle (j). (k and l) Western blot analysis
of Patient 1 muscle with glyceraldehyde 3-phosphate dehydrogenase shown as a loading control. (k) Normal levels of a-skeletal actin are present in Patient
1 muscle. Lanes 1 and 3 show adult control skeletal muscle, lane 2 contains patient skeletal muscle. (l) Cardiac actin is markedly upregulated in Patient 1
skeletal muscle compared with normal controls. Lane 1 contains baboon cardiac muscle, lanes 2 and 4 contain control adult skeletal muscle and lane 3
contains muscle from Patient 1. The full colour version of this figure is available at European Journal of Human Genetics online.
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polypeptide sequence adversely affect protein function.4 All previously
described patients with recessive ACTA1 disease (B10% of ACTA1
patients) have had functional ‘null’ variants and make no a-skeletal
actin.1,4,5 All have had severe congenital nemaline myopathy and
survival after birth is only possible due to persistence of cardiac
a-actin in the skeletal muscle of these children.5 We describe the first
recessive ACTA1 variant associated with expression of a-skeletal actin
in skeletal muscle and survival well into adulthood. A limitation of
this study is that we have not performed a comprehensive screen for
other genetic variants that may influence the patient’s phenotype.
Nevertheless, the ACTA1 recessive variants segregate with disease in
the family and are predicted to be pathogenic by molecular modeling.
As in other recessive ACTA1 myopathies, cardiac actin was
upregulated in patient muscle, but only in a subset of myofibers.
Occasional cardiac actin-positive fibers may be regenerating fibers in
which fetal sarcomeric isoforms, including cardiac actin and neonatal
myosin, are expressed, but this explanation is unlikely to account for
most cardiac actin-positive myofibers. We suspect cardiac actin is
upregulated as a specific response to abnormalities in a-skeletal actin,
as cardiac actin expression is unusual in congenital myopathies or
dystrophies after the neonatal period, except in the context of
myofiber regeneration.
The finding of mild dystrophic changes on muscle biopsy has not
been previously reported in association with variants in ACTA1 and
expands the histological phenotype for ACTA1-related myopathies.
Another notable histological feature was the presence of prominent
internalized nuclei. Extensive Z-band streaming and the presence of
occasional rods on EM may also provide a clue to the genetic
diagnosis.
On clinical examination, spinal rigidity was a notable feature and
the mild to moderately raised CK levels in both probands, together
with the muscle biopsy findings led to a clinical diagnosis of
congenital muscular dystrophy with spinal rigidity. Congenital
muscular dystrophy with a rigid spine and variably elevated CK has
been previously described in association with variants in SEPN1,
LMNA and collagen VI genes, and we screened these genes for
variants.6 The lack of limb contractures in Patient 1 by adulthood is
also atypical for LMNA- and COLVI-related myopathies, and
almost all SEPN1-related myopathy patients develop nocturnal
hypoventilation by this age. These clinical features and a different
pattern of lower limb muscle involvement in our family may be useful
clinical clues to identify additional patients with ACTA1-CMD.
This report extends the phenotypic spectrum of ACTA1myopathies
to include congenital muscular dystrophy associated with rigid spine.
Until recently, genetic testing has generally been limited to the analysis
of disease genes known to be associated with the patient’s phenotype
and expense has been a major barrier to broad genetic screens.
Advances in sequencing technologies now mean that testing of all
known myopathy genes is widely available for patient diagnosis and
there are many examples of when such testing has revealed unex-
pected genotype–phenotype associations.7 Even though ACTA1 was
one of the first known congenital myopathy genes,8 and ACTA1
diagnostic sequencing has been available for over 14 years, the family
we report raises the possibility that variants in ACTA1 may be
responsible for a much wider spectrum of disease than is currently
appreciated.
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Recessive ACTA1 mutation causes congenital muscular dystrophy with rigid 
spine 
Supplementary Methods  
PCR and Sequencing 
A reaction volume of 20 µl was made up of 1 µl gDNA (20 ng), 10 µl Buffer D (Astral), 0.2 
µl Taq DNA polymerase recombinase (5 units/µl), 6.8 µl DEPC water (Bioline), 1 µl forward 
(5’-CGCTGAGMGCCTAGCCTCGG-3’) and 1 µL reverse primer (5’-
TGCGGAGGGCAGAAGCAGGA-3’) (10 µM, Sigma-Aldrich). PCR was carried out with a 
33 cycle 2 x 3 step temperature gradient PCR. An initial 5 min activation at 95°C was 
followed by 14 cycles of: 94°C 30 sec, 68°C (-0.5°C/cycle), 72°C for 1 min; followed by 19 
cycles of: 94°C for  30 sec, 60°C for  30 sec, 72°C for  1 min; and a terminal extension at 
72°C for 10 mins. PCR for the FFPE gDNA was altered due to gDNA fragmentation. Four µl 
of gDNA (80ng) was used and the second PCR cycle increased to 26 to give 40 PCR cycles 
total. PCR products were run on a 1% agarose gel using hyperladder IV (Bioline). Prior to 
sequencing the PCR reactions were exosapped [0.3 µl Sap and 1 µl exo/tube (New England 
Biolabs); 37°C for 30 mins, 80°C for 20 mins]. The sequencing reactions were prepared (2 
µL ExoSapped PCR reaction, 1 µl betaine, 1 µl reverse or forward primer, 10 µl DPEC 
water) and Sanger sequencing was carried out by Australian Genome Research Facility, 
Sydney. The sequence was aligned on Sequencer 4.9 with the reference sequence from NCBI, 
NM_001100. 
 
Immunohistochemistry 
Frozen muscle biopsy sections were cut at 8 µm, fixed with 3% paraformaldehyde (Sigma-
Aldrich) for 3 min at room temperature and ice-cold methanol for 5 minutes -20°C, and 
stained with α-skeletal actin or cardiac actin. Primary antibodies used: polyclonal rabbit anti 
α-skeletal-actin, 1:100 (Sophie Clement, University of Geneva); monoclonal mouse cardiac 
actin produced in a sheep, 1:250 (American Research Products); monoclonal mouse neonatal 
myosin, 1:20 (Novocastra). Secondary antibodes; Alexa Fluor® 488 donkey anti-rabbit IgG, 
1:200 (Invitrogen); Alexa Fluor® 555 goat anti-mouse IgG, 1:200 (Invitrogen). The sections 
were imaged on an Olympus BX50 microscope linked to a SPOTTM digital imaging camera 
(Diagnostics Instruments Inc).  
 
Western blot analysis 
Frozen muscle biopsies were cut at 8 µm thickness to a total surface area of 200 mm2 per 
sample. Solubilising solution [4% SDS (Sigma-Aldrich), 12 mM Tris pH 8.8, 20% glycerol 
(Astral Scientific), bromethol blue powder (Sigma-Aldrich) with the addition of 500 mM 
dithiothreitol (Biorad) and 1:500 protease inhibitor cocktail (Sigma-Aldrich) immediately 
prior to loading] was added at a ratio of 10 mm2: 5 µl. Each sample was sonicated to 
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homogenise the muscle before heat inactivating at 94°C for three minutes and solubilising for 
20 minutes on ice. Samples were separated on a 4-12% 1 mm, 10 well Biorad polyacrylamide 
gel by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) at 150 V 
constant voltage with 5 µl of PagerulerTMPlus prestained protein ladder (Thermoscientific). A 
loading gel was used to determine equal loading based on myosin expression levels by 
coomassie staining. The experimental gel was transferred at 400 mA for one hour onto a 
PVDF membrane (Millipore) in transfer buffer (25 mM Tris, 192 mM glycine and 20% 
methanol, pH 8.3). Membranes were blocked for one hour in 5% skim milk diluted in 
phosphate buffer saline with 0.1% tween (PBST, Biochemicals) and probed with primary 
antibody diluted in 5% skim milk in PBST for 2 hours at room temperature [α-skeletal actin 
1:2000, cardiac actin 1:1500, Glyceraldehyde 3-phosphate dehydrogenase 1:10,000 
(GAPDH, Chemicon)]. Membranes were washed three times in PBST, blocked for 10 
minutes and blotted with secondary antibody diluted 1:2000 in 5% skim milk in PBST at 
room temperature for 2 hours [α-skeletal actin probe with donkey anti-rabbit IgG HRP 
conjugate (GE Healthcare Biosciences) and cardiac actin & GAPDH probes with sheep anti-
mouse IgG HRP conjugate, (VWR)]. The membrane was washed four times in PBST and 
developed with ECL Chemiluminescent reagents using Hyperfilm (VWR).   
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2.3 Part B: Molecular investigations into the ACTA1 Val154Leu 
variant 
2.3.1 Results 
2.3.1.1 ACTA1 c.460C>G variant segregates with disease 
The ACTA1 c.460C>G variant was identified by targeted next-generation sequencing in the 
older affected brother (II-3), causing a missense change Val154Leu. To determine if the 
identified variant segregated with disease, we carried out Sanger sequencing of ACTA1 on the 
two probands, parents and four unaffected siblings. We identified the same homozygous 
variant, c.460C>G, in the younger affected brother (II-6) (Figure 2.3B, right chromatograms). 
By Sanger sequencing, the parents (I-1 and I-2) and two out of four unaffected siblings (II-1 
and II-2) are heterozygous for c.460C>G (Figure 2.3, left chromatograms). Two out of four of 
the unaffected siblings (II-4 and II-5) are homozygous for wild type, c.460C, ACTA1 (Figure 
2.3, middle chromatograms). These results show recessive inheritance of the c.460C>G ACTA1 
variant segregates with congenital muscular dystrophy with rigid spine.  
  
23 
 
 
 
 
Figure 2.3: Sanger sequencing confirms ACTA1 c.460C>G segregates with disease. 
(A) Pedigree of affected family - Black fill indicates probands, red line indicates deceased. (B) 
Sanger sequencing chromatograms of ACTA1 from position 455 to 465. Position 460 indicated 
with a red asterisk. Left chromatogram shows the unaffected parents, I-I & I-2, and two 
unaffected siblings, II-1 & II-2, are heterozygous for the ACTA1 c.460C>G variant. The middle 
chromatogram shows two unaffected siblings, II-4 & II-5, do not carry the c.460C>G variant. 
The right chromatogram shows the two affected siblings, II-3 and II-6, are homozygous for the 
c.460C>G variant.  
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2.3.1.2 Levels and localisation of sarcomeric proteins within patient muscle 
Protein levels 
On histology, we observed protein aggregates which are structurally equivalent to nemaline 
bodies in the muscle of patient II-3. In order to determine whether the pathological pattern was 
similar to that described for other ACTA1 NM patients, we carried out protein studies, 
particularly focusing on proteins commonly found in nemaline rods. Serial dilutions of skeletal 
muscle lysates of patient II-3 and a healthy age-matched control show upregulation of desmin, 
filamin, αβ-crystalin and α-actinin 2 in patient muscle (Figure 2.4).  
 
 
Figure 2.4: Patient muscle shows upregulation desmin, filamin, αβ-crystalin and α 
actinin-2. Western blot of skeletal muscle lysates. Loading is normalised to total myosin. 
Fractions indicate serial dilutions. Healthy muscle (17 years) and patient II-3 (17 years) were 
probed for desmin, filamin, αβ-crystalin and α actinin-2 levels. Sarcomeric actin and GAPDH 
were probed for as loading controls. Desmin, filamin, αβ-crystalin and α actinin-2 are 
upregulated in patient muscle. 
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Composition of inclusions 
The adenosine triphosphatase reaction was carried out on patient II-3 muscle at pH 4.3 (ATPase 
4.3) and showed inclusions within type I (slow twitch) fibres (Figure 2.5A, black arrows). We 
wanted to determine the protein composition of the inclusions seen within patient muscle. We 
stained patient II-3 muscle for proteins we found to be upregulated by western blot – desmin, 
filamin, αβ-crystalin, α-actinin-2 (Figure 2.5) and myotilin (result not shown). Inclusions 
consistent with those observed with the ATPase 4.3 reaction stained positively for myotilin and 
filamin (Figure 2.5B, white arrows). In addition, we observed aggregates positive for myotilin 
which differed in location, shape and size to those observed with the ATPase 4.3 reaction 
(Figure 2.5C, white arrows).   
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Figure 2.5: Patient inclusions contain myotilin and filamin. (A) The adenosine 
triphosphatase reaction was carried out at pH 4.3 (ATPase 4.3) on skeletal muscle of patient 
II-3 (17 years). Small, rounded inclusions near the centre of the myofibre were observed within 
type I fibres (black arrows). (B, C) Skeletal muscle of patient II-3 (17 years) and control (17 
years) were stained for myotilin and filamin. Inclusions consistent in size, shape and location 
with those observed with ATPase 4.3 stained positively for myotilin and filamin (B, white 
arrows). Larger aggregates near the periphery of the myofibre of inconsistent shape stained 
positively for myotilin (C, white arrows). Note: Exposure times are 5s and 3.8s for panel B and 
C respectively. The ATPase 4.3 reaction was carried out by the pathology department at 
the Children’s Hospital at Westmead using standard procedures and imaged by 
Simranpreet Kaur on a Scanscope CS2 microscope (Aperio). 
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2.3.1.3 Investigating the presence of cardiac actin 
We established in Part A that the ACTA1 c.460C>G variant is the first recessive variant within 
ACTA1 where α-skeletal actin is made. Survival of ACTA1-myopathy patients who do not 
produce α-skeletal actin is due to the maintenance of cardiac actin expression within skeletal 
muscle beyond birth (Nowak et al., 2007). Similar to other recessive ACTA1 mutations, and 
thus in support of ACTA1 c.460C>G being a pathogenic variant, we observed cardiac actin 
expression within a subset of skeletal muscle fibres of the elder affected son (Part A, Figure 
2I). There was variation in the size and staining intensity of cardiac actin positive fibres. 
The presence of cardiac actin within patient muscle can be a sign of either 
regeneration/degeneration or compensatory upregulation due to loss of functional skeletal 
actin. We further characterised cardiac actin positive fibres to determine the cause of cardiac 
actin expression within patient skeletal muscle.  
Fibre typing cardiac actin positive fibres  
To investigate if cardiac actin was produced selectively in fast or slow fibres we co-stained 
patient muscle with cardiac actin and slow-myosin (a marker of slow-twitch fibres) (Figure 
2.6). Our results show that cardiac actin positive fibres within patient skeletal muscle is not 
restricted to fast or slow-twitch muscle fibres. However, only ~ 20% of cardiac actin positive 
fibres stained positively for slow myosin (Figure 2.4, white arrows). This differed from the 
Duchenne Muscular Dystrophy (DMD) positive control where ~50% of cardiac positive fibres 
stained positively for slow myosin (Figure 2.4, middle panel). This suggests ~80% of cardiac 
positive fibres within patient skeletal muscle are fast twitch fibres.  
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Figure 2.6: Slow twitch fibres are the minority of cardiac actin positive fibres. Skeletal 
muscle sections were co-stained with slow myosin (green), cardiac actin (red) and DAPI (blue). 
Patient II-3 (17 years) showed a small subset of cardiac actin positive fibres staining positive 
for slow myosin (white arrows). A Duchenne muscular dystrophy muscle biopsy (DMD, 2 
years) was used as a positive control for cardiac actin. Approximately 50% of cardiac actin 
positive fibres within the DMD control stained positive for slow myosin. A muscle biopsy from 
a healthy adult (17 years) was used as negative control for cardiac actin, showing only 
background staining for cardiac actin. 
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Regenerating fibres within patient muscle  
The foetal cardiac isoform, cardiac actin, is present within regenerating muscle fibres of 
dystrophic muscle (Dubowitz & Sewry, 2007). Therefore, we wanted to determine if the high 
proportion of cardiac actin positive fibres in patient muscle was attributed to regenerating fibres 
by co-staining sections with cardiac actin and markers for fibre regeneration 
(neonatal/developmental myosin, Figure 2.7A and B). Our results show the high proportion of 
cardiac actin positive fibres seen in patient muscle cannot be attributed to regenerating fibres. 
We do observe cardiac actin positive regenerating fibres – fibres staining positive for neonatal 
and/or developmental myosin (Figure 2.7, white arrows). However, we observe more cardiac 
positive non-regenerating fibres – fibres negative for developmental and neonatal myosin 
(Figure 2.7, white arrowhead). Interestingly, the non-regenerating cardiac actin positive fibres 
have a lower staining intensity than the regenerating cardiac actin positive fibres.  
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Figure 2.7: Regenerating fibres do not account for the majority of cardiac actin positive 
patient fibres. Sequential sections of skeletal muscle were co-stained with (A) neonatal or (B) 
developmental myosin (green), cardiac actin (red) and DAPI (blue). Fibres in Patient II-3 (17 
years) strongly positive for cardiac actin, stained positively for neonatal and/or developmental 
myosin (white arrows). Fibres in Patient II-3 (17 years) weakly positive for cardiac actin, 
stained negatively for neonatal and/or developmental myosin (example - white arrowhead, 
same fibre). A Duchenne muscular dystrophy muscle biopsy (DMD, 2 years) was used as a 
positive control for regenerating fibres. A muscle biopsy from a healthy adult (17 years) was 
used as a negative control for regenerating fibres. 
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2.3.1.4 Molecular modelling of ACTA1 Val154Leu 
Molecular modelling was used to investigate how ACTA1 Val154Leu may alter the function 
of α-skeletal actin and therefore cause disease. Molecular modelling suggests ACTA1 
Val154Leu may compromise actin polymerisation.  
The tertiary structure of α-skeletal actin was not predicted to be influenced by the Val154Leu 
variant. Substitution of valine with leucine at position 154 is a conservative change (Figure 
2.8A) within a β-sheet of subdomain 3 of α-skeletal actin (Figure 2.8B, left). In silico analysis 
suggested the substitution of valine with leucine at position 154 does not alter this β-sheet 
structure (Figure 2.8B, right).  
Interaction between α-skeletal actin and other sarcomeric proteins is not predicted to be 
influenced by the Val154Leu variant. Position 154, within subdomain 3, is in close proximity 
to the hydrophobic binding pocket, where many proteins bind to actin. However, subdomain 3 
faces the interior of the filamentous actin structure and the Val154Leu variant is therefore 
unlikely to interact with sarcomeric proteins. We investigated amino acids within a 4Å radius 
of Val154Leu and changes in hydrogen bonding (Figure 2.8C, left and middle). All amino acids 
influenced by Val154Leu were internal and also unlikely to bind to sarcomeric proteins. 
Interestingly, three amino acids in the hinge region - Ser143, Leu144 and Met301 – were 
influenced by Val154Leu (Figure 2.8C, right). 
The hinge region allows relative movement of the two domains. Movement of the two domains 
is required for ATP and a metal ion (calcium or magnesium) to bind in the ATP-binding pocket. 
ATP-ADP exchange is a crucial step for actin polymerisation. Therefore, if the Val154Leu 
variant influences the hinge region, ATP binding and/or ATP-ADP exchange may be 
compromised and in turn, polymerisation. 
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Figure 2.8: Molecular modelling predicts hinge region residues are influenced by the 
Val154Leu variant. (A) Valine to leucine is a conservative amino acid change. (B) Valine 154 
is part of a β-sheet (black arrow) in subdomain 3. The change of valine to leucine at position 
154 is not predicted to alter the secondary structure of α-skeletal actin. The β-sheet is 
maintained at position 154 (black arrow). (C) When valine (left) is changed to leucine (middle) 
at position 154 (orange) the residues and hydrogen bonding (black dashed lines) within a 4Å 
radius change. Leu144 (yellow) is lost, and Ser143 & Met299 are gained (light blue). The 
hydrogen bond with Val165 is lost. Leu144, Ser143 and Val165 are within the hinge region of 
α-skeletal actin (right). Molecular modelling of α-skeletal actin was carried out in 
DeepView/Swiss-Pdb Viewer (v 4.1.0) http://www.expasy.org/spdbv/(4) from the crystal 
structure solved by Kabsch et al. (1990).  
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2.3.2 Discussion 
We have established the first recessive variant within ACTA1 as the genetic cause of congenital 
muscular dystrophy with rigid spine. ACTA1 variants typically present with a congenital 
myopathy pathology and severe clinical presentation. Dystrophic pathology (Wallgren-
Pettersson & Laing, 2001) and stiffness (Jain et al., 2012) has been reported previously, but not 
in combination. The unique combination of clinical and histological presentation of our two 
patients expands the spectrum of ACTA1 disease, and will help guide clinical care and future 
genetic diagnoses. 
We observed upregulation of desmin, filamin, αβ-crystalin, myotilin and α-actinin 2 in patient 
muscle (Figure 2.4). The upregulation of filamin and myotilin can be readily explained by the 
presence of these proteins in aggregates within patient muscle (Figure 2.5). However, the 
degree of upregulation of filamin and myotilin is inconsistent with the number of 
inclusions/aggregates observed within the patient muscle. We did not find evidence of desmin, 
αβ-crystalin or α-actinin 2 within aggregates. Both affected brothers are homozygous for 
ACTN3 R577X (previous diagnostic investigations, results not shown). ACTN3 encodes α-
actinin 3, a component of the Z-line. ACTN3 R577X is a common polymorphism which results 
in an absence of α-actinin 3 (North et al., 1999). Patient II-3 muscle is absent for α-actinin 3 
(previous diagnostic investigations, results not shown). Absence of α-actinin 3 results in 
compensatory upregulation of α-actinin-2 (MacArthur et al., 2007). Furthermore, the Actn3 
knockout mouse shows upregulation of desmin, filamin, αβ-crystalin and myotilin (Quinlan et 
al., 2010; Seto et al., 2011). Therefore, the ACTN3 R577X polymorphism carried by both 
affected brothers may cause the upregulation of desmin, αβ-crystalin and α-actinin 2; and 
exacerbate the upregulation of myotilin and filamin, seen within patient muscle. 
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Chapter 3 - The link between LMOD3 and KLHL40: two disease 
genes for nemaline myopathy 
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3.1 Introduction 
3.1.1 Nemaline myopathy 
Nemaline myopathy is a heterogeneous type of congenital myopathy first described in 1963 
(Conen, Murphy, & Donohue, 1963; Shy, Engel, Somers, & Wanko, 1963) with an incidence 
of 1 in 50,000 live births (Sanoudou & Beggs, 2001). Nemaline myopathy is characterised by 
generalised muscle weakness and hypotonia (loss of muscle tone) as well as the presence of 
electron-dense protein aggregates, termed ‘nemaline bodies’, within skeletal muscle. Nema is 
the latin word for thread-like, explaining the etymology of the nomenclature, nemaline 
myopathy. While the presence of nemaline bodies are a requirement for a diagnosis of nemaline 
myopathy, the number and size of nemaline bodies within a muscle biopsy does not correlate 
with disease severity (Shimomura & Nonaka, 1989). The clinical spectrum of nemaline 
myopathy is broad, with sub-classification into six subtypes (Sanoudou & Beggs, 2001): 
Severe congenital, intermediate congenital, typical congenital, childhood onset, adult onset and 
Amish. Involvement of the respiratory muscles is common and can result in death due to 
respiratory insufficiency.  
Nemaline myopathy is genetically heterogeneous and is associated with variants in thirteen 
genes to date. Ten of the thirteen genes linked with nemaline myopathy encode sarcomere thin 
filament proteins: Tropomyosin-3 (TPM3) (Laing et al., 1995), α-skeletal actin (ACTA1) 
(Nowak et al., 1999), troponin T1 (TNNT1) (Johnston et al., 2000), tropomyosin-2 (TPM2) 
(Donner et al., 2002), nebulin (NEB) (Lehtokari et al., 2006), cofilin-2 (CFL2) (Agrawal et al., 
2007), leiomodin-3 (LMOD3) (Yuen et al., 2014), Myosin XVIIIB (MYO18B) (Malfatti et al., 
2015), Myopalladin (MYPN) (Miyatake et al., 2017) and troponin T3 (TNNT3) (Sandaradura 
et al., 2017). This led nemaline myopathy to be considered a disease of the thin filament 
(Nance, Dowling, Gibbs, & Bonnemann, 2012). Three out of the thirteen genes linked with 
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nemaline myopathy are part of the kelch protein family: Kelch-like family member 40 
(KLHL40) (Ravenscroft et al., 2013), kelch-like family member 41 (KLHL41) (Gupta et al., 
2013) and kelch-repeat and BTB (POZ) domain containing 13 (KBTBD13) (Sambuughin et al., 
2012). Our understanding of the role kelch proteins play in nemaline myopathy and their link 
to the thin filament is at its early stages and is reviewed in sections 3.1.3 and 3.1.4. 
3.1.2 The leiomodin family  
The leiomodin (LMOD) family is related to the tropomodulin (TMOD) family of actin capping 
proteins (Conley, Fritz-Six, Almenar-Queralt, & Fowler, 2001). The N-terminal two-thirds of 
the leiomodins share ~40% amino acid homology to the TMOD family. The LMOD family has 
a C-terminal extension which the TMODs lack (Conley et al., 2001). The LMOD family is 
made up of three members: leiomodin-1 (LMOD1), leiomodin-2 (LMOD2) and leiomodin-3 
(LMOD3) (Nanda & Miano, 2012). The gene structure of LMOD is simple, each containing 
three exons, with the majority of the protein-coding region within exon 2 (Conley et al., 2001). 
LMOD1 is predominantly expressed in smooth muscle, while LMOD2 and LMOD3 are 
predominantly expressed in striated muscle (Conley, 2001; Conley et al., 2001; Nanda & 
Miano, 2012). 
In skeletal muscle, the LMOD and TMOD families play an important role in regulating actin 
turnover at the pointed end of the thin filament (reviewed in Fowler & Dominguez, 2017). The 
TMODs cap the pointed end of the thin filament, preventing actin monomer addition or 
dissociation (Weber, Pennise, Babcock, & Fowler, 1994). The LMODs are powerful actin 
filament nucleators, functioning both in the formation of new actin filaments (nucleation), and, 
in the addition of actin monomers to an established actin filament at the pointed end 
(polymerisation) (Boczkowska, Rebowski, Kremneva, Lappalainen, & Dominguez, 2015; 
Chereau et al., 2008). LMOD contains one tropomyosin binding domain (TM-h) and three actin 
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binding domains – A-H (Actin-binding helix), LRR (Leucine rich repeat) and WH2 (Wiskott-
Aldrich-Syndrome protein homology 2 domain). LMOD can bind three G-actin monomers and 
form the ‘nucleus’ of a de novo actin filament. The interface of the nucleus is thought to be 
bound by the LRR, with the N-terminal wrapping around the nucleus positioning A-H to bind 
the first actin monomer and allowing TM-h to recruit tropomyosin. The C-terminal is thought 
to wrap around the nucleus, positioning the WH2 domain to bind the third actin monomer 
(Figure 3.1) (Fowler & Dominguez, 2017).   
Variants within LMOD genes have been associated with disease in humans (Abbott et al., 2017; 
Berkenstadt et al., 2018; Halim et al., 2017; Yuen et al., 2014) and recapitulated in mouse 
models (Cenik et al., 2015; Halim et al., 2017; Tian et al., 2015). Loss of LMOD1 is linked 
with megacystis microcolon intestinal hypoperistalsis (Halim et al., 2017). Our group 
established LMOD3 as a disease gene for severe nemaline myopathy (Yuen et al., 2014), and 
mice deficient in Lmod2 present with a lethal dilated cardiomyopathy (S. Li et al., 2016; Pappas 
et al., 2015).  
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Figure 3.1: LMOD as a nucleator. LMOD contains a tropomyosin binding domain (TMBS1, 
green) and three actin binding domains (ABS1, purple; ABS2, purple; and WH2, red). LMOD 
can bind three G-actin monomers and form the ‘nucleus’ of a de novo actin filament. ABS2 is 
thought to bind at the interface of the actin nucleus. Reproduced from Fowler and Dominguez 
(2017). PRD – proline-rich domain.  
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3.1.3 Kelch-like superfamily 
Kelch proteins 
The kelch proteins are part of a large superfamily of genes defined by the presence of a kelch-
repeat domain (Dhanoa, Cogliati, Satish, Bruford, & Friedman, 2013). Kelch proteins carry out 
a range of processes within the cell inclusive of actin binding, cell morphology and gene 
expression - but are best known for their role in the ubiquitin-proteasome pathway as ubiquitin 
ligase adaptor proteins (Adams, Kelso, & Cooley, 2000; Dhanoa et al., 2013; Shibata, Zhang, 
Puthumana, Stone, & Lifton, 2013). The kelch superfamily is made up of 63 protein-coding 
genes (plus three non-coding genes), divided into three families: (1) KLHL (42 members); (2) 
KBTBD (nine members); and (3) KLHDC (12 members) (Gupta & Beggs, 2014) (Figure 3.2A). 
The different classes of kelch proteins are defined by the presence or absence of three domains: 
(1) BTB/POZ domain: Broad complex, tramtrack and bric à brac (Zollman, Godt, Prive, 
Couderc, & Laski, 1994)/poxviruses and zinc finger (Bardwell & Treisman, 1994); (2) BACK 
domain: BTB and C-terminal kelch repeats (Stogios & Prive, 2004); and (3) a variable number  
of kelch-repeats.  
KLHL proteins contain a BTB/POZ domain, BACK domain and kelch repeats (Dhanoa et al., 
2013). KBTBD are similar to KLHL proteins but frequently lack the BACK domain. KLHDC 
proteins contain kelch repeats but typically lack BTB/POZ and BACK domains, and have other 
domains in their place (Figure 3.2B). 
The BTB domain is involved in protein-protein interaction (Albagli, Dhordain, Deweindt, 
Lecocq, & Leprince, 1995) as well as self-dimerization (Zipper & Mulcahy, 2002). An 
important role of the BTB domain within kelch proteins is the interaction with the E3 ligase 
Cullin 3 (Cul3), mediating substrate-specific ubiquitination (Pintard, Willems, & Peter, 2004). 
The kelch-repeat domain is the region within kelch proteins which binds the specific substrate, 
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for example, KLHL37 binds actin (Adams et al., 2000). The kelch-repeat forms a β-propeller 
structure (Ito, Phillips, Yadav, & Knowles, 1994); each blade of the propeller is formed from 
a single kelch-motif folding into a four-stranded antiparallel β-sheet (Adams et al., 2000). The 
BACK domain has no known function to date, however, it is hypothesised to position the kelch-
repeat-bound substrate in proximity to Cul3 (Stogios & Prive, 2004). 
 
 
Figure 3.2: The kelch-like superfamily. (A) The kelch-like superfamily consisting of 63 
proteins is sub-divided into three families: KLHL, KBTBD and KLHDC. (B) Typical domain 
organisation of KLHL, KBTBD and KLHDC families. KLHL consist of a BTB/POZ domain, 
a BACK domain and kelch repeats. KBTBD consist of a BTB/POZ domain and kelch repeats, 
typically missing the BACK domain. KLHDC contain kelch repeats with or without other 
domains (depicted in purple and orange) and typically lack the BTB/POZ and BACK domains. 
Reproduced from Gupta and Beggs (2014). 
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Ubiquitination  
Ubiquitin (Ub) is an evolutionarily conserved 76-amino acid polypeptide present within 
eukaryotes (Pickart & Fushman, 2004). Ub forms an isopeptide bond with its substrate through 
Gly76 and most often a lysine (Lys) within the target substrate (Busch & Goldknopf, 1981; 
Hunt & Dayhoff, 1977; Orrick, Olson, & Busch, 1973). Substrate proteins may be mono-
ubiquitinated or polyubiquitinated (Pickart & Fushman, 2004).  
Ubiquitination occurs over three steps, catalysed by three enzymes (Hershko, Heller, Elias, & 
Ciechanover, 1983 and reviewed in Lecker et al., 2006): Ub-activating Enzyme 1 (E1), Ub-
carrier proteins (E2) and Ub-ligases (E3) (Figure 3.3). Ub is activated by E1 in an ATP-
dependent reaction, generating a highly reactive Ub thiolester. The activated Ub is then 
transferred to a sulfhydryl group of E2. E3 subsequently catalyses the transfer of Ub from E2 
to a lysine within the substrate, and then a lysine within each additional Ub resulting in a 
polyubiquitinated substrate. In mammals, there is a single E1 per cell and 20-40 E2s, increasing 
ubiquitination specificity. E3s are the major source of specificity in the Ub-proteasome 
pathway, of which there are 500-1000 in mammals. Some E3s are able to bind Ub directly, 
mediating transfer to the substrate. Some E3 ligases bind both E2 and the substrate, bringing 
each into close proximity for Ub transfer. Other E3 ligases bind E2, and require an adaptor 
protein to bind the substrate. The Cullins are a subgroup of E3 ligases which require a substrate 
specific adaptor protein for ubiquitination. Kelch proteins act as adaptors for one cullin E3 
ligase called Cullin-3 (Sarikas, Hartmann, & Pan, 2011).  
Ubiquitination is responsible for a range of intracellular signals which differ based on the 
number of Ubs conjugated to the substrate, and through which lysine within Ub a polyubiquitin 
chain is formed (Pickart & Fushman, 2004). Polyubiquitination between Lys48 of Ub was the 
first discovered and is the most well studied (Chau et al., 1989; Finley et al., 1994). A single 
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polyubiquitin chain linked through Lys48 is sufficient to target a protein to the 26S proteasome 
for subsequent degradation. Lys68-linked polyubiquitin chains have been shown to be involved 
in ribosomal protein synthesis (Spence et al., 2000), protein trafficking (Hicke & Dunn, 2003), 
DNA damage tolerance (Ulrich, 2002) and inflammatory response (Sun & Chen, 2004). 
Monoubiquitination has been shown to be involved in protein trafficking (Hicke & Dunn, 
2003). Lys29-linked polyubiquitination can target a protein for lysosomal degradation 
(Chastagner, Israel, & Brou, 2006), and kinases have been shown to be inhibited by 
polyubiquitination through Lys29 or Lys33 (Al-Hakim et al., 2008).  
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Figure 3.3: Protein ubiquitination. Three sequential steps are required to conjugate Ub onto 
a protein. E1 catalyses the activation of Ub which is subsequently transferred to E2 and the 
transfer of Ub onto the substrate is catalysed by E3. Reproduced from Lecker et al. (2006). 
  
44 
 
Kelch protein and disease 
Variants within kelch proteins have been associated with a number of diseases (reviewed in 
Gupta & Beggs, 2014). Variants within KLHL6, KLHL19, KLHL20 and KLHL37 are linked 
with cancer (Q. K. Li, Singh, Biswal, Askin, & Gabrielson, 2011; Liang, Avraham, Jiang, & 
Avraham, 2004; Puente et al., 2011; Yuan et al., 2011). Variants within KLHL1, KLHL9, 
KLHL16, KLHL40, KLHL41 and KBTBD13 are linked with neuromuscular disease (Bomont 
et al., 2000; W. L. Chen et al., 2008; Cirak et al., 2010; Gupta et al., 2013; Ravenscroft et al., 
2013; Sambuughin et al., 2010). Variants within KLHL3, KLHL7 and KLHL10 are a cause of 
pseudohypoalsosteronism type II (Louis-Dit-Picard et al., 2012), retinitis pigmentosa 
(Friedman et al., 2009) and oligozoospermia (Yatsenko et al., 2006), respectively. 
Kelch proteins in skeletal muscle disease  
To date, variants within genes encoding four kelch proteins have been identified as the cause 
of inherited skeletal muscle disorders in humans: KLHL9 (Cirak et al., 2010), KBTBD13 
(Sambuughin et al., 2010), KLHL40 (Ravenscroft et al., 2013) and KLHL41 (Gupta et al., 
2013). A dominant KLHL9 pathogenic variant found within the BTB domain is associated with 
distal myopathy (Cirak et al., 2010; Furukawa, He, Borchers, & Xiong, 2003). Dominant 
variants within KBTBD13 (Sambuughin et al., 2010) and recessive variants within KLHL40 
(Ravenscroft et al., 2013) and KLHL41 (Gupta et al., 2013) cause nemaline myopathy. 
Interestingly, there is high amino acid homology between the kelch domains of KBTBD13, 
KLHL40 and KLHL41; with KLHL40 and KLHL41 being the most closely related (Gupta & 
Beggs, 2014). This suggests these proteins may bind the same, or related, substrates and be 
involved in the same or similar biological processes. In contrast to the proteins encoded by the 
ten other genes associated with nemaline myopathy, KBTBD13 and KLHL41 do not localise 
to the sarcomere thin filament (Garg et al., 2014; Gupta et al., 2013; Ravenscroft et al., 2013; 
Sambuughin et al., 2010). KLHL40, however, was reported to localise to the thin filaments 
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(Garg et al., 2014). Nemaline myopathy due to variants within kelch proteins may result from 
dysregulation of thin filament related pathways and kelch proteins may play a role in sarcomere 
maintenance. Human KLHL40 and mouse Klhl41 have been reported to bind thin filament 
proteins  (Garg et al., 2014; Ramirez-Martinez et al., 2017). Mouse Klhl40 has been shown to 
be involved in the regulation of the MRTF/SRF pathway, which plays an important role in the 
transcriptional control of cytoskeletal proteins (Cenik et al., 2015). Klhl40 is considered to be 
a tight regulator of Lmod3 protein levels, this will be reviewed in detail in section 3.1.4. 
Dominant KBTBD13 pathogenic variants cause nemaline myopathy with cores, with variants 
thus far identified affecting residues within the kelch-repeats (Sambuughin et al., 2010). 
Pathogenic variants within KLHL40 and KLHL41 affect residues within the BTB, BACK and 
kelch-domains (Gupta et al., 2013; Ravenscroft et al., 2013). KLHL40 mutations result in 
severe nemaline myopathy. A genotype-phenotype relationship was found for variants in 
KLHL41. Truncating variants cause a severe form of nemaline myopathy, whereas missense 
variants cause a mild or intermediate form of nemaline myopathy (Gupta et al., 2013).  
The suggested disease mechanism for myopathies due to variants in KLHL9, KBTBD13, 
KLHL40 and KLHL41 is proposed to relate to protein ubiquitination and turnover (Cirak et al., 
2010; Sambuughin et al., 2012; Sanoudou & Beggs, 2001). KLHL9, KBTBD13, KLHL40 and 
KLHL41 proteins have each been shown to form a complex with the Cul3 Ub E3 ligase 
(Canning et al., 2013; Sambuughin et al., 2012; Sumara et al., 2007; Zhang et al., 2005). 
KLHL9 and KLHL13 form a complex together with Cul3, Cul-KLHL9-KLHL13. The Cul3-
KLHL9-KLHL13 complex has been shown to bind, and ubiquitinate, Aurora B (Sumara et al., 
2007). Interestingly, KLHL41 (sarcosin) forms a complex with Cul3, which results in self-
ubiquitination (Zhang et al., 2005). 
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3.1.4 The link between LMOD3 and KLHL40  
Recent studies on the involvement of kelch proteins in nemaline myopathy provided a link 
between kelch and thin filament proteins (Cenik et al., 2015; Garg et al., 2014; Ramirez-
Martinez et al., 2017). Mouse Klhl41 has been shown to associate with nebulin (Ramirez-
Martinez et al., 2017). Garg et al. (2014) showed KLHL40 associated with two thin filament 
proteins – nebulin and LMOD3. In vitro studies suggest mouse Klhl40 interacts with mouse 
Lmod3 through the kelch repeat domain, and protects Lmod3 from Ub-dependent proteasome 
degradation.  
Additionally, Garg et al. (2014) showed that co-transfection of a mouse Lmod3 expression 
construct, together with an empty vector, resulted in no Lmod protein detected by western blot. 
Whereas, co-transfection of Lmod3 and a mouse Klhl40 expression construct resulted in robust 
detection of Lmod3 protein by western blot. Robust detection of Lmod3 protein could also be 
achieved when cells co-transfected with Lmod3 and an empty vector were treated with the 
proteasome inhibitor MG132. Further investigations suggested that when Lmod3 was co-
transfected with an empty vector, higher levels of polyubiquitinated Lmod3 were observed, 
compared to when co-transfected with Klhl40. This study suggested polyubiquitin chains were 
conjugated through Lys48 (Garg et al., 2014); a signal able to target a protein to the proteasome 
(Chau et al., 1989; Finley et al., 1994). These results suggested Klhl40 protected Lmod3 from 
Ub-mediated proteasomal degradation.   
Garg et al. (2014) also generated a Klhl40 knock-out (KO) mouse, and showed that Klhl40 
deficient muscle had reduced Lmod3 protein levels. They further utilised their cell transfection 
assay with Klhl40 deletion constructs, to refine the kelch repeat domains as being important in 
mediating a protective role upon Lmod3 protein levels. A paradigm of disease mechanism for 
severe KLHL40-nemaline myopathy was proposed, where KLHL40 either stabilises LMOD3 
47 
 
or protects it from degradation. The authors hypothesise that muscle weakness in severe 
KLHL40-nemaline myopathy patients may result from a secondary loss of LMOD3.  
Cenik et al. (2015) showed Lmod3 and Klhl40 are involved in the feedforward loop that 
regulates the transcription of G-actin and other structural sarcomeric proteins in skeletal muscle 
(Figure 3.4). Studies carried out in transgenic mice, where the MEF2 or SRF consensus sites 
within Lmod3 were fused to LacZ, demonstrated mouse Lmod3 transcription is regulated by 
MRTF/SRF and MEF (myocardin-related transcription factors/ serum response factor and 
myocyte enhancer factor-2). Klhl40 has previously been shown to be regulated by MEF2 (Liu 
et al., 2014). Cenik et al. (2015) used luciferase reporter assays to demonstrate Lmod3 and 
Klhl40 protein promote MRTF/SRF activity. Klhl40 alone was sufficient for MRTF reporter 
activity which was increased with the addition of Lmod3. Whereas Lmod3 alone was not 
sufficient for MRTF reporter activity. Furthermore, Mrtfa mRNA levels were reduced in the 
Lmod3-KO mice (Cenik et al., 2015).  This study suggests loss of Lmod3 results in an 
accumulation of G-actin in the cytoplasm and reduced production of proteins essential for the 
contractile apparatus, resulting in nemaline myopathy.  
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Figure 3.4: Proposed model for the promotion of MRTF/SRF dependent transcription by 
LMOD3 and KLHL40. MRTF (myocardin-related transcription factor) is sequestered in the 
cytoplasm when bound to G-actin. Polymerisation incorporates G-actin into F-actin, depleting 
the cytoplasmic G-actin pool and enabling MRTF to enter the nucleus where MRTF co-
activates SRF (serum response factor). MRTF/SRF in combination with MEF (myocyte 
enhancer factor-2) regulates the transcription of genes crucial for the contractile apparatus, 
inclusive of LMOD3 and KLHL40. KLHL40 and LMOD3 promote actin polymerisation, 
therefore depleting the G-actin pool and promoting translocation of MRTF to the nucleus. 
Reproduced from Cenik et al. (2015).  
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3.1.5 Study aims 
The overarching goal of this part of my PhD was to lend insight into the pathogenesis of 
nemaline myopathy by: (1) Furthering our understanding of the LMOD family and their role 
as regulators of actin filament length; and (2) understanding the link between the Cul3-adapter 
kelch proteins (linked to proteasomal degradation) and LMOD proteins.  
More specifically, we investigated the following aims: 
PARTA: Investigating LMOD splice isoforms and tissue expression 
Aim 1: Investigate expression of splice isoforms of LMOD1, LMOD2 and LMOD3 in mouse 
and human tissues. 
PART B: Investigating the link between KLHL40 and LMOD proteins 
Aim 2: Define regulation of LMOD protein expression by KLHL40:  
(1)  Determine if LMOD2 and LMOD3 developmental expression patterns 
correspond with KLHL40. 
(2) Determine whether human LMOD3 protein levels are regulated by human 
KLHL40 (previously characterised in murine models). 
(3) Define the region within LMOD3 that mediates regulation by KLHL40. 
(4) Establish whether protein levels of LMOD1 and LMOD2 are similarly regulated 
by KLHL40. 
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 3.2 Results 
PART A: Investigating LMOD splice isoforms and tissue expression 
3.2.1: Splice isoforms of LMOD1, LMOD2 and LMOD3 in mouse and human tissues 
Our group established variants within LMOD3 as a new genetic cause of a severe, lethal form 
of congenital nemaline myopathy and showed LMOD3 has an indispensable role for striated 
muscle function (Yuen et al., 2014). Preliminary western blot data collated during this project 
showed multiple bands on western blot analysis when tissues and cells were probed with 
antibodies recognising LMOD2 or LMOD3. This suggested additional LMOD isoforms may 
be expressed at the protein level, likely arising from alternate splice isoforms. To date, no 
studies have investigated the existence of alternatively spliced versions of LMOD proteins, or 
their potential function. The first focus of this chapter encompasses investigations into the 
tissue-specific expression of LMOD splice isoforms, as a correlation with data from protein 
biochemistry. 
We utilised publicly-available data from the GTEx portal (https://www.gtexportal.org/home/) 
(Consortium, 2013) to investigate the tissue-specific expression of mRNA isoforms of human 
LMOD1, LMOD2 and LMOD3. Mining GTEx data identified three putative mRNA isoforms 
for LMOD1, four putative mRNA isoforms for LMOD2 and three putative mRNA isoforms for 
LMOD3. We used protein prediction programs and published data to compile known domains 
of the LMODs, and annotated the putative splice isoforms to lend insight into their potential 
different functions. Western blot was then carried out on a range of mouse and human tissues, 
to determine if these splice isoforms were detected at the protein level. Triplicate blots were 
probed with antibodies recognising each of the LMOD paralogues: LMOD1, LMOD2 or 
LMOD3.  
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LMOD1 
Splice isoforms: The canonical isoform of LMOD1 (NM_012134) is depicted in Figure 3.5A, 
and corresponds to the LMOD1.1 isoform from the GTEx database. Canonical LMOD1 is made 
up of three exons with the majority of the protein coding region encoded by exon 2. Exon 3 
consists largely of a long 3’ untranslated region (UTR). LMOD1.1 has a predicted molecular 
weight of 67 kDa (NM_012134). The second isoform of LMOD1 described in GTEx, 
LMOD1.2, lacks a 152 bp from within exon 2 compared to LMOD1.1 (encoding residues with 
no described feature or function to date), and has a shortened 5’ and 3’UTR. LMOD1.2 has a 
predicted molecular weight of 62 kDa. The third isoform of LMOD1 described in GTEx, 
LMOD1.3, lacks a stop codon, suggesting mis-annotation of this isoform. All three LMOD1 
mRNA isoforms were annotated in GTEx as being expressed in smooth muscle-containing 
tissues (Figure 3.5B). LMOD1.1 was the predominant mRNA isoform detected. 
Protein studies: Western blots of a range of mouse tissues, as well as human cardiac and skeletal 
muscle were probed with an antibody against human LMOD1 (Abcam ab104858, antibody 
binding site within amino acids 2-51 of NP_036266). We identified a band migrating at 75 
kDa, which likely corresponds to the canonical LMOD1 isoform (Figure 3.5C, red arrow, 
predicted molecular weight of 67 kDa). It is present at low levels in human skeletal muscle and 
was not detected in human heart. In murine tissues, Lmod1 was detected at high levels in 
smooth muscle-containing tissues – aorta, bladder, uterus and ovary, consistent with the 
published observation that LMOD1 is expressed predominantly in smooth muscle (Conley, 
2001; Conley et al., 2001; Nanda & Miano, 2012); and we detected lower levels in skeletal 
muscle, pancreas and testis.  
We also observed a lower molecular weight band at ~65 kDa in most mouse tissues. This may 
plausibly correspond to LMOD1.2, with a predicted molecular weight of 62 kDa. However, 
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LMOD1.2 mRNA is not identified in GTEx as being expressed in many of the tissues shown 
to have a 65 kDa band on western blot (Figure 3.5B, green). Kidney, liver and pancreas, for 
example, show no reported expression of LMOD1.2 (Figure 3.5B, green), but show a 65 kDa 
band on western blot (Figure 3.5C). In addition, a band of 27 kDa was observed recurrently in 
several tissues. We excluded that this 27 kDa band corresponds to endogenous immunoglobulin 
light chains, as it was not detected in the absence of the anti-LMOD1 primary antibody (when 
the membrane was probed with secondary antibody only, see Appendix Figure A.1). Additional 
bands were observed that do not correspond to any of the predicted mRNAs and are of unknown 
significance. Unfortunately, tissues from an Lmod1 KO mouse were not available to establish 
the specificity of other bands recognised by the anti-LMOD1 antibody. 
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Figure 3.5: Investigating LMOD1 splice isoforms. (A) Aligned genomic schematics (to 
scale) illustrating protein domains and genetic features of canonical LMOD1 (NM_012134) 
and GTEx isoforms LMOD1.1 (ENST00000367288), LMOD1.2 (ENST00000412469) and 
LMOD1.3 (ENST00000400965). Gene structure is annotated as per UCSC 
(https://genome.ucsc.edu/) and ENSEMBL (http://www.ensembl.org/index.html) entries. 
Genomic features are annotated as follows: Untranslated regions (green), exons (blue), introns 
(white), numerals refer to base pairs. Protein structure predictions were adapted  from Uniprot 
(http://www.uniprot.org/), Chereau et al. (2008), Prosite (http://prosite.expasy.org/), 
InterProScan (http://www.ebi.ac.uk/interpro/search/sequence-search), COILS (https://npsa-
prabi.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_lupas.html), pfam (http://pfam.xfam.org/),  
ScanProsite (http://prosite.expasy.org/scanprosite/), SMART (http://smart.embl-
heidelberg.de/) and LRR finder (http://www.lrrfinder.com/result.php)  analysis and marked on 
the canonical isoform. Protein domains are indicated as follows: Tm – tropomyosin binding 
domain (pink), A-H - actin-binding helix (pink), LRR – Leucine rich repeat (yellow), Polypro 
– PolyProline rich region (pink), WH2 – Wiskott-Aldrich-syndrome protein homology 2 
domain (pink); (B) Tissue expression of LMOD1 mRNA isoforms from the GTEx database 
(https://www.GTExportal.org/home/).  LMOD1.1 (red), LMOD1.2 (green) and LMOD1.3 
(blue). LMOD1 mRNA is expressed in tissues consisting of smooth muscle. Isoforms are 
ranked based on mRNA expression (highest to lowest). RPKM – reads per kilobase per million; 
(C) Western blot of tissues harvested from a wild type C57BL/6J mouse (Lanes 1-14), human 
skeletal muscle (lane 15) and human heart (lane 16). Lmod1 is detected at high levels in mouse 
tissues with smooth muscle – aorta, pancreas, bladder, uterus, ovary and at low levels in the 
skeletal muscle and testis. LMOD1 is detected at low levels in human skeletal muscle; Smooth 
muscle actin, cardiac actin and sarcomeric actin were used as markers for smooth, cardiac and 
striated muscle respectively. β-tubulin and GAPDH served as loading controls. Red arrow 
indicates the canonical LMOD1 (NM_012134) isoform. 
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LMOD2 
Splice isoforms: The canonical isoform of LMOD2 (NM_207163) is depicted in Figure 3.6A. 
The canonical LMOD2 isoform is consistent with the LMOD2.1 isoform from the GTEx 
database with additional sequence to the 3’ UTR of LMOD2.1. LMOD2.1 protein has a 
predicted molecular weight of 62 kDa. The second LMOD2 isoform described in the GTEx 
database, LMOD2.2, lacks the C-terminal portion of the Glu-rich and polyproline regions, as 
well as shortened 5’ and 3’ UTRs. The LMOD2.2 isoform has a predicted molecular weight of 
56 kDa. The third LMOD2 isoform described in the GTEx database, LMOD2.3, has a shortened 
5’UTR, and lacks the majority of exon 2, including the C-terminal portion of the Glu-rich 
region and the entire PolyProline and PolyLys regions. LMOD2.3 extends into intron 2 the 
majority of which becomes 3’ UTR after an alternative stop codon. The LMOD2.3 isoform has 
a predicted molecular weight of 18 kDa. The fourth isoform described in the GTEx database, 
LMOD2.4, has a shortened 5’UTR and lengthened 3’UTR. LMOD2.4 lacks a portion of exon 
2 inclusive of the C-terminal segment of the Glu-rich region. The LMOD2.4 isoform has a 
predicted molecular weight of 57 kDa. The mRNA isoforms of LMOD2 showed highest 
expression in skeletal muscle and heart tissue (Figure 3.6B). 
Protein Studies: Western blots of a range of mouse tissues, as well as human cardiac and 
skeletal muscles, were probed with a polyclonal antibody against human LMOD2 (Santa Cruz 
Biotechnology sc-135493, antibody binding site near the N-terminus of human LMOD2). We 
identified the canonical isoform of LMOD2 (NM_207163, predicted molecular weight of 62 
kDa) at a position corresponding to a size of approximately 70 kDa (as determined by the 
molecular weight marker) on western blot (Figure 3.6C, red arrow). LMOD2 was detected in 
human skeletal muscle and at higher levels in human heart. Lmod2 was detected at high levels 
in mouse heart and testis; and at lower levels in mouse thymus. Interestingly, we did not detect 
Lmod2 in mouse skeletal muscle (quadricep). This may suggest higher skeletal muscle 
56 
 
expression of LMOD2 in humans compared to mice or be due to higher LMOD2 expression in 
slow muscle fibres [which are more abundant in human than mouse skeletal muscle (Schiaffino 
& Reggiani, 2012)]. 
We observed a lower molecular weight band migrating at ~65 kDa in most mouse tissues and 
human heart, similar to that observed with the LMOD1 antibody (refer to Figure 3.5). The 65 
kDa western blot band may plausibly correspond to LMOD2.2 (56 kDa) and/or LMOD2.4 (57 
kDa). However, these mRNA transcripts are identified by GTEx as being expressed only in 
skeletal muscle and heart tissue (Figure 3.2B). Isoform LMOD2.3 (18 kDa) did not correspond 
to a band on western blot (Figure 3.2C). However, the LMOD2 antibody binding site is near 
the N-terminus (specific residues unknown) and therefore LMOD2.3 protein may not contain 
the LMOD2 antibody binding site for detection by western blot. We observed a ~45 kDa band 
in mouse and human skeletal muscle. Cross-reactivity of the anti-LMOD2 antibody for 
tropomodulin-4 migrating at 45 kDa was considered, and explored through western analyses 
with recombinant tropomodulin-4 protein (a generous gift from Prof Velia Fowler, see 
Appendix Figure A.2). Thus, cross-reactivity with tropomodulin-4 may explain the 45 kDa 
band observed with the anti-LMOD antibodies. Additional bands were observed which did not 
correspond to a detected mRNA and are thus of unknown origin and significance. 
Unfortunately, tissues from an Lmod2 KO mouse were not available to establish the specificity 
of other bands recognised by the anti-LMOD2 antibody. 
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Figure 3.6: Investigating LMOD2 splice isoforms. Annotations, protein structure predictions 
and membrane probes were performed as described above (Figure 3.5) with additions:  (A) 
Aligned genomic schematics (to scale) illustrating protein domains and genetic features of 
canonical LMOD2 (NM_207163) and GTEx isoforms LMOD2.1 (ENST00000458573.2), 
LMOD2.2 (ENST00000332074.7), LMOD2.3 (ENST00000456238.2), LMOD2.4 
(ENST00000444702.1); Glu-rich – Glutamic acid-rich region (yellow) and polylys – 
Polylysine-rich region (pink) (B) Tissue expression of LMOD2 RNA isoforms from the GTEx 
database (https://www.GTExportal.org/home/). LMOD2 mRNA is expressed in the heart and 
at higher levels in skeletal muscle. Isoforms are ranked based on mRNA expression (highest to 
lowest). 
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(C) Lmod2 is detected at high levels in mouse heart and testis, and at low levels in the thymus. 
LMOD2 is detected in human heart at lower levels in human skeletal muscle. Red arrow 
indicates canonical LMOD2 (NM_207163) isoform. 
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LMOD3 
Splice isoforms: The canonical isoform of LMOD3 (NM_198271) is depicted in Figure 3.7A. 
Interestingly, the three LMOD3 isoforms detected by the GTEx database have the same coding 
region (CDS) which match the CDS of the canonical LMOD3 (NM_198271) isoform and are 
predicted to result in a protein with a molecular weight of 65 kDa. The three isoforms differ 
only in the length of their 5’ and 3’ UTRs. None of the GTEx LMOD3 isoforms exactly match 
the combination of 5’UTR and 3’UTR annotated in ENSEMBL for NM_198271. The first 
isoform of LMOD3 described in GTEx, LMOD3.1.1, lacks a portion of the 5’ UTR and has a 
shortened 3’ UTR. The second isoform of LMOD3 described in GTEx, LMOD3.1.2, is the 
closest match to the canonical LMOD3 (NM_198271) isoform, but has a slightly shortened 
5’UTR and slightly lengthened 3’UTR. The third LMOD3 isoform detected in GTEx 
substitutes a portion of the 5’ UTR for an upstream sequence, and has a shortened 3’UTR. The 
three LMOD3 mRNA isoforms were reported by GTEx as being predominantly expressed in 
skeletal muscle and heart tissue (Figure 3.7B). In skeletal muscle, LMOD3.1.1 is the highest 
expressed isoform. Whereas in heart tissue, LMOD3.1.2 is the highest expressed isoform.  
Protein Studies: Western blots of a range of mouse tissues, as well as human cardiac and 
skeletal muscles, were probed with a polyclonal antibody raised against human LMOD3 
(Proteintech 14948-1-AP, BC039202). Our group has determined that this antibody is able to 
bind to a fragment consisting of the first 50 amino acids of LMOD3. The canonical isoform of 
LMOD3 (NM_198271) has a predicted molecular weight of 65 kDa and was detected on 
western blot at a position corresponding to approximately 75 kDa (Figure 3.7C, red arrow). 
LMOD3 was detected in human skeletal muscle and at slightly lower levels in human heart. 
Lmod3 was detected at high levels in mouse skeletal muscle and heart; and at lower levels in 
kidney, liver and pancreas. We again observed an abundant lower molecular weight band at 
~65 kDa in most tissues, as well as a higher molecular weight band in kidney and brain. 
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Immunorecognition of proteins of this size could not be explained by isoforms detected in 
GTEx. Unfortunately, tissues from an Lmod3 KO mouse were not available to verify the 
specificity of bands recognised by the anti-LMOD3 antibody. 
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Figure 3.7: Investigating LMOD3 splice isoforms. Annotations, protein structure predictions 
and membrane probes were performed as described above (Figure 3.5) with additions: (A) 
Aligned genomic schematics (to scale) illustrating protein domains and genetic features of 
canonical LMOD3 (NM_198271) and GTEx isoforms LMOD3.1 (ENST00000489031.1), 
LMOD3.2 (ENST00000420581.2) and LMOD3.3 (ENST00000475434.1); Glu-rich – 
Glutamic acid-rich region (yellow); (B) Tissue expression of LMOD3 mRNA isoforms from 
the GTEx database (https://www.GTExportal.org/home/). LMOD3 mRNA is expressed highest 
in skeletal muscle followed by heart tissue. LMOD3.1.1 is the dominant mRNA transcript in 
skeletal muscle. LMOD3.1.2 is the dominant isoform in heart tissue. Isoforms are ranked based 
on mRNA expression (highest to lowest). Numbering of LMOD3 refers to the identical CDS, 
followed by mRNA expression rank; (C) Lmod3 is detected at high levels in mouse skeletal 
muscle and heart, and at low levels in aorta, kidney, liver and pancreas. LMOD3 is detected at 
high levels in human skeletal muscle and slightly lower levels in human heart. Red arrow 
indicates canonical LMOD3 (NM_198271) isoform. 
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PART B: Investigating the link between KLHL40 and LMOD proteins 
This project required collaborative experimentation by three laboratory members; myself, Dr 
Michaela Yuen and research assistant Adam Bournazos. Dr Yuen and myself had collaborative 
roles in experimental concept and design as well as carrying out and interpreting experiments. 
Experimentation performed by Adam Bournazos is defined within the figure legends, and in 
these cases my role was in experimental concept, design and interpretation. 
Synopsis 
Garg et al. (2014) generated a Klhl40 KO mouse that recapitulated the severe nemaline 
myopathy associated with KLHL40 variants in humans. They observed dramatically reduced 
Lmod3 protein levels in the Klhl40 KO mouse. In vitro studies showed KLHL40 can 
immunoprecipitate LMOD3 and the interaction between Klhl40 and Lmod3 was required in 
order for Lmod3 protein to be detected within transfected cells. Because expression of Lmod3 
protein levels were ‘rescued’ following treatment with the proteasome inhibitor MG132, the 
authors proposed a mechanism whereby Klhl40 protected Lmod3 from ubiquitination and 
subsequent degradation by the proteasome in mice.  
Garg et al. (2014) also examined LMOD3 protein levels in KLHL40-NM muscle biopsies. The 
study found two severe KLHL40-NM skeletal muscle biopsies, which showed a complete 
absence of KLHL40 protein, also had reduced levels of LMOD3 protein. Thus, Garg et al. 
(2014) proposed that the severe presentation of KLHL40-NM may be due mechanistically to 
secondary loss of LMOD3 protein in skeletal muscle (refer to Section 3.1.4). 
This project explored whether the mechanistic paradigm proposed by Garg et al. (2014) was 
restricted to mice or was also true for humans, by determining whether human KLHL40 
protects human LMOD3 from ubiquitination and subsequent proteasome degradation in cell 
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models. The aims of this chapter were originally: (1) To show human LMOD3 and KLHL40 
are expressed at the same time in developing and differentiating skeletal muscle; (2) to show 
levels of human LMOD3 protein are regulated (i.e. stabilised) by human KLHL40 protein; (3) 
to define the region within human LMOD3 mediating regulation by human KLHL40; and (4) 
to determine if human KLHL40 also regulates human LMOD1 and/or LMOD2. However, we 
quickly accumulated convincing data that made us question the interpretation of results 
presented in Garg et al. (2014) and ultimately call into question the central paradigm of: ‘the 
kelch protein KLHL40 protects LMOD3 from Ub-mediated proteasomal degradation’. 
3.2.2 Do LMOD2 and LMOD3 developmental expression patterns correspond with 
KLHL40? 
As a first step to investigating the biological relevance of findings from Garg et al. (2014) in 
humans, we wanted to establish if KLHL40, LMOD2 and LMOD3 protein were expressed at 
the same time in developing and differentiating human skeletal muscle. The domain and 
functional similarities between LMOD2 and LMOD3 lead us to consider that KLHL40 may 
plausibly also regulate LMOD2 protein levels.  
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Developing human muscle 
Western blot was carried out on human skeletal muscle from healthy individuals or disease 
controls (without a known genetic neuromuscular condition), ranging from age 14 gestational 
weeks to 60 years. Triplicate membranes were probed with antibodies recognising LMOD2, 
LMOD3 and KLHL40 (Figure 3.8).  
Two bands were detected with the LMOD2 antibody, 70 kDa and 65 kDa. A 70 kDa LMOD2 
band (red arrow) was not clearly evident in muscle samples from early gestation (14 and 19 
weeks), though observed in muscle samples from 25 gestational weeks onwards (although 
appears at lower levels in the 37 week, 21 years, 31 years and 60 years samples). The diffuse 
band at 65 kDa, is present in most gestational and childhood samples, though appears absent 
from adult samples (21 years, 31 years and 60 years). The 65kDa band does not correspond to 
splice isoforms described in section 3.2.1. The identity of this band is uncertain, though our 
later experiments raise a possibility this band may represent an LMOD2 protein from alternate 
initiation methionine(s) (to be discussed in further detail in Section 3.2.3). KLHL40 and 
LMOD3 were detected in human skeletal muscle samples at all developmental time points 
tested. Thus, expression of LMOD3 and KLHL40 appears to precede that of LMOD2 in human 
skeletal muscle. 
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Figure 3.8: Human LMOD3 and KLHL40 are expressed throughout skeletal muscle 
development. Western blot of human skeletal muscle through development from 14/40 weeks 
gestation to 60 years of age. LMOD2 (red arrow) is detected from 25/40 weeks gestation to 60 
years of age.  LMOD3 and KLHL40 are detected from 14/40 weeks gestation to 60 years of 
age.  It is unclear why LMOD2 and LMOD3 cannot be detected in one sample (4 month). 
Cardiac actin was used as a control for pre-natal skeletal muscle; GAPDH was used as a loading 
control; sarcomeric actin and α-actinin 2 were used as loading controls for skeletal muscle. W 
- weeks of gestation, D - days, M - months, Y - years.  
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Differentiating human myoblasts 
Western blot was carried out on differentiating primary human myoblasts from day 0 to day 8 
of differentiation, and triplicate membranes were probed for antibodies recognising LMOD2, 
LMOD3 and KLHL40 (Figure 3.9).  An LMOD2 band was detected from differentiation day 
3, increasing in levels with differentiation day. An LMOD3 band was detected weakly at 
differentiation day 0, and at higher levels from differentiation day 1. The KLHL40 antibody 
detected three bands in primary human myoblasts. The red arrow denotes the band most likely 
representing KLHL40 (corresponds to the molecular weight of an untagged KLHL40 
expression construct, refer to section 3.2.3), and is detected from differentiation day 3, and 
increasing in levels. Higher (65 kDa) and lower (55kDa) bands were also detected throughout 
differentiation. It is unclear if the higher and lower molecular weight bands are KLHL40 or 
non-specific bands. Uniprot predicts a KLHL40 isoform of 53 kDa which may correspond to 
the 55 kDa band.  
In summary, our collective results suggest expression of LMOD3 precedes that of LMOD2 and 
KLHL40 in differentiating human myoblasts. 
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Figure 3.9: Human KLHL40 mimics LMOD2 expression in differentiating primary 
human myoblasts. Western blot of primary human myoblasts differentiating into myotubes 
from day 0 through to day 8. KLHL40 (red arrow) and LMOD2 are expressed from 
differentiation day 3. LMOD3 is expressed from differentiation day 0. LMOD2 expression 
mirrors that of KLHL40, being expressed at low levels at differentiation day 3 and then 
increasing. LMOD3 expression is seen weakly at differentiation day 0, increasing sharply at 
day 1 LMOD3 levels remain relatively constant from day 1 to day 8.
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KLHL40 expression in fast and slow fibres  
We wanted to further define protein expression of KLHL40 within skeletal muscle to determine 
whether KLHL40 and LMOD3 were present in the same muscle fibres in humans, allowing 
them to interact as suggested by Garg et al. (2014). We determined levels of LMOD3 and 
KLHL40 in fast and slow fibres by single fibre western blot (Figure 3.10). We found LMOD3 
and KLHL40 were expressed in both fast and slow fibres, with slightly higher LMOD3 and 
KLHL40 protein levels in slow fibres.  
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Figure 3.10: KLHL40 and LMOD3 protein levels are slightly higher in slow twitch muscle 
fibres. Western blot of control human single skeletal muscle fibres (Lanes 1-6 – 0.25 µg 
loaded) and whole muscle lysates (Lanes 7-10 – loading amounts indicated). Triplicate blots 
were probed for LMOD3 and KLHL40. Fast myosin and slow myosin were probed for to 
determine fibre type (fast and slow, respectively). Sarcomeric actin was probed for as a loading 
control. Serial dilutions of skeletal muscle lysate indicate 0.25 µg of total protein is within the 
linear range of detection for the LMOD3 and KLHL40 antibodies. KLHL40 and LMOD3 
protein levels are slightly higher in slow twitch muscle fibres (Lanes 1-3). 
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3.2.3 Defining the regulation of LMOD protein levels by KLHL40  
 Reproducing published results with human LMOD3 
The Olsen laboratory (Department of Molecular Biology, University of Texas Southwestern 
Medical Center, Dallas, United States) generously provided us with the panel of mouse Lmod3 
and mouse Klhl40 expression constructs (mLmod3 and mKlhl40 respectively) reported in Garg 
et al. (2014). The Laing laboratory (Centre for Medical Research, The University of Western 
Australia & the Harry Perkins Institute of Medical Research, Perth, WA, Australia) generously 
provided us with the human KLHL40 expression construct (hKLHL40). We performed 
transfection experiments with mLmod3 or human LMOD3 (hLMOD3) expression constructs, 
with and without co-transfection of hKLHL40 or mKlhl40 constructs. We reproduced results 
in transfected Cos-7 cells published by Garg et al. (2014) with both mLmod3 and hLMOD3 
(Figure 3.11). Namely, co-transfection of pcDNA3.1-hLMOD3 or pcDNA3.1-mLmod3MycHis 
with pEGFP-NI-Empty produced scant levels of hLMOD3 or mLmod3 (Lane 7 and 8 
hLMOD3; Lane 13 mLmod3). Co-transfection with mKlhl40 rescued protein levels of 
hLMOD3 and mLmod3 (Lanes 11 and 12 hLMOD3; Lane 15 mLmod3). However, co-
transfection with hKLHL40 in pEGFP-N1 (GFP was not expressed due to the presence of a 
stop codon), did not rescue levels of hLMOD3 or mLmod3 protein (Lanes 9 and 10 hLMOD3, 
Lane 14 mLmod3). Interestingly, when hLMOD3 was expressed within pMT3 with an N-
terminal FLAG tag (pMT3-FLAGhLMOD3) normal levels of hLMOD3 protein were detected 
when co-transfected with pEGFP-NI-Empty (Lanes 1 and 2), hKLHL40 (Lanes 3 and 4) or 
mKLHL40 (Lanes 5 and 6).   
 
 
 
72 
 
 
Figure 3.11: hLMOD3 is stable in the absence of hKLHL40 or mKLHL40 when expressed 
within the pMT3 expression vector. Western blot of Cos-7 cells co-transfected with 
hLMOD3 with an N-terminal FLAG tag in the pMT3 vector (pMT3-FLAGhLMOD3), hLMOD3 
untagged in the pcDNA3.1 vector (pcDNA3.1-hLMOD3.1) or mLmod3 in pcDNA3.1 with C-
terminal MycHis tags with empty pEGFP-NI (pEGFP-NI-Empty), hKLHL40 untagged in the 
pEGFP-NI vector (pEGFP-NI-hKLHL40) or mKlhl40 with C-terminal Myc and His tags in the 
pcDNA3.1 vector (pcDNA3.1-mKlhl40MycHis). pMT3-FLAG-hLMOD3 is detected when co-
transfected with pEGFP-NI-Empty, pEGFP-NI-hKLHL40 or pcDNA3.1-mKlhl40MycHis. 
pcDNA3.1-hLMOD3 and pcDNA3.1-mLmod3MycHis protein is not detected when co-
transfected with pEGFP-NI-Empty, weakly detected when co-transfected with pEGFP-NI-
hKLHL40 and strongly detected when co-transfected with pcDNA3.1-mKlhl40MycHis. 
Duplicate western blots were probed for LMOD3 and KLHL40 with GAPDH probed for as a 
loading control. 
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The ‘necessity’ for Klhl40 disappears in the absence of the pEGFP-NI vector 
Surprisingly, when we carried out a single transfection of pcDNA3.1-hLMOD3, we detected 
normal hLMOD3 protein levels (Figure 3.12, Lane 2), with hLMOD3 protein levels unchanged 
or slightly increasing when treated with MG132 (Lane 3). When pcDNA3.1-hLMOD3 was co-
transfected with pEGFP-NI-Empty, low levels of hLMOD3 protein levels were detected (Lane 
4), with hLMOD3 protein levels increasing slightly with MG132 treatment (Lane 6). These 
results strongly suggest a factor within the pEGFP-NI vector reduces pcDNA3.1-hLMOD3 
protein levels, which is partially rescued by MG132 treatment.  
Despite having a very good antibody to the N-terminus of LMOD3, we did not detect 
breakdown products of mLmod3, nor hLMOD3 with or without MG132, as might be expected 
if mLmod3 or hLMOD3 protein is very rapidly degraded by the proteasome when mKlhl40 or 
hKLHL40 is not present. We also did not observe higher-migrating polyubiquitinated 
mLmod3, or hLMOD3 with or without treatment of MG132. However, we consistently 
observed a lower migrating band of ~65 kDa (similar to the band identified in mouse and 
human tissues in Section 3.2.1), for both hLMOD3 and mLmod3, over many experiments.  This 
lower migrating band will be discussed later in this section.  We now suspect this band 
corresponds to an LMOD3 protein translated via use of an alternate downstream start 
methionine.  
The regulation of mLmod3 and hLMOD3 in cell models may be at the transcription, translation 
or protein surveillance level. It is unlikely to be at the transcription level as: (1) Garg et al. 
(2014) carried-out quantitative PCR and showed mouse Lmod3 mRNA levels did not differ 
between samples where mLmod3 protein was and was not detected; and (2) the expression 
vectors all used a CMV promotor and thus should similarly drive transcription of mLmod3 and 
hLMOD3. Experiments with MG132 did not provide any consistent evidence for proteasomal 
74 
 
surveillance. Therefore, we investigated whether an artefact of transient transfections was 
influencing post-transcriptional regulation of hLMOD3 and complicating result interpretation. 
 
 
 
 
Figure 3.12: The pEGFP-NI vector reduces pcDNA3.1-hLMOD3 protein levels which are 
partially ‘rescued’ by MG132. Western blot of Cos-7 cells treated with MG132 or DMSO 
(vehicle control) and untransfected (UT), transfected with full length hLMOD3 untagged in the 
pcDNA3.1 vector (pcDNA3.1-hLMOD3) or co-transfected with pcDNA3.1-hLMOD3 and 
pEGFP-NI-Empty. As a single transfection, pcDNA3.1-hLMOD3 protein is robustly detected 
at equal levels with and without MG132 treatment. When pcDNA3.1-hLMOD3 is co-
transfected with pEGFP-NI-Empty LMOD3 protein levels are low and are partially ‘rescued’ 
with MG132. GAPDH and β-tubulin were probed for as loading controls. This experiment was 
performed by Adam Bournazos. 
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Proposed double-stranded RNA interference from the pEGFP-NI vector suppressing 
LMOD3 translation 
Reviewing the literature revealed published evidence linking co-transfection of pEGFP-CI 
(same backbone sequence as pEGFP-NI) to double-stranded RNA (dsRNA) interference and 
suppression of translation of transiently transfected (sensitive) cDNAs (Nejepinska, Malik, 
Moravec, & Svoboda, 2012; Nejepinska, Malik, Wagner, & Svoboda, 2014). pEGFP-C1 (and 
N1) are reported to produce dsRNA due to bidirectional transcription of genes within the vector 
backbone. dsRNA activates cellular defence pathways linked to activation of Phosphokinase-
R (PKR), which in turn phosphorylates the eukaryotic initiation factor 2 (eIF2-α), inhibiting 
translation.  
Translational inhibition of transiently transfected genes through dsRNA and PKR has been 
reported previously for numerous genes including chloramphenicol acetyltransferase, 
neomycin phosphotransferase and dihydrofolate reductase (Kalvakolanu, Bandyopadhyay, 
Tiwari, & Sen, 1991; Kaufman, 1997; Kaufman, Davies, Pathak, & Hershey, 1989). 
Importantly, dsRNA induced translational suppression is not observed on endogenous genes, 
or exogenous genes integrated into the genome (Nejepinska, Malik, Filkowski, et al., 2012; 
Nejepinska, Malik, Moravec, et al., 2012; Terenzi et al., 1999). The Kanamycin/neomysin 
resistance cassette within the pEGFP-CI backbone is one source of spurious sense and anti-
sense RNA, which complements to form dsRNA (Nejepinska, Malik, Moravec, et al., 2012; 
Nejepinska et al., 2014).  
It is therefore possible that the vectors used in co-transfection experiments reported in Garg et 
al. (2014) also generated dsRNA and suppressed translation of mLMOD3. To test this, we 
generated empty pcDNA3.1 and pCMV10 vectors and performed co-transfections. Scant levels 
of hLMOD3 protein were detected when pcDNA3.1-hLMOD3 was co-transfected with 
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pcDNA3.1-Empty (Figure 3.13, lane 5) or pCMV10 (-KanR)-Empty (Lane 9) which were 
‘rescued’ with MG132 treatment (Lanes 6 and 10 respectively).  
This suggests co-transfection of empty pEGFP-N1, pcDNA3.1 or pCMV10 activates the 
dsRNA interference response, likely suppressing translation of transiently transfected genes 
sensitive to this interference – resulting in only low levels of translation of hLMOD3. 
 
 
 
Figure 3.13: Low pcDNA3.1-hLMOD3 protein levels are detected when co-transfected 
with pcDNA3.1-Empty or pCMV10 (-KanR). Western blot of Cos-7 cells treated with 
MG132 or DMSO (vehicle control). Cells were left untransfected (UT), singularly transfected 
with hLMOD3 untagged in the pcDNA3.1 vector (pcDNA3.1-hLMOD3) or co-transfected 
with pcDNA3.1-hLMOD3 and pcDNA3.1-Empty, TOPO-Empty (used as a neutral vector) or 
empty pCMV10 with the kanamycin resistance cassette removed (pCMV10(-Kanr)-Empty). 
pcDNA3.1-hLMOD3 protein is readily detected when singularly transfected, or co-transfected 
with TOPO-Empty with no change in hLMOD3 protein levels with MG132 treatment. Low 
levels of hLMOD3 protein are detected when pcDNA3.1-hLMOD3 is co-transfected with 
either pcDNA3.1-Empty or pCMV10(-Kanr)-Empty, with hLMOD3 protein levels returning to 
normal with MG132 treatment. GAPDH and β-tubulin were probed for as loading controls. 
This experiment was performed by Adam Bournazos.  
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pEGFP-NI reduces protein levels of hLMOD2 and hLMOD3 but not hLMOD1 
We asked whether the proposed double-stranded RNA interference from the pEGFP-NI vector 
also suppressed hLMOD1 and hLMOD2 translation, or if this was specific to hLMOD3. 
hLMOD1 protein was readily detected when untagged hLMOD1 in pcDNA3.1 (pcDNA3.1-
hLMOD1) was co-transfected with pEGFP-NI-Empty (Figure 3.14, Lane 1). Whereas, only 
low levels of hLMOD2 protein were detected with co-transfection of untagged hLMOD2 in 
pcDNA3.1 (pcDNA3.1-hLMOD2) and pEGFP-NI-Empty (Lane 4) - hLMOD3 protein was 
virtually undetectable with co-transfection of pcDNA3.1-hLMOD3 with pEGFP-NI-Empty 
(Lane 7). Protein levels of each hLMOD slightly increased when co-transfected with pEGFP-
NI-hKLHL40 (Lanes 2, 5 and 8), and were robust when co-transfected with pcDNA3.1-
mKlhl40MycHis (Lanes 3, 6 and 9). An additional lower molecular weight band was observed 
for hLMOD3 when co-transfected with pcDNA3.1-mKlhl40MycHis (Lane 9), the significance of 
this is unclear. These results suggest that hLMOD2 and hLMOD3, but not hLMOD1, are 
sensitive to the dsRNA interference response elicited by the pEGFP-NI vector, resulting in 
reduced hLMOD2 and hLMOD3 protein levels in the presence of pEGFP-NI.  
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Figure 3.14: pcDNA3.1-hLMOD1 protein is detected and pcDNA3.1-hLMOD2 protein is 
detected weakly when co-transfected with pEGFP-NI-Empty. Western blot of Cos-7 cells 
co-transfected with hLMOD1 untagged in the pcDNA3.1 vector (pcDNA3.1-hLMOD1), 
hLMOD2 untagged in the pcDNA3.1 vector (pcDNA3.1-hLMOD2) or hLMOD3 untagged in 
the pcDNA3.1 vector (pcDNA3.1-hLMOD3) and empty pEGFP-NI (pEGFP-NI-Empty), 
hKLHL40 untagged in the pEGFP-NI vector (pEGFP-NI-hKLHL40) or mKlhl40 with C-
terminal Myc and His tags in the pcDNA3.1 vector (pcDNA3.1-mKlhl40MycHis). pcDNA3.1-
hLMOD1 protein is detected when co-transfected with pEGFP-NI-Empty with levels slightly 
increased with co-transfection of pEGFP-NI-hKLHL40 and levels are higher again with co-
transfection of pcDNA3.1-mKlhl40MycHis. pcDNA3.1-hLMOD2 protein is detected weakly 
when co-transfected with the pEGFP-NI-Empty with levels slightly increased with co-
transfection with pEGFP-NI-hKLHL40 and levels are robust with co-transfection of 
pcDNA3.1-mKlhl40MycHis. pcDNA3.1-hLMOD3 protein is not detected when co-transfected 
with pEGFP-NI-Empty with levels slightly increased when co-transfected with pEGFP-NI-
hKLHL40 and robust when co-transfected with pcDNA3.1-mKlhl40MycHis. Quadruplicate 
western blots were probed for LMOD1, LMOD2, LMOD3 and KLHL40 with β-tubulin and 
GAPDH probed for as a loading controls. This experiment was performed by Adam Bournazos. 
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LMOD3 has signals for poor translation in vivo 
We next wanted to determine why LMOD3 protein levels were susceptible to co-expression 
with pEGFP-NI. There are five main structural features of mRNAs that influence the efficiency 
of translation initiation (reviewed in (Kozak, 1991a, 1991c)): (1) the presence of a 7-
methylguanylate cap; (2) the sequence surrounding the AUG codon, ie. the strength of the 
Kozak sequence; (3) position of the initiating AUG codon; (4) length of the 5’ UTR; and (5) 
secondary structure 5’ and 3’ of the ATG. 
Analysing the sequences of the three LMOD3 mRNA isoforms (refer to Figure 3.3) revealed 
three structural features typical of poor translation: (1) A weak Kozak sequence. The Kozak 
sequence of all LMOD3 isoforms is AAAATAATGT. The absence of a G at position +4 (where 
the A of ATG is +1) weakens the strength of the Kozak sequence of LMOD3 (Kozak, 1997); 
(2) The 5’UTR length of each LMOD3 isoform is beyond the efficient translation range of 17-
80 nucleotides (Kozak, 1991b): LMOD3.1.1 – 155 bp; LMOD3.1.2 – 180 bp; and LMOD3.1.3 
– 184 bp; and (3) All 5’UTRs of the LMOD3 isoforms are predicted to have hairpins within 
the first 12 nucleotides (http://rtools.cbrc.jp/). Hairpins within the first 12 nucleotides of the 
5’UTR stalls translation by interfering with 40s ribosome binding (Kozak, 1989). Thus, in 
silico analyses suggested that LMOD3 mRNA may be subject to inefficient translation.  
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Possible LMOD3 protein translated via use of an alternate downstream start methionine 
During in silico analysis we found a second methionine within LMOD3 at position 39 preceded 
by a strong Kozak sequence. If translation initiated at methionine 39, the predicted molecular 
weight of LMOD3 would decrease by 4.4 kDa. The predicted shift in molecular weight 
corresponds to the lower molecular weight band consistently detected by our LMOD3 
antibody. We made a deletion construct removing amino acids 1-38 (pMT3-hLMOD3∆1-38) 
which ran at approximately the same molecular weight as the consistently detected lower 
molecular weight band (Figure 3.15, red arrow), with protein levels increasing with MG132 
treatment as previously observed. Furthermore, when duplicate blots of pMT3-FLAGhLMOD3 
were probed with an antibody against FLAG one band was observed which matched the upper 
band detected by our LMOD3 antibody (Figure 3.15 Lanes 1 and 2, green asterisks). These 
results suggest: (1) The consistently detected lower molecular weight band is an LMOD3 
protein; and (2) this LMOD3 protein may be produced through the use of an alternate start 
codon.  
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Figure 3.15: Consistently detected lower molecular weight band is LMOD3 and likely the 
result of an alternate start codon. Western blot of Cos-7 cells treated with MG132 or DMSO 
(vehicle control) and transfected with full length hLMOD3 with an N-terminal tag in pMT3 
(pMT3-FLAGhLMOD3) or hLMOD3∆1-38 untagged in pMT3 (pMT3-hLMOD3∆1-38). 
Duplicate membranes were probed with antibodies raised against LMOD3 and FLAG. The 
FLAG antibody detected one band which matched the upper band detected by the LMOD3 
antibody (green asterisks). The pMT3-hLMOD3∆1-38 construct ran at a similar molecular 
weight to the lower band detected by the LMOD3 antibody (red arrow) with protein levels 
slightly increasing with MG132 treatment. GAPDH and β-tubulin were probed for as loading 
controls. This experiment was performed by Adam Bournazos. 
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The influence of the FLAG tag and Kozak sequence of the pMT3 vector on ‘rescuing’ 
proposed inefficient translation of LMOD3  
We hypothesised that if LMOD3 mRNA is translated inefficiently, that the coding sequence of 
LMOD3 present within expression vectors would be susceptible to poor translation signals. We 
observe normal hLMOD3 protein levels when pMT3-FLAGhLMOD3 protein is co-transfected 
with pEGFP-NI-Empty however, pcDNA3.1-hLMOD3 protein is not detected when co-
transfected with pEGFP-NI-Empty (refer to Figure 3.11). This suggests that a component 
within the pMT3 vector, lacking from the pcDNA3.1 vector, is rescuing translational 
suppression of hLMOD3 elicited from the pEGFP-NI vector. 
Upon analysing each vector sequence, we found a weak Kozak in the pcDNA3.1 vector, and a 
strong Kozak sequence preceding the N-terminal FLAG tag in pMT3-FLAGhLMOD3 (Figure 
3.16A). We hypothesised that in the presence of the pEGFP-NI vector: (1) LMOD3 is 
translated inefficiently when in the pcDNA3.1 vector due to a weak translation initiation signal 
(weak Kozak sequence); and (2) LMOD3 is translated efficiently in the pMT3 vector due to a 
strong translation initiation signal (strong Kozak sequence).  
We sub-cloned the Kozak sequence and FLAG tag from the pMT3-FLAGhLMOD3 vector into 
the pcDNA3.1-HumanLMOD3 vector. Protein levels of pcDNA3.1-FLAGKOZAKhLMOD3 and 
pcDNA3.1-hLMOD3 were low when co-transfected with pEGFP-NI-Empty (Figure 3.16B, 
Lanes 1 and 3) and readily detected when co-transfected with pcDNA3.1-MouseKlhl40MycHis 
(Lanes 2 and 4). This suggests the Kozak sequence and FLAG tag from pMT3 are insufficient 
to rescue LMOD3 protein levels. 
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Figure 3.16: A strong Kozak sequence is insufficient to restore LMOD3 protein levels in 
pcDNA3.1 in the presence of pEGFP-NI. (A) Kozak sequence - proposed optimal sequence 
for translation initiation (Kozak, 1987), position +4 indicated with a blue asterisks. Six base 
pairs 5’ and one base pair 3’ flanking the initiating ATG of pMT3-FLAGhLMOD3 and 
pcDNA3.1-hLMOD3. Red letters indicate alterations from the Kozak sequence. pMT3-
FLAGhLMOD3 has a strong Kozak sequence and pcDNA3.1-hLMOD3 has a weak Kozak 
sequence; (B) Western blot of Cos-7 cells co-transfected with hLMOD3 in pcDNA3.1 with the 
Kozak sequence and FLAG epitope tag from pMT3-FLAGhLMOD3 (pcDNA3.1-FLAGKozak-
hLMOD3), LMOD3 in pcDNA3.1 (pcDNA3.1-hLMOD3) or LMOD3 in pMT3 (pMT3-
FLAGKozak-hLMOD3) and empty pEGFP-NI (pEGFP-NI-Empty) or mKlhl40 with C-terminal 
Myc and His tags in pcDNA3.1 (pcDNA3.1-mKlhl40MycHis). LMOD3 in pcDNA3.1 is weakly 
detected when co-transfected with pEGFP-NI-Empty and readily detected when co-transfected 
with pcDNA3.1-mKlhl40MycHis irrespective of the presence of the Kozak sequence and FLAG 
tag from the pMT3 vector. Duplicate western blots were probed for LMOD3 and KLHL40 with 
GAPDH probed for as a loading control. This experiment was performed by Adam Bournazos. 
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The influence of the VA segment within pMT3 on ‘rescuing’ proposed inefficient translation 
of LMOD3.  
The pMT3 vector was generated by modifying the pMT2 vector (Kaufman et al., 1989). The 
pMT2 vector contains an adenoviral VA sequence absent from the pcDNA3.1 vector. The VA 
segment has high sequence homology to the human integrated adenovirus 2 virus associated 
(VA) RNA (Figure 3.17A). VA is a short mRNA, with internal transcriptional control regions, 
involved in supressing translation inhibition resulting from an anti-viral defence (Mathews & 
Shenk, 1991). Adenovirus virus-associated RNAs I and II (VAI and VAII) are used in 
expression vectors to enhance translation of exogenous genes (Kaufman & Murtha, 1987). We 
hypothesised that: (1) The VA sequence within pMT3 rescues the inefficient translation of 
hLMOD3 in the presence of the pEGFP-NI vector; and (2) How VA mRNA acts to enhance 
hLMOD3 translation may be related to the mechanism by which pEGFP-NI inhibits hLMOD3 
translation. 
Translation begins with the initiating Met-tRNA being transferred to the initiating AUG, 
mediated by eIF2-α-GTP (Baird & Wek, 2012). Transfer of Met-tRNA to the initiating 
methionine metabolises eIF2-α-GTP to eIF2-α-GDP. After the transfer of Met-tRNA, eIF2α-
GDP leaves the ribosome complex. The guanosine nucleotide exchange factor (GEF) then 
exchanges GDP with GTP, allowing eIF-2α-GTP to initiate further rounds of translation.  
Phosphorylation of eIF2-α at Ser51 prevents the exchange of GDP with GTP by GEF and 
therefore halts further translation. A very modest increase in p-eIF2-α can have detrimental 
effects on translation of proteins. Phosphorylation of eIF2-α can be carried out by the double-
stranded RNA-activated inhibitor (DAI) also named Phosphokinase R (PKR). DAI is activated 
by binding to double-stranded RNA and has antiviral properties. VA has been shown to inhibit 
DAI (Aparicio, Razquin, Zaratiegui, Narvaiza, & Fortes, 2006). We hypothesised that LMOD3 
translation is inhibited due to high levels of phosphorylated eIF2-α, elicited by dsRNA 
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produced from the pEGFP-NI vector, and VA can overcome translational suppression by 
preventing the phosphorylation of eIF2-α, resulting in robust detection of hLMOD3 (Figure 
3.17B).  
We sub-cloned the VA segment from the pMT3 vector into the TOPO shuttle vector. The 
TOPO vector does not contain a mammalian promotor and therefore VA could only be 
produced from its internal promoter sequences. We carried out co-transfections in Cos-7 cells 
and determined hLMOD3 protein levels by western blot (Figure 3.17C). hLMOD3 protein was 
readily detected when pcDNA3.1-hLMOD3 was co-transfected with pMT3-Empty (Lane 4) 
and at slightly lower levels when co-transfected with the VA element in the TOPO shuttle 
vector (TOPO-VA, Lane 5). This correlated with lower levels of phosphorylated eIF2-α (p-
eIF2-α) when compared to co-transfecting with pEGFP-NI-Empty (Figure 3.17C, Lane 3 and 
Figure 3.17D, red asterisk). These results suggest that the pEGFP-NI vector is increasing levels 
of p-eIF2-α, suppressing translation of hLMOD3 and resulting in reduced hLMOD3 protein 
levels. Further, that phosphorylation of eIF2-α is diminished by the VA segment, but this is not 
sufficient to fully restore hLMOD3 protein levels.    
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Figure 3.17: pcDNA3.1-hLMOD3 protein is readily detected when co-transfected with 
the pMT3-Empty or the VA element within the TOPO vector. (A) Alignment of human 
integrated adenovirus 2 VA RNA (M3596.1) and pMT2 showing high sequence homology; 
(B) Hypothesis schematic of VA inhibiting DAI and in turn allowing the translation of LMOD3 
through un-phosphorylated eIF-2α; (C) Western blot of Cos-7 cells co-transfected as indicated. 
hLMOD3 levels are detected when pcDNA3.1-hLMOD3 is co-transfected with TOPO-VA, 
and slightly higher when co-transfected with pMT3-Empty; (D) Densitometry (ImageJ) of (C). 
Levels of p-eIF2-α are reduced when pcDNA3.1-hLMOD is co-transfected with pMT3-Empty 
or TOPO-VA. Levels of p-eIF2-α are highest when pcDNA3.1-hLMOD3 is co-transfected with 
pEGFP-NI-Empty (red asterisk). This experiment was performed by Adam Bournazos. 
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Overall, our results suggest the data published by Garg et al. (2014) have been mis-interpreted, 
due to:  
1) Sensitivity of Lmod3 translation to the double-stranded RNA response elicited by co-
transfection of certain vector backbones. In particular, pEGFP-N1 has previously been reported 
to evoke a powerful dsRNA response that can silence initiation of translation of sensitive 
transiently co-transfected cDNAs (Nejepinska, Malik, Moravec, et al., 2012; Nejepinska et al., 
2014). Our results suggest this effect is also seen with the vector backbones pcDNA3.1 and 
pCMV10 used in Garg et al. (2014). 
2) The wide-ranging roles of the proteasome and MG132. In addition to protein surveillance, 
the proteasome plays a role in transcription by degrading the inhibitor of the transcription factor 
NF-κβ (Palombella, Rando, Goldberg, & Maniatis, 1994);.  MG132 has been shown to induce 
JNK-dependent apoptosis (Meriin, Gabai, Yaglom, Shifrin, & Sherman, 1998), prevent 
cleavage of β-secretase (Steinhilb, Turner, & Gaut, 2001), suppress global protein synthesis by 
increasing the phosphorylation of eIF2α (Yerlikaya, Kimball, & Stanley, 2008) and reprogram 
translation following cellular stress (Cowan & Morley, 2004). It is possible that MG132 
overcomes the translational suppression of hLMOD3 induced by the dsRNA response. This 
hypothesis required further investigation.  
Overall, our results do not support the hypothesis that KLHL40 is required for the stability of 
LMOD3 by binding to and protecting LMOD3 from ubiquitination and subsequent degradation 
by the proteasome. We propose instead, that LMOD3 coding sequences are sensitive to dsRNA 
pathways that act to suppress initiation of translation. Our experiments are consistent with 
LMOD3 protein not being translated, rather than being ‘unstable’ and proteolytically degraded. 
Whilst caveats of in vitro expression systems abound, our research may have also elucidated 
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pathways relevant to regulation of the LMOD family of proteins in vivo. Namely: LMOD3 
transcripts are subject to multiple layers of translational regulation. 
  
90 
 
3.3 Discussion  
Taken together, our results suggest LMOD3 is tightly regulated at the level of translation. Three 
LMOD3 mRNA isoforms are reported with the same CDS; alternative splicing within the 
5’UTRs and several structural features within the 5’UTRs and CDS are indicative of inefficient 
translation. Each LMOD3 mRNA isoform varies in the length of the 3’UTR, the longer 
transcripts may be regulated by nonsense-mediated decay. We observe reduced hLMOD3 
protein levels when hLMOD3 is co-transfected with the following vectors: pEGFP-NI, 
pcDNA3.1 and pCMV10. Our results are consistent with translational suppression elicited 
from the dsRNA response originating from transiently co-transfected vectors. Our preliminary 
results with hLMOD2 indicate similar regulation at the level of translation, which is not 
observed with hLMOD1. This suggests tight translational regulation is specific to the striated 
muscle LMODs. 
3.3.1 Alternate LMOD isoforms 
We used gencode v12 annotated mRNA transcripts of LMOD1, LMOD2 and LMOD3 from the 
GTEx database to investigate the presence of alternate splice isoforms within the LMODs. 
However, the predicted molecular weight of these isoforms did not correlate well with protein 
bands detected by western blot, using antibodies recognising LMOD1, LMOD2 and LMOD3. 
Additional bands were observed which do not correspond to any of the isoforms within GTEx 
and are of unknown significance, acknowledging that there may be splice isoforms of the 
LMODs other than those annotated in gencode v12. Unfortunately, we did not have access to 
biospecimens from LMOD KO animals to show these bands indeed correspond to LMOD 
isoforms (or breakdown products) to warrant further investigation. Of note, the LMOD proteins 
run ~10 kDa higher than their predicted molecular weight. This may be due to a post-
translational modification, a structural feature, or an influence from the highly acidic regions 
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within LMOD proteins on the stoichiometric binding of SDS. It has been shown previously 
that hairpins can cause a protein to migrate between -10% to +30% of their predicted molecular 
weight on SDS-PAGE (Rath, Glibowicka, Nadeau, Chen, & Deber, 2009) and charge can 
influence the migration of a protein through SDS-PAGE (Shi et al., 2012). 
Regulation of LMOD3 by alternative UTRs 
GTEx detects three mRNA transcripts for LMOD3 with the same CDS, each with a unique 5’ 
UTR, and varying length of the 3’ UTR. Each transcript is reported to be expressed in human 
skeletal muscle and heart, however, the dominant transcript expressed differs between striated 
muscle tissues. The expression of multiple isoforms with different UTRs from a single gene is 
not uncommon, and alternate 5’UTRs often result from alternate promoter use for example, 
nine isoforms with alternate 5’UTRs have been described for neuronal nitric oxide synthase 
(nNOS) and relate to transcriptional initiation in different tissues through alternate promoter 
use (Y. Wang et al., 1999). Tissue-specific transcripts have also been shown to influence 
protein expression by the effect of the 5’UTRs on translation efficiency. For example, Axin-2 
has three mRNA isoforms with alternate 5’UTRs that structurally influence the translation 
efficiency of Axin-2 (Hughes & Brady, 2005). In contrast, varying lengths of 3’UTRs have 
been shown to influence transcript stability. Specifically, long extended 3’UTRs are linked to 
regulation of transcript (and protein) levels via deployment of nonsense mediated decay, as 
shown in immunoglobulin-µ (Buhler, Steiner, Mohn, Paillusson, & Muhlemann, 2006). 
Incorrect expression of alternate UTRs can lead to disease highlighting the functional 
importance of alternative UTRs. For example, MDM2 protein is increased in soft tissue 
tumours (Brown, Mize, Pineda, George, & Morris, 1999), T-cell receptor zeta chain protein is 
reduced in systemic lupus erythematosus (Chowdhury et al., 2005) and BRCA1 protein is 
reduced in breast and ovarian cancer (Sobczak & Krzyzosiak, 2002) due to incorrect alternate 
UTR expression. Alternate LMOD3 transcripts expressed in skeletal muscle and heart may 
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influence the different protein levels observed in these tissues (Yuen et al., 2014), and possibly 
the location of LMOD3. Yuen et al. (2014) observed LMOD3 at the pointed ends as well as 
along the thin filament. 
Alternate start AUG used in LMOD 
Reproducible recognition of a band migrating at ~65 kDa with antibodies probing for LMOD1, 
LMOD2 and LMOD3 was observed on western blot of tissues and cells. We also observed a 
second band with mLmod3 and hLMOD3 expression constructs, running ~5 kDa lower than 
the dominant mLmod3 and hLMOD species on western blot. Analysis of the LMOD3 sequence 
showed the presence of a methionine at position 39 with a strong Kozak sequence. Use of the 
methionine at position 39 as the initiating methionine is predicted to form a protein ~5 kDa 
smaller than full length LMOD3, correlating to the bands observed on western blot. 
Importantly, this band is absent when probed with an antibody against the N-terminal epitope 
tag. This raises the possibility that the western blot band detected by the LMOD antibodies 
migrating at ~65 kDa is the result of alternate start codon use within the LMODs.  
Initiation at the first and second AUGs of eukaryotic genes has been described previously 
within the same reading frame, generating two functionally similar protein products (Makela, 
Saksela, & Alitalo, 1989; Soldati, Schafer, & Perriard, 1990). Interestingly, use of two AUGs 
generating two protein products that are functionally distinct are predominately found in 
viruses (Kozak, 1991a). The use of an alternate AUG in the above cases is due to an 
unfavourable Kozak sequence surrounding the first AUG. This leads to the first AUG being 
occasionally skipped, and the translational machinery reading the second AUG as the initiation 
codon. The first AUG of LMOD3 is surrounded by an unfavourable Kozak sequence with the 
second AUG surrounded by a favourable Kozak. This supports the hypothesis that the first 
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AUG within LMOD3 is occasionally skipped, and the second AUG is used for translation 
initiation. 
An LMOD protein lacking amino acids 1-38 effectively disrupts the N-terminal tropomyosin 
binding domain, shown to encompass residues 27-38 of LMOD2 (Chereau et al., 2008) and 
29-40 of LMOD3 (Yuen et al., 2014). The tropomyosin binding domain of LMOD2 has been 
shown to be important for its nucleation activity and localisation to the pointed ends of the thin 
filament (Ly et al., 2016; Skwarek-Maruszewska et al., 2010). Therefore, an LMOD3 protein 
with a loss of, or disruption to, tropomyosin binding would likely confer a different role. Of 
note, inhibiting the proteasome with MG132 increases detection of the ~65 kDa band more so 
than the canonical ~70 kDa band. This suggests a susceptibility of the ~65 kDa protein to 
proteasomal degradation.  
Several factors of genomic LMOD3 DNA show features consistent with poor translation – a 
weak Kozak sequence, long 5’UTR and strongly predicted secondary structure within the 
5’UTR. A 5’UTR burdened with secondary structure is common in cytoskeletal genes, and is 
proposed that poor translation is a requirement for regulation of these proteins (Kozak, 1991a). 
While further experiments are required to confirm if LMOD3 uses the second AUG as an 
initiating codon, we speculate it would be a secondary effect of poor translation used in 
LMOD3 protein regulation.  
3.3.2 Regulation of LMOD translation by dsRNA  
Caveats associated with transient transfection of expression vectors  
Transient transfections are a common molecular biology tool, though, as with all experimental 
approaches, holds potential artefacts originating from the expression vector (Nejepinska, 
Malik, Moravec, et al., 2012). Many backbones of expression vectors commonly used today 
were generated decades ago, when the current technologies did not permit detailed 
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investigations of the plasmids (Chalfie, Tu, Euskirchen, Ward, & Prasher, 1994; de Wet, Wood, 
DeLuca, Helinski, & Subramani, 1987; Lorenz et al., 1996). Peer-reviewed studies of vector 
artefact are decades old and infrequently cited, making them difficult to source (Farr & Roman, 
1992; Sorscher & Cordeiro-Stone, 1994). Collective analysis of our research data and the 
published literature support translation of hLMOD2 and hLMOD3 (but not hLMOD1) is 
strongly silenced by the double-stranded RNA cellular defence mechanism. Our study 
illuminates the layers of complexity arising from transient co-transfection artefact, and 
highlights the necessity of stringent vector controls in transient co-transfection assays.  
Proposed regulation of LMOD by dsRNA in vivo.  
It has been reported previously that specific cDNA sequences are more sensitive to vector 
artefact if the process is already occurring in vivo for example, transcripts containing a 
premature stop codon (inducing nonsense-mediated decay (NMD)) expressed within the 
pIREShyg2 vector are sensitised to NMD induced by structural features within the vector 
(Shikama et al., 2010). This raises the possibility that LMOD2 and LMOD3 coding sequences 
are more sensitive to the dsRNA response in vitro due to natural regulation of expression of 
LMOD2 and LMOD3 by dsRNA in vivo. Hairpins are evident within the UTRs and CDS of 
LMOD2 and LMOD3. The hairpins within LMOD2 and LMOD3 transcripts are a source of 
dsRNA. While translational suppression from the cellular response to dsRNA (generated from 
a plasmid) is specific to exogenous genes (Nejepinska, Malik, Moravec, et al., 2012; 
Nejepinska et al., 2014; Terenzi et al., 1999), translational suppression of genes within genomic 
DNA by dsRNA is observed during a viral attack (reviewed in (Mathews & Shenk, 1991)). We 
therefore speculate that the dsRNA generated by LMOD2 and LMOD3 may be used to regulate 
the translation of LMOD2 and LMOD3 in vivo. 
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3.3.3 Regulation of the Lmod3 and LMOD3 by kelch-like proteins 
Alternate interpretation of Garg et al. (2014) 
We show that pcDNA3.1-hLMOD3 protein levels are low when co-transfected with pEGFP-
NI-Empty, pcDNA3.1-Empty or pCMV10(-KanR)-Empty compared to a single transfection or 
co-transfection with TOPO-Empty. We hypothesise that the pEGFP-NI, pcDNA3.1 and 
pCMV10 vectors generate dsRNA that supresses translation of mLmod3 and hLMOD3. The 
source of dsRNA from the pEGFP-NI vector has been linked previously to the kanamycin 
resistance cassette (Nejepinska, Malik, Moravec, et al., 2012; Nejepinska et al., 2014). 
However, we removed this cassette within the pCMV10 vector in our control ‘empty vector’ 
experiments. We therefore hypothesise that the source of the dsRNA from the pcDNA3.1 and 
pCMV10 vectors is the SV40 promoter sequence, present in both vectors, and shown 
previously to be a source of spurious RNA transcription (Nejepinska, Malik, Moravec, et al., 
2012).  
As previously published, we also observe increased pcDNA3.1-hLMOD3 protein levels when 
co-transfected with a kelch protein (mKlhl40 or hKLHL40) expressed within pEGFP-NI or 
pcDNA3.1. We speculate that the presence of a gene within these vectors reduces the amount 
of spurious dsRNA produced (and therefore, a reduction on translational suppression), due to 
the transcriptional machinery ‘focusing’ on the inserted gene.  
Garg et al. (2014) generated a Klhl40 KO mouse and showed Lmod3 protein levels were 
reduced 3-fold at postnatal day 1. This demonstrates that while Lmod3 protein levels are 
reduced, Lmod3 is detectable by western blot in the absence of Klhl40. At postnatal day 8, 
Lmod3 protein levels were reduced ten-fold, suggesting the levels of Lmod3 protein in the 
Klhl40 KO mouse reduces over time. Cenik et al. (2015) showed LMOD3 and KLHL40 
promote activity of the transcription factors MRTF/SRF which in turn coactivate the 
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transcription of cytoskeletal proteins, including LMOD3 and KLHL40. Their work 
demonstrated that LMOD3 alone was not sufficient to activate MRTF/SRF however, KLHL40 
alone was sufficient, and MRTF/SRF activity was enhanced with the addition of LMOD3. An 
alternate explanation to reduced levels of Lmod3 protein over time in the Klhl40 KO mouse, 
and in human KLHL40-NM samples, is the loss of a player in the feedforward loop. Over time, 
loss of Klhl40 would reduce the transcription of Lmod3, as well as other cytoskeletal proteins. 
Reduced Lmod3 protein would reduce actin filament polymerisation, therefore increasing the 
amount of actin monomers in the cytoplasm. Actin monomers sequester MRTF in the 
cytoplasm, preventing activation of MRTF/SRF dependent genes, including Lmod3 (Cenik et 
al., 2015). Therefore, a reduction in Lmod3 protein would indirectly reduce the transcription 
of Lmod3 further. This would result in Lmod3 protein in the Klhl40 KO mouse at a very young 
age, but reduced Lmod3 protein levels over time. This may also explain why KLHL40-NM 
patients who express some KLHL40 protein have normal levels of LMOD3 protein. 
Collectively, our data and published work suggest the mechanism of KLHL40-NM would not 
be targeted with proteasome-inhibitors. Instead, we support the therapeutic target proposed by 
Cenik et al. (2015) of enhancing the MRTF/SRF pathway to treat KLHL40-NM, LMOD3-NM 
and possibly other types of nemaline myopathy caused by disease genes regulated by the 
MRTF/SRF pathway. 
Proposed role of KLHL40 in LMOD3 ubiquitination and localisation 
Many members of the kelch family are substrate adaptor proteins for the E3 ligase Cul3, 
mediating monoubiquitination (Beck et al., 2013; Jin et al., 2012; Werner et al., 2015) or 
polyubiquitination of specific substrates (Kasahara et al., 2014; Yanagiya et al., 2012), and in 
some cases autoubiquitination of the Kelch adaptor protein itself (Lin et al., 2016; Zhang et al., 
2005). Our data strongly suggests KLHL40 does not protect LMOD3 from ubiquitination and 
subsequent degradation by the proteasome. However, due to the large number of kelch proteins 
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characterised as mediating the ubiquitination of the substrates they bind, it is highly likely that 
KLHL40 ubiquitinates LMOD3. Cul3-Kelch mediated ubiquitination results in various 
outcomes for the ubiquitinated protein inclusive of localisation, degradation and protein 
interactions (Beck et al., 2013; Kasahara et al., 2014; Werner et al., 2015). While the most 
common lysine linking Ub in a polyubiquitin chain is Lys48, targeting a protein for Ub-
mediated proteasome degradation (Pickart & Fushman, 2004), Cul3-kelch has been shown to 
link Ub through alternative lysines. For example, Cul3-KLHL20 polyubiquitinates Coronin 7, 
linking Ub through Lys33 and targeting Coronin 7 to the trans-golgi network (Yuan et al., 
2014).  
We propose KLHL40 mono- or polyubiquitinates LMOD3 where Ub is linked through a lysine 
other than Lys48 – most likely resulting in a different fate for LMOD3 than Ub-mediated 
proteasome degradation (Pickart & Fushman, 2004). Monoubiquitination or the lysine linking 
polyubiquitin is correlated with the fate of the ubiquitinated protein and the cellular process it 
is involved in, which may lend insight into how KLHL40 regulates LMOD3. Alternatively, we 
suggest, if LMOD3 is polyubiquitinated through Lys48 that this will not target LMOD3 to the 
proteasome for degradation, but result in a proteolysis-independent fate for LMOD3. This has 
been shown previously with the transcription factor Met4 (Flick et al., 2004). One approach to 
determine if KLHL40 ubiquitinates LMOD3, the number of ubiquitins and through which 
lysine they are linked would be mass spectrometry. We speculate that ubiquitination of 
LMOD3 targets LMOD3 to the pointed ends of the thin filament, influencing actin 
polymerisation and the MERF/SRF pathway.  
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3.3.4 Conclusions and Future directions 
Additional LMOD protein products 
Our work suggests LMOD mRNA isoforms detected on the GTEx database are not translated 
into protein, and instead represent regulation of LMOD at the level of translation. Preliminary 
results suggest the LMODs may use an additional start AUG and this is likely a secondary 
effect of poor translation of the LMODs in vivo. Additional bands were observed on western 
blot which do not correspond to any of the predicted mRNAs investigated and are of unknown 
significance. An important next step is to use tissues from Lmod1, Lmod2 and Lmod3 KO mice 
as controls to determine if this lower molecular weight band are also absent, providing further 
evidence they represent LMOD proteins. If these bands are specific to the LMODs it will be 
important to investigate their origin and if they perform distinct functions, inclusive of 
regulatory roles, within the cell.  
Translational suppression of LMOD2 and LMOD3 by dsRNA generated by vector backbones 
Our results strongly suggest that translation of hLMOD3 in co-transfection models is 
suppressed due to the dsRNA response elicited by the pEGFP-NI vector. It will be important 
to determine whether dsRNA mechanisms regulate levels of LMOD2 and LMOD3 in vivo. 
We also show reduced hLMOD3 protein levels in the presence of pcDNA3.1 and pCMV10 
vectors and hypothesis that this originates from spurious dsRNA from these vectors. Garg et 
al. (2014) used the pcDNA3.1 and pCMV10 vectors to conclude mKlhl40 binds to and protects 
mLmod3 from Ub-mediated proteasome degradation. It will be important to determine if these 
vectors also generate dsRNA leading to translational suppression of mLmod3. A sign of 
dsRNA editing is the presence of A/G conversions (Nejepinska, Malik, Filkowski, et al., 2012). 
Therefore, analysing pcDNA3.1 and pCMV10 sequences for A/G conversions should flag if 
any regions generating dsRNA and warrant further investigation. It is also plausible that the 
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discrepancies between results presented in Garg et al. (2014) and our results are due to 
differences between mouse and human orthologues. It will be important to determine which of 
the two hypotheses are true to: (1) Elucidate the functional consequences of interaction between 
mKlhl40 and mLmod3; and (2) to understand the differences between mLmod3 & mKlhl40 
and the human paralogues.  
To determine if each of the pEGFP-NI, pcDNA3.1 and pCMV10 vectors influence hLMOD3 
and mLmod3 protein levels through dsRNA mediated translational suppression several 
approaches should be taken. Co-transfections of hLMOD3 or mLmod3 with serial dilutions of 
each vector complemented with a ‘neutral’ vector (does not elicit an artefact on transiently co-
transfected genes, to normalise for transfected DNA concentrations) should be used to confirm 
the involvement of each vector in hLMOD3 and mLmod3 protein levels. This should also be 
carried out with a three-way co-transfection of hLMOD3 or mLmod3, empty vector and serial 
dilutions of hKLHL40 or mKlhl40 to determine if this kelch protein is involved in rescuing 
hLMOD3 and/or mLmod3 from translational suppression. To determine if hLMOD3 and 
mLmod3 are influenced by dsRNA co-transfections should be carried out with vectors 
designed to generate dsRNA (antisense/sense DNA sequences). Lastly, to determine if PKR 
and eIF2-α are the mechanism by which hLMOD3 and mKlhl40 translation is suppressed, 
rescue of hLMOD3 and mLmod3 protein detection should be tested by: (1) treating co-
transfected cells with 2-aminopurine, an inhibitor of PKR phosphorylation (Farrell, Balkow, 
Hunt, Jackson, & Trachsel, 1977); (2) serial dilutions of TOPO-VA; and (3) serial dilutions of 
a mutant eIF2-α (serine to alanine) construct that cannot be phosphorylated (Kaufman et al., 
1989). 
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Chapter 4 - PYROXD1: A novel, previously unstudied early-onset 
myopathy gene - essential for life and a key to unlock how 
oxidative distress impacts muscle pathology. 
Prologue  
As part of the INMR translational genomics program, we identified variants within the 
oxidoreductase PYROXD1 as a new genetic cause of early-onset myopathy. This was a large 
inter-disciplinary collaboration providing the first characterisation of PYROXD1-myopathy, 
and establishes oxidative distress as a primary mechanistic pathway in the myopathies. I hold 
joint first author in this published work, presented in Part A. Part A functions as the introduction 
to this chapter. 
My contribution to this article was in the genetic and molecular functional studies of 
PYROXD1 in healthy and diseased states. PYROXD1 had not been previously characterised, 
therefore, a large part of this work involved establishing tools in our lab to study PYROXD1. 
During this process we uncovered cellular, molecular and biochemical properties of 
PYROXD1 that were vital to enable the characterisation of PYROXD1 and PYROXD1-
myopathy, but were not included in our publication. These studies are presented as Part B of 
this chapter. 
To further investigate the role of PYROXD1 in fundamental biology and disease we established 
two mouse models. These studies are presented in Part C of this chapter.  
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4.1 Part A: PAPER - Variants in the oxidoreductase PYROXD1 
cause early-onset myopathy with internalized nuclei and 
myofibrillar disorganisation  
ARTICLE
Variants in the Oxidoreductase PYROXD1 Cause
Early-Onset Myopathy with Internalized Nuclei
and Myofibrillar Disorganization
Gina L. O’Grady,1,2,3,25 Heather A. Best,1,2,25 Tamar E. Sztal,4,25 Vanessa Schartner,5,26
Myriam Sanjuan-Vazquez,6,26 Sandra Donkervoort,7,26 Osorio Abath Neto,5 Roger Bryan Sutton,8
Biljana Ilkovski,1 Norma Beatriz Romero,9,10 Tanya Stojkovic,10 Jahannaz Dastgir,7 Leigh B. Waddell,1
Anne Boland,11 Ying Hu,7 Caitlin Williams,4 Avnika A. Ruparelia,4 Thierry Maisonobe,10
Anthony J. Peduto,12 Stephen W. Reddel,13 Monkol Lek,14,15 Taru Tukiainen,14,15
Beryl B. Cummings,14,15 Himanshu Joshi,1 Juliette Nectoux,16,17 Susan Brammah,18
Jean-Franc¸ois Deleuze,11 Viola Oorschot Ing,19 Georg Ramm,19,20 Didem Ardicli,21 Kristen J. Nowak,22
Beril Talim,21 Haluk Topaloglu,21 Nigel G. Laing,22 Kathryn N. North,1,23 Daniel G. MacArthur,14,15
Sylvie Friant,6 Nigel F. Clarke,1,2 Robert J. Bryson-Richardson,4 Carsten G. Bo¨nnemann,7
Jocelyn Laporte,5,24,27 and Sandra T. Cooper1,2,27,*
This study establishes PYROXD1 variants as a cause of early-onset myopathy and uses biospecimens and cell lines, yeast, and zebrafish
models to elucidate the fundamental role of PYROXD1 in skeletal muscle. Exome sequencing identified recessive variants in PYROXD1 in
nine probands from five families. Affected individuals presented in infancy or childhood with slowly progressive proximal and distal
weakness, facial weakness, nasal speech, swallowing difficulties, and normal to moderately elevated creatine kinase. Distinctive histo-
pathology showed abundant internalized nuclei, myofibrillar disorganization, desmin-positive inclusions, and thickened Z-bands.
PYROXD1 is a nuclear-cytoplasmic pyridine nucleotide-disulphide reductase (PNDR). PNDRs are flavoproteins (FAD-binding) and cata-
lyze pyridine-nucleotide-dependent (NAD/NADH) reduction of thiol residues in other proteins. Complementation experiments in yeast
lacking glutathione reductase glr1 show that human PYROXD1 has reductase activity that is strongly impaired by the disease-associated
missense mutations. Immunolocalization studies in humanmuscle and zebrafishmyofibers demonstrate that PYROXD1 localizes to the
nucleus and to striated sarcomeric compartments. Zebrafishwith ryroxD1 knock-down recapitulate features of PYROXD1myopathywith
sarcomeric disorganization, myofibrillar aggregates, and marked swimming defect. We characterize variants in the oxidoreductase
PYROXD1 as a cause of early-onset myopathy with distinctive histopathology and introduce altered redox regulation as a primary cause
of congenital muscle disease.Introduction
Myopathies are a group of genetically heterogeneous con-
ditions characterized by muscle weakness, with overlap in
the clinical presentation and histopathological features of
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nia and weakness, often from birth, commonly with the
presence of facial weakness, with or without ptosis and
ophthalmoplegia. There are 25 recognized genetic causes
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currently a genetic diagnosis is achieved in only ~50% ofldren’s Hospital at Westmead, Sydney, NSW 2145, Australia; 2Discipline of
ey, NSW 2006, Australia; 3Paediatric Neurology Service, Starship Children’s
niversity, Melbourne, VIC 3800, Australia; 5Institut de Ge´ne´tique et de Bio-
of Molecular and Cellular Genetics, UMR7156, Universite´ de Strasbourg,
and Stroke Neurogenetics Branch, Neuromuscular and Neurogenetic Disor-
t of Cell Physiology and Molecular Biophysics, and Center for Membrane
TX 79430, USA; 9Sorbonne Universite´s, UPMC Univ Paris 06, INSERM
ie`re, 47 Boulevard de l’hoˆpital, 75013 Paris, France; 10Centre de Re´fe´rence
peˆtrie`re, Assistance Publique-Hoˆpitaux de Paris, 7503 Paris, France; 11Centre
France; 12Department of Radiology, Westmead Hospital, Western Clinical
Neurology, Concord Clinical School, University of Sydney, Sydney, NSW
eneral Hospital, Boston, MA 02114, USA; 15Broad Institute of Harvard and
ice de Biochimie et Ge´ne´tique Mole´culaire, HUPC Hoˆpital Cochin, Paris
e´ Paris Descartes, Paris 75014, France; 18Electron Microscope Unit, Concord
d Vera Ramaciotti Centre for Structural Cryo-Electron Microscopy, Monash
d Molecular Biology, Monash University, Melbourne, VIC 3800, Australia;
al, 06100 Ankara, Turkey; 22Centre for Medical Research, The University of
6009, Australia; 23Murdoch Children’s Research Institute, The Royal Chil-
de Strasbourg, 67081 Illkirch, France
mber 3, 2016
patients,2,3 driving ongoing gene discovery. The introduc-
tion of next-generation sequencing technologies has seen
a rapid acceleration in the identification of new genetic
causes of neuromuscular disorders.4,5
Through international whole-exome sequencing pro-
grams in Australia, France, the United States, and Turkey,
we identified five families (nine probands) with four
different recessive variants (missense and splicing variants)
in PYROXD1. PYROXD1 is located at 12p12.1 and encodes
pyridine nucleotide-disulfide oxidoreductase domain-con-
taining protein 1, a 500 amino acid protein previously
undescribed in published literature. Pyridine nucleotide-
disulphide reductases (PNDRs) are flavoproteins (FAD-
binding) and catalyze the pyridine nucleotide (NAD/
NADH)-dependent reduction of cysteine residues in their
substrates.6 PNDRs catalyze complex reduction reactions
and use several steps of electron transfer via their
enzymatic co-factors FAD and NAD. Although func-
tionally uncharacterized, PYROXD1 is classified as a class
1 oxidoreductase and bears two putative enzymatic do-
mains: a pyridine nucleotide-disulphide oxidoreductase
domain (amino acids 39–361) and a NADH-dependent
nitrite reductase domain (amino acids 447–494) (see
Figure 3).
Herein we establish PYROXD1 as a nuclear-cytoplasmic
oxidoreductase that underlies an early-onset myopathy
characterized by generalized weakness with multiple inter-
nalized nuclei and myofibrillar aggregates on biopsy.Subjects and Methods
Genetic Analysis
Family A was the index family identified through whole-exome
sequencing of a large cohort of undiagnosed myopathy and dys-
trophy patients (367 individuals from 193 families) recruited
from The Institute for Neuroscience andMuscle Research (Sydney,
Australia). No further families were identified in this cohort with
PYROXD1-related disease. Exome sequencing was performed on
gDNA from both brothers and their unaffected parents at the
Broad Institute using the XBrowse bioinformatics platform as
described previously.7 Family B was identified through the French
Myocapture project (1,000 exomes from 397 families with myop-
athies or dystrophies). Exome sequencing was performed for
both affected brothers and their parents at Centre National de
Ge´notypage (CNG, Evry, France). Common variants (>1%) found
in dbSNP, 1000 Genomes, Exome Variant Server, and an inter-
nal database of 1,550 exomes including ethnically matched
individuals were filtered out. The Varank pipeline was used for var-
iants scoring and ranking.8 Data were filtered for homozygous
recessive variants based on the known consanguinity of the
family. Family B was the only family identified with recessive
PYROXD1 variants in theMyocapture cohort. For family C, exome
sequencing was performed through the NIH Intramural
Sequencing Center (NISC) on genomic DNA obtained from both
affected siblings. Data were analyzed using a custom analysis pro-
gram, MPG (Most Probable Genotype) based on a probabilistic
Bayesian algorithm.9 For families D and E, exome sequencing
was performed on gDNA from both siblings and unaffected par-The American Jouents at the Theragen Etex Bio Institute. ANNOVAR was used to
functionally annotate genetic variants.10 Table S1 provides a list
of recessive variants shown to segregate with disease for each
family.
Phylogenetic Analysis and Calculation of the
PYROXD1 Homology Model
PYROXD1sequence alignmentswere performedusingCLUSTAL.11
Identity and similarity were calculated using Sequence Manipula-
tion Suite.12,13 Modeler14 was used to compare the primary
sequence of PYROXD1 with homologous proteins in the PDB
database. The primary sequence of PYROXD1 was aligned with
eight of the most similar protein sequences determined from
Modeler using Promals3D:15 Shewanella PV-4 NADH-dependent
persulfide reductase (PDB: 3NTD), Staphylococcus Coenzyme A-di-
sulfide reductase (PDB: 1YQZ), Bacillus Coenzyme A-disulfide
reductase (PDB: 3CGC), Novosphingobium ferredoxin reductase
(PDB: 3LXD), Rhodopseudomonas ferredoxin reductase (PDB:
3FG2), Pseudomonas p. putidaredoxin reductase (PDB: 1Q1R), Pseu-
domonas sp. ferredoxin reductase (PDB: 2GQW), and Enterococcus
NADH peroxidase (PDB: 1NHQ). Modeler was used to compute
the homology model of human PYROXD1 using information
from all eight homologous crystal structures. The resulting model
with the lowest energy was further refined using Modrefiner.16
FAD binding residues were determined via the 3DLigandSite
server.17 Figureswere generatedwithPymol (ThePyMOLMolecular
Graphics System, v.1.8, Schro¨dinger, LLC).
Western Blot
Western blot of skeletal muscle and skin fibroblasts was carried
out as described in Yuen et al.18 Primary antibodies used were
anti-PYROXD1 (1:1,000; Abcam cat# ab122458; RRID: AB_
11129858), b-tubulin (1:1,000; E7, Developmental Studies Hybrid-
oma bank), GAPDH (1:10,000; Millipore cat# MAB374; RRID:
AB_2107445), Emerin (NCL 1:300, Novocastra), and sarcomeric
alpha-actinin (EA-53 1:2,500, Sigma-Aldrich). For zebrafish, em-
bryos were deyolked and protein extracted as described.19 13 mL
of protein sample was reduced using NuPAGE Reducing Agent
(Thermo Fisher) and equal amounts loaded onto a NuPAGE
4%–12% Bis-Tris Gel using MES SDS running buffer (Thermo
Fisher). Membranes were blocked and probed with antibodies
diluted in 13 phosphate-buffered saline, 0.1% Tween20 (Sigma-
Aldrich), and 5% skim milk. Primary antibodies used were
1:1,000 anti-Ryroxd1-C (Abmart), 1:1,000 anti-GFP (Abcam cat#
ab137827), and 1:2,000 a-tubulin (Sigma-Aldrich cat# T6074;
RRID: AB_477582). The secondary antibody used was 1:10,000
HRP-conjugated mouse IgG (Southern Biotech) and developed
using chemiluminescent detection (GE Life Sciences). For yeast,
total yeast extracts were obtained by NaOH lysis followed by
TCA precipitation. The equivalent of 1.5 OD600nm unit of yeast
cells were resuspended in 50 mL of 23 Laemmli buffer plus Tris
Base. Samples were incubated 5 min at 37C and analyzed by
10% SDS-PAGE followed by immunoblotting with anti-PYROXD1
(1:500), polyclonal R3500 produced in rabbit with human
PYROXD1 immunogen amino acid 488–500 (Cys Leu Leu Asp
Pro Asn Ile Asp Ile Glu Asp Tyr Phe Asp). Images were acquired
with the ChemiDoc Touch Imaging System (Bio-Rad).
Immunostaining and Microscopy
For skeletal muscle, 8 mm muscle cryosections were fixed in 3%
paraformaldehyde for 15 min, extracted with cold methanol forrnal of Human Genetics 99, 1086–1105, November 3, 2016 1087
10 min, and probed with primary antibodies diluted in 2% BSA/
PBS for 16 hr at 4C: PYROXD1 (1:50; Abcam cat# ab122458 or
ab204560; RRID: AB_11129858), desmin (1:50; NCL-Des, Nova-
castra), myosin (1:20; RS034, Novacastra), and lamin A/C (1:80;
NCL-LAM-A/C, Novacastra). After washing in PBS, samples were
incubated with secondary antibody for 1 hr at room temperature,
washed, and mounted with ProLong Gold with DAPI antifade
reagent (Life Technologies). Goat anti-rabbit IgGAlexa555 goat
anti-mouse IgGAlexa488 (HþL) (1:200, A21428 and A110018, Life
Technologies). Specimens were imaged on a Leica SP5 confocal
microscope. For zebrafish, 4% paraformaldehyde (PFA)-fixed
2 dpf whole-mount or 4 dpf whole-mount and vibratome-
sectioned embryos were stained as described.19 Antibodies used
were a-actinin2 (Sigma clone A7811, 1:100) and an AlexaFluor-
labeled-488 secondary antibody (Molecular Probes, 1:200) and
rhodamine-Phalloidin (Molecular Probes, 1:200). Imaging was
performed with an LSM 710 confocal microscope (Zeiss), using a
203 1.0 numerical aperture water-dipping objective.
For yeast, living cells expressing EGFP C-terminal-tagged
PYROXD1, PYROXD1-Asn155Ser, or -Gln372His were imaged on
a fluorescence Axio Observer D1 microscope (Zeiss) using GFP fil-
ter and DIC optics with 1003/1.45 oil objective (Zeiss). Images
were captured with a CoolSnap HQ2 photometrix camera (Roper
Scientific).Cell Culture, Constructs, cDNA Synthesis, and
Transfections
HEK293 cells were cultured and transfected as described.20 Cos-7
cells and primary human fibroblasts were cultured in DMEM/
F12 with 10% FBS and 1:200 gentamycin (all from Life
Technologies). Cos7 cells were transfected with Lipofect-
amine LTX (15338-100, Life Technologies) as per the manufac-
turer’s instructions in 10 cm2 dishes. Human PYROXD1 cDNA
(GenBank: NM_024854) was cloned into pEGFP-CI (Genscript)
via BspE1/Sal1. GFP was then removed via AgeI/BspEI. RNA
extraction of primary human fibroblasts was carried out using
TRIzol (Invitrogen) and alcohol precipitation. cDNA was synthe-
sized using random primers p(dn)6 (Roche 11043921) or
Oligo(dt)20 primers (Invitrogen 55063) and Superscript III reverse
transcriptase (Invitrogen 56575) according to the manufacturer’s
instructions. Primers used for PCR of PYROXD1 cDNA were
exon 1 F: 50-AGGGAAGTTCGTGGTGGTC-30; exon 6 R: 50-TGGCC
CAAATCACTTCACAG-30; exon 12 R: 50-AGGACGAGAATACAT
CAAAGTCG-30.Plasmids, Strains, Media, and Methods for Yeast Cells
The PYROXD1 andmissensemutants p.Asn155Ser or p.Gln372His
cDNA sequences were cloned into pDONR221 entry vector
(Invitrogen) and then into yeast destination vectors (Addgene)
via the Gateway (Invitrogen) method to obtain the pAG415-
promGPD-PYROXD1, p.Asn155Ser or p.Gln372His (pSF371 to
pSF373) and pAG415-promGPD-PYROXD1-EGFP, p.Asn155Ser or
p.Gln372His (pSF374 to pSF376) plasmids. Plasmid sequences
were verified (GATC Biotech). S. cerevisiae strains used were
BY4742 WT (MATa leu2D0 ura3D0 his3D0 lys2D0) and glr1D
(BY4742 glr1:kanMX). Yeast were grown in YPD-rich medium
(1%yeast extract, 2%peptone, 2%glucose) or in SyntheticMedium
(SD): 0.67% yeast nitrogen base (YNB) without amino acids,
2% glucose, and the appropriate –Leu dropout mix to maintain
the plasmid. Yeast cells were transformed using the modified
lithium acetate method.211088 The American Journal of Human Genetics 99, 1086–1105, NoveZebrafish
Production of Transgenic Constructs, Morpholino Injections, and RNA
Rescue Experiments
Zebrafish were maintained according to standard protocols.22
Transgenic constructs were assembled with the modular tol2 kit.
N-terminal eGFP-tagged wild-type or mutant PYROXD1 con-
structs were created using p5E-actc1b,23 p5E-SP6-CMV,24 p3E-pA,
and pDEST-Tol2-pA2. Transgenic constructs used were actc1b-
h2afv-mCherry24 and actc1b-actinin3-mCherry.25 For morpho-
lino injections, ryroxd1 morpholinos (splice MO: 50-TCGATGG
TTTCTTACCTGTTCTGCA-30, 0.25 mM and ATG MO: 50-CCATT
GAACTTCAGCACATGGAGAT-30, 0.25 mM) and GFP morpholino
(50-GTTCTTCTCCTTTACTCAGGATC-30, 0.5 mM) were diluted in
distilled water and co-injected with Cascade Blue-labeled dextran
(Molecular Probes) into one-cell embryos. For RNA rescue experi-
ments, wild-type PYROXD1-eGFP RNA, lacking the morpholino
binding site, was synthesized using the mMessage mMachine
SP6 Transcription Kit (Ambion). RNA was co-injected at a concen-
tration of either 0.5 or 1 ng/mL into one-cell stage embryos with
Cascade Blue. Injected embryos were sorted for Cascade Blue label-
ing prior to analysis.
In Situ Hybridization
Whole-mount in situ hybridization was carried out as described
previously.26 Probes were constructed using specific gene primers
(F: 50-AGAAACCGAAGATGGTCAGAGA-30 and R: 50-GAGCGAA
GACGCTTCTCTTCTA-30). Imaging was performed with an
Olympus SZX16 stereomicroscope.
cDNA Synthesis and Quantitative PCR
Total RNA was extracted using TRIzol reagent (Invitrogen Life
Technologies) and cDNA was synthesized using Protoscript first
strand cDNA synthesis kit (New England Biosciences). Quantita-
tive PCR (qPCR) was performed on a Roche Lightcycler instrument
using b-actin as a reference gene. Primers for qPCR are b-actin
(F: 50-GCATTGCTGACCGTATGCAG-30 and R: 50-GATCCACATCT
GCTGGAAGGTGG-30) and ryroxd1 (F: 50-TCAATGGCTTCAGA
GAAACAAG-30 and R: 50-CTGTTCTGCACAAGTGACACC-30).
Swimming Assays
Touch-evoked response assays and analysis were performed on
48 hr post fertilization zebrafish as per Sztal et al.19
Electron Microscopy
Zebrafish were fixed in 2.5% gluteraldehyde, 2% paraformalde-
hyde in 0.1 M sodium cacodylate buffer, with post-fixation in
1% OsO4 1.5% K3Fe(III)(CN)6 in 0.065 M sodium cacodylate
buffer. Samples were dehydrated through an ethanol series and
embedded in Epon 812. 80 nm sections were stained with Uranyl
acetate and lead citrate before imaging using a Hitachi H-7500.
Muscle biopsies were fixed in 2.5% glutaraldehyde in 0.1 M so-
dium cacodylate buffer and processed routinely for electronmicro-
scopy. Ultrathin sections were examined in an FEI Tecnai Spirit
Biotwin.Study Approval
Ethical approval for this research was obtained from the Human
Research Ethics Committees of the Children’s Hospital at West-
mead, Australia (10/CHW/45), The University of Western
Australia, the Comite´ de Protection des Personnes Est IV (DC-
2012-1693), France, the Institutional Review Board of the National
Institute of Neurological Disorders and Stroke, NIH (12-N-0095),
and Ethical Committee of Hacettepe University, Faculty of Medi-
cine. Written informed consent was obtained from participants
for genetic testing, biobanking of DNA, muscle, and fibroblasts,mber 3, 2016
Figure 1. Clinical Features of PYROXD1-Related Myopathy
(A) Pedigrees of the five affected families.
(B) Posterior view of A-II1 (i) demonstrating generalized reduction of muscle bulk and prominent scapulae. Hands of A-II2 (ii) demon-
strating marked wasting of the thenar and hypothenar eminence. Foot of A-II1 (iii) showing pes cavus and skin discoloration. C-II1 (iv)
demonstrating hyperextension of the elbow and reduced muscle bulk. C-II1 (v) wrist hyperextension. C-II2 (vi) hand and wrist
hyperextension.
(C) Axial T1 muscle MRI of calf and thigh of individuals A-II2, B-II2, B-II3, and C-II2. In all individuals, the thigh shows generalized
reduction in muscle, atrophy, and fatty marbling. There is relative sparing of rectus femoris relative to vastus lateralis. The calf of indi-
viduals in family B is more mildly affected.
(D) Top: Agarose gel of PCR products of fibroblast cDNA from two affected siblings from family A (left) and family C (right). For both
families, sequencing of the lower band established in-frame skipping of exon 3 in family A and exon 4 in family C. Sequencing of
the upper band in family A identified only transcripts bearing the maternal c.1116 G>C (p.Gln372His) missense variant. Sequencing
(legend continued on next page)
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and publishing of photographs of affected individuals. Fish main-
tenance and handling were carried out as per standard operating
procedures approved by the Monash Animal Services Ethics
Committee.Results
Recessive PYROXD1 Variants Cause Early-Onset
Myopathy with Combined Histopathology of
Multiple Internalized Nuclei and Myofibrillar
Disorganization
Clinical Features of PYROXD1 Myopathy
Nine affected individuals from five families presented with
childhood-onset muscle weakness (infancy to 8 years)
(Figure 1A; Table 1). Perinatal history and early gross motor
milestones were largely within normal limits. All affected
individuals walked between 9 and 20 months of age. Two
probands had poor head control in infancy (family C, II1
and II2). Weakness was slowly progressive. All affected
individuals were still ambulant at 7–31 years but had diffi-
culty with running and stairs. A-II1 required a cane for
support and was unable to climb stairs from 24 years. All
individuals had generalized reduction in muscle bulk
(Figure 1B) and displayed symmetrical proximal weakness
of the upper and lower limbs. Triceps brachii power was
disproportionally reduced in three affected individuals.
Distal weakness of the upper and lower limbs was also pre-
sent in families A, B, C, and E. A-II1 and A-II2 showed
marked wasting of distal musculature, in particular the
thenar and hypothenar muscles (Figure 1B, ii), with
abductor digiti minimi strength graded 3/5 and abductor
pollicus brevis 0/5 in A-II2.
Neck weakness and mild scapular winging (5/9) were
present (Figure 1B, i). Deep tendon reflexes were reduced
or absent. Moderate joint laxity was present in families A
and C (Figure 1B, iv–vi) but had resolved in family A by
adulthood. Joint contractures did not occur, with the
exception of mild tendoachilles contractures in A-II1.
Mild scoliosis was seen in 2/9, pectus excavatum in 2/9,
and thoracolumbar rigidity in family C. All affected indi-
viduals had mild to moderate facial weakness and mild
ptosis was present in 3/9. A high arched palate and dental
malocclusion were present in 7/9. Nasal speech was pre-
sent in all individuals, swallowing difficulties in 6/9,
fatigue with chewing in 2/9, and A-II2 required surgery
for velopharyngeal incompetence. Ophthalmoplegia was
not present.of the upper band in family C identified only transcripts bearing the
PYROXD1 exon skipping events in family A and family C (not to sca
(E) Sequencing chromatogram of the total PCR mixture using exon 1
heights for the paternal wild-type and maternal missense variant c.1
equal abundance of exon 3 skipped transcripts and missense c.1116
contrast, family C shows evidence for maternal allele bias, with a
c.464G variant (red asterisks).
Collective data (D, right and E, right) suggest that the paternal exon 4
(p.Asn155Ser) among the total mRNA pool.
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cific learning difficulties. Mild restrictive lung disease was
present in the teenage years, but no individual had
nocturnal hypoventilation. Frequent respiratory infec-
tions were seen in 4/9. Cardiac evaluations were normal,
except for A-II1 who had developed abnormal septal wall
motion and a low normal ejection fraction (50%) on his
most recent assessment at 27 years of age.
Creatine kinase levels ranged fromnormal tomoderately
elevated (up to 1,051 IU/L). Electromyography (EMG) was
myopathic in all individuals tested. Electrophysiological
studies are summarized in Table S2. Nerve conduction
studies in A-II1 and A-II2, the oldest affected individuals
(26 and 29 years of age), found compound muscle action
potential (CMAP) amplitudes reduced to 1%–10% of
normal, absent peroneal CMAPs, reduced sural sensory po-
tentials, but normal upper limb sensory amplitudes, sug-
gestive of a mild length-dependent axonal neuropathy.
Muscle MRI imaging of family A showed diffuse muscle
atrophy and fatty marbling with relative sparing of rectus
femoris relative to vastus lateralis in the thigh. In family
B, only mild changes were seen, with vastus lateralis
most affected in the upper leg and gastrocnemius in the
lower leg (Figure 1C).
Histopathological Features of PYROXD1 Myopathy
Muscle biopsies were available from five affected individ-
uals (Table 1). Haemotoxylin and eosin staining showed
marked variation in fiber size and multiple internalized
nuclei, commonly occurring in clusters (Figure 2A, i, v, ix,
and see EM in Figure 2B, i and vi). Occasional degenerating
and regenerating fibers were seen, with a moderate in-
crease in interstitial connective tissue. Oxidative stains
showed large central core-like zones devoid of mitochon-
drial activity (Figure 2A, ii, vi, x NADH). Immunohisto-
chemical staining of skeletal muscle demonstrated large
myofibrillar inclusions positive for desmin (Figure 2A, iii,
vii, and xi), myotilin (Figure 2A, iv and viii), alpha-actin
(Figure 2A, xii), and aB crystallin (not shown). Electron mi-
croscopy showed extensive sarcomeric disorganization,
with small atrophied fibers showing complete loss of sarco-
meric architecture, absence of aligned thick filaments, and
accumulation of thin filaments (Figure 2B, i, iii, iv, vi, vii,
viii). In some small fibers, electron-dense thickened z-line
remnants or small nemaline rods were also present
(Figure 2B, iv and vii). Large fibers showed multiple areas
of Z-band streaming and large, focal zones of sarcomeric
disorganization (Figure 2B, ii), devoid of mitochondria
and organelles (Figure 2B, v). Thus, PYROXD1 myopathymaternal c.464A>G (p.Asn155Ser) variant. Bottom: Schematic of
le).
forward and exon 12 reverse primers. Family A shows equal peak
116 G>C (p.Gln372His) (red asterisks), suggesting approximately
G>C (p.Gln372His) transcripts among the total mRNA pool. In
lower peak height of the paternal c.464A relative to maternal
-skipped transcripts are less abundant than thematernal c.464A>G
mber 3, 2016
Table 1. Clinical Characteristics of Affected Individuals with PYROXD1 Variants
ID Family A-II1 Family A-II2 Family B-II2 Family B-II3 Family C-II1 Family C-II2 Family D-II1 Family D-II3 Family E-II2
Gender, current age male, 29 y male, 26 y male, 31 y male, 21 y female, 9 y male, 7 y female, 22 y male, 17 y female, 15 y
Ethnicity;
consanguinity
European
descent; no
European
descent; no
Turkish; yes Turkish; yes Persian Jewish; no Persian Jewish; no Turkish; yes Turkish; yes Turkish; yes
PYROXD1 variants c.285þ1G>A
(chr12:
g.21598401G>A),
c.116G>C
(p.Gln372His,
chr12:
g.21615796G>C)
c.285þ1G>A
(chr12:
g.21598401G>A),
c. 0.116G>C
(p.Gln372His,
chr12:
g.21615796G>C)
Hom. c.464A>G
(p.Asn155Ser,
chr12:
g.21605064A>G)
Hom. c.464A>G
(p.Asn155Ser,
chr12:
g.21605064A>G)
c.414þ1G>A
(chr12:
g.21602626G>A),
c.464A>G
(p.Asn155Ser,
chr12:
g.21605064A>G)
c.414þ1G>A
(chr12:
g.21602626G>A),
c.464A>G
(p.Asn155Ser,
chr12:
g.21605064A>G)
Hom. c.464A>G
(p.Asn155Ser,
chr12:
g.21605064A>G)
Hom. c.464A>G
(p.Asn155Ser,
chr12:
g.21605064A>G)
c.464A>G (p.Asn155Ser,
chr12: g.21605064A>G),
c.1159_1160insCAAA,
chr12: g.21620457_
21620458insCAAA)
Onset/progression onset 5 y,
difficulty
running; slowly
progressive
weakness from
20 y; unable to
climb stairs from
24 y; slow walk
with a cane
onset 8 y; stable
in childhood;
mild progression
from teenage
years; increasing
difficulty with
stairs
onset 10 y;
ambulant with
difficulty
ascending stairs
onset 10 y;
ambulant
congenital onset;
hypotonia; mild
gross motor delay;
walked age 20 mo;
weakness from
6 y; increasing
difficulty with
stairs
infantile onset
with hypotonia;
walked age 13 mo;
stable strength;
difficulty with
stairs
onset 2 y;
ambulant;
difficulty running
and climbing;
frequent falls;
slowly progressive
weakness from
20 y
onset 2.5 y;
ambulant;
difficulty
climbing; stable
in childhood
onset 4 y; easy fatigue;
frequent falls; difficulty
on stairs; slowly
progressive; increasing
difficulty with stairs
Pattern of limb
weakness
(HP:0001324)
symmetrical; UL,
LL, axial; P, D
symmetrical; UL,
LL, axial; P, D
symmetrical; UL,
LL, axial; P UL,
D LL
symmetrical; UL,
LL, axial; P
symmetrical; UL,
LL, axial
symmetrical; UL,
LL, axial
symmetrical; UL,
LL, axial; P
symmetrical;
UL, LL, axial; P
symmetrical: UL, LL; P, D
Severity of limb
weakness
all 4 and 4/5,
except deltoid
2/5, shoulder
abduction 1/5
all 4þ and 5/5,
except deltoid 2/5,
ADM 3/5, APB 0/5;
lower limbs 4/5
except hip flex 3/5
– – all 4þ and 4/5,
except shoulder
abd. 3/5, wrist flex
3þ/5, neck flex 2/5,
hip abduction 3/5
all 4 and 4/5,
except deltoid
3þ/5, finger
spread 3þ/5, neck
flex 2/5; hip
extension 5/5
proximal 4,
distal 4þ/5, lower
limbs more
affected
proximal 4þ
and 5/5,
distal 5/5
proximal 4 and 4þ/5;
hip flexion 3/5; thenar
wasting
Hyporeflexia
(HP:0001265)
reduced or absent reduced or absent reduced or absent reduced or absent reduced or absent reduced or absent reduced or absent reduced or
absent
reduced or absent
Achilles
contractures
(HP:0001771)
yes no no no yes no no no no
Joint contracture
5th finger
(HP:0009183)
yes no no no yes no no no no
Joint hypermobility
(HP:0001382)
distal laxity,
resolved
with age
distal laxity,
partial patella
subluxations
no no elbow and MCP
joints
mild at elbow,
wrist, and MCP
joints
no no no
Facial weakness
(HP:0002058)
yes yes yes yes yes yes yes yes yes
Ptosis (HP:0000508) no no no mild no no mild mild no
(Continued on next page)
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Table 1. Continued
ID Family A-II1 Family A-II2 Family B-II2 Family B-II3 Family C-II1 Family C-II2 Family D-II1 Family D-II3 Family E-II2
Ophthalmoplegia
(HP:0000602)
no no no no no no no no no
High arched palate
(HP:0000218)
yes yes no no yes yes yes yes yes
Additional facial
features
dental
malocclusion
(HP:0000689),
elongated face
dental malocclusion
(HP:0000689),
elongated face
no micrognathia
and retrognathia
(HP:0000308)
int. exotropia,
surgical correction
(HP:0000577)
no elongated face
(HP:0000276)
elongated face
(HP:0000276)
no
Dysphagia
(HP:0002015)
present from
12 y; improved
yes, plus nasal
regurgitation from
9 y; surgery for VPI
yes no no no yes yes yes
Chewing difficulties
(HP:0030193)
no no no no yes yes no no no
Nasal speech
(HP:0001611)
yes yes yes yes yes yes yes yes yes
Scoliosis
(HP:0002650)
mild thoracic
scoliosis
from 20 y
no no no mild scoliosis
from 7 y
no no no no
Spinal rigidity
(HP:0003306)
no no no no thoracolumbar
rigidity
thoracolumbar
rigidity
no no no
Pectus excavatum
(HP:0000767)
yes no no no yes no no no no
Scapular winging
(HP:0003691)
yes no mild mild mild mild, asymmetric no no no
Pes cavus
(HP:0001761)
yes no no no no no no no no
Pes planus
(HP:0001763)
no yes yes yes no no yes yes no
Restrictive lung
disease
(HP:0002091)
yes, from 15 y no no yes no no no no no
Recurrent infections
(HP:0002783)
no no no no yes yes yes no yes
Cardiac disease abnormal septal
motion and low
normal ejection
fraction at 27 y
no no no mild to moderate
pulmonic
insufficiency
no no no mild mitral and
tricuspid insufficiency
(HP:0001653)
Elevated CK (IU/L)
(HP:0040081)
no (148–262) yes (118–1,051) yes (500–700) yes (700–800) no no yes (400–700) no (290–376) no
(Continued on next page)
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The American Jouhas a distinctive histopathology that combines features
seen in central andminicore disease, centronuclear, myofi-
brillar, and nemaline myopathies.
Genetic Analyses
Exome sequencing in five unrelated families identified
compound heterozygous variants in PYROXD1 (GenBank:
NM_024854.3) in families A, C, and E and the same homo-
zygous recessive missense variant in consanguineous Turk-
ish families B and D (Figures 1A and 3). Sanger sequencing
confirmed all variants and familial segregation was consis-
tent with autosomal-recessive inheritance. DNA was not
available for D-II2 or D-II4.
In family A, a paternally inherited essential splice site
variant, c.285þ1G>A (chr12: g.21598401G>A),was identi-
fied. The variant is found at low frequency in the heterozy-
gous state in the Exome Aggregation Consortium (ExAC)
database (allele frequency 4.295 3 105).27 cDNA analysis
performed on muscle from A-II1 (not shown) and fibro-
blasts fromA-II1 andA-II2 (Figure1D) confirmeddisruption
of the donor splice site, with in-frame skipping of exon 3 a
common consequence of the splice variant (Figure 1D, left
gel, approximately equal levels of normal splicing [upper
band] and exon 3 skipping [lower band]). PCR using
exon1 forward and intron3 reverse primers didnot provide
evidence for increased frequency of exon 3 extension in
family A relative to control fibroblasts (not shown). A sec-
ond maternally inherited missense variant, c.1116G>C
(p.Gln372His; chr12: g.21615796G>C), was not found in
the ExAC database.27 In silico predictions support pathoge-
nicity (PolyPhen-2 score 1.0 ¼ probably damaging;28 Pro-
vean score 4.68 ¼ deleterious;29 MutationTaster score
0.999 ¼ disease causing30). c.1116 G>C is the terminal 30
base of exon 10, but cDNA analyses revealed no obvious
consequence for splicing (Figures 1D and 1E) and approxi-
mately equal levels of the c.1116 G>C (p.Gln372His)
variant on cDNA (Figure 1E, family A; equal peak heights
at position c.1116G>C are asterisked).
In families B and D, exome sequencing identified a
homozygous missense variant c.464A>G (p.Asn155Ser;
chr12: g.21605064A>G) in the affected siblings (B-II2
and B-II3 and D-II1 and D-II3, Figure 1A). The variant
was found at very low frequency in the ExAC database
and always in the heterozygous state (allele frequency
7.157 3 105).27 In silico predictions support pathoge-
nicity (PolyPhen-2 score 1.0 ¼ probably damaging;28 SIFT
score 0.74 ¼ tolerated; Provean score 4.97 ¼ delete-
rious;29 MutationTaster score 0.999 ¼ disease causing30).
Families C and E (Figure 1A) had compound heterozy-
gous variants including the c.464A>G (p.Asn155Ser;
chr12: g.21605064A>G) missense variant described in
family B and D. In family C an essential splice site variant
c.414þ1G>A (chr12: g.21602626G>A) was paternally
inherited. The c.414þ1G>A variant is present in the het-
erozygous state at very low frequency in ExAC (allele
frequency 4.295 3105).27 The c.414þ1G>A (chr12:
g.21602626G>A) variant is predicted to disrupt the donor
splice site of exon 4.30 cDNA analysis on skin fibroblastsrnal of Human Genetics 99, 1086–1105, November 3, 2016 1093
Figure 2. Histopathological Findings in PYROXD1 Myopathy
(A) Histopathological findings in skeletal muscle sections from family A (A-II1, quadriceps biopsy at 11 years of age), family B (B-II3,
quadriceps biopsy at 16 years of age), and family C (C-II2, quadriceps biopsy at 4 years of age). Haemotoxylin and eosin (H&E) staining
of muscle biopsy specimens from each family shows variation in fiber size, multiple internalized nuclei, and increased fibrous
connective tissue. Immunofluorescent staining of skeletal muscle from A-II1 and C-II2 and immunoperoxidase staining from B-II3
demonstrate inclusions highly immunoreactive to desmin, myotillin, and alpha-actin (and aB-crystallin, not shown). H&E and
immunoperoxidase images are provided via Hospital Pathology without a scale bar. Fibers in sequential sections of B-II3 are marked
with a yellow star.
(B) Electron microscopy of muscle biopsy specimens. Family A: (i) small atrophic fiber with a central nucleus and loss of sarcomeric or-
ganization; (ii) large region of Z-band streaming with only occasional areas of normal sarcomeric register; and (iii, iv) atrophic fibers
showing total loss of sarcomeric register, loss of thick filaments, and prominent Z-bands sometimes forming small nemaline bodies. Fam-
ily B: (v) Large fibers show large central minicore-like regions devoid of normal myofibrillar structure and lacking mitochondria and
organelles, with adjacent small fibers showing total loss of sarcomeric structure, accumulations of thin filaments, and loss of thick
(legend continued on next page)
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from C-II1 and C-II2 confirmed that the c.414þ1G>A
splice site variant disrupts normal splicing, effecting in-
frame skipping of exon 4 in a subset of transcripts
(Figure 1D, right gel: normal splicing [upper gel], exon 4
skipping [lower gel]). PCR was also performed with exon
1 forward and intron 3 or intron 4 reverse primers. Family
C fibroblast cDNA showed higher levels of exon 3 exten-
sion, relative to controls; no evidence for exon 4 extension
was observed (not shown). Sanger sequencing of cDNA
across the c.464A>G (chr12: g.21605064A>G) maternal
variant showed some evidence for maternal allele bias
(Figure 1E, family C, note lower peak height of the paternal
c.464A relative to maternal c.464G variant, red asterisks).
Collectively, our data suggest at least two outcomes from
the c.414þ1G>A donor splice variant; in-frame skipping
of exon 4 and ectopic inclusion of intron 3 sequences
that create a premature stop codon after 97 amino acids
and may be subject to nonsense-mediated decay.
In family E the second variant was a heterozygous 4 bp
insertion, c.1159_1160insCAAA (p.Ala387fs*13; chr12:
g.21620457_21620458insCAAA), which was paternally in-
herited. This frameshift variant will encode a truncated
protein lacking the conserved NADH-nitrile reductase
domain and bearing 13 ectopic amino acids downstream
of Ala387 before an early termination codon.
Families B, D, and E are Turkish. SNP markers in the re-
gion of the c.464A>G (chr12: g.21605064A>G) variant
are consistent with a shared minimal confirmed haplotype
between the three families of at least 348 Kb, from chr12:
21,331,987 to 21,680,609 (Table S3).
PYROXD1 Belongs to an Ancient Family of
Oxidoreductases
PYROXD1 (pyridine nucleotide-disulphide oxidoreductase
[PNDR] domain-containing protein 1) is classified as a
class I pyridine nucleotide-disulphide oxidoreductase by
neXtprot and UniProtKB. PNDRs are an ancient family of
enzymes that regulate the redox state of other proteins. Un-
like thefiveother humanclass I PNDRs—dihydrolipoamide
dehydrogenase (DLD [MIM: 238331]), glutathione reduc-
tase (GSR [MIM: 138300]), and thioredoxin reductases 1,
2, and 3 (TXNRD1 [MIM: 601112], TXNRD2 [MIM:
606448], TXNRD3 [MIM: 606235])—PYROXD1 does not
bear a consensus redox active site within the oxidoreduc-
tase domain (Gly Gly Thr Cys Val Asn Val Gly Cys in GSR
and thioredoxin reductases, Gly Gly Thr Cys Leu Asn Val
Gly Cys in DLD; reactive cysteine disulphide underlined).
Moreover, PYROXD1 does not bear a conserved C-terminal
dimerization domain identified in all other class I PNDRs,
and instead bears a highly evolutionarily conserved nitrile
reductase domain (69% identity and 85% similar inDictyos-
telium). Though apparently divergent to other class Ifilaments; (vi) many large fibers have multiple internalized nuclei, o
with electron-dense aggregates that resemble thickened z-lines and
loss of sarcomeric register. A large fiber shows multiple areas of Z-ba
myofibrillar structure.
The American JouPNDRs, PYROXD1 is highly evolutionarily conserved,
with 63% identity (78% similarity) of human PYROXD1
to zebrafish PYROXD1 and 39% identity (54% similarity)
to Dictyostelium PYROXD1 (slime mold). Structural
modeling of PYROXD1 using eight homologous solved
crystal structures derived from other PNDRs support a pre-
dicted FAD-binding site (Figure 3B) that is vital for oxidore-
ductase activity of the PNDR family.6
The amino acids affected by the p.Gln372His and
p.Asn155Ser substitutions are both highly evolutionarily
conserved (Figure 3C), and removal of amino acids en-
coded by exon 3 (family A) or exon 4 (family C) (see Figures
3A and 3B) appears likely to significantly impact tertiary
folding and abolish FAD binding and enzymatic function.
Missense Variants in Human PYROXD1 Impair
Reductase Activity in Yeast
Redox activity of PYROXD1 was not previously reported,
so we established a complementation assay in yeast to
test the reductase activity of human PYROXD1 and the
impact of identified missense variants. Replacing the yeast
gene by its human counterpart is a powerful approach to
help decipher the role of the human protein.31,32 Saccharo-
myces cerevisiae has two overlapping oxidoreductase path-
ways, a cytoplasmic and a mitochondrial thioredoxin
system, sharing some enzymes. To determine the localiza-
tion of exogenous human PYROXD1 in yeast, GFP-tagged
constructs were expressed in wild-type (WT) S. cerevisiae
(Figure 3D). Fluorescent imaging of GFP-tagged PYROXD1
revealed widespread cytosolic localization, with wild-type,
p.Asn155Ser, and p.Gln372His missense mutants showing
similar, high expression in transformed S. cerevisiae by
western blot (Figure 3F). Among the cytoplasmic yeast ox-
idoreductases, the Grl1 glutathione reductase localizes to
the cytoplasm and mitochondria and is required for sur-
vival under oxidative stress.33 Expression of non-tagged
human PYROXD1 in glr1Dmutant yeast that are hypersen-
sitive to H2O2 due to lack of oxidoreductase activity
rescued the growth defect of the glr1D mutant strain
(Figure 3E), with wild-type and missense mutants showing
similar, high protein levels in transformed S. cerevisiae by
western blot (Figure 3F). Conversely, p.Asn155Ser and
p.Gln372His PYROXD1 mutants failed to complement
glr1D (Figure 3F). These data show that human PYROXD1
has a reductase activity that is strongly impaired by both
identified missense variants.
Individuals with PYROXD1 Variants Show
Near-Normal or Reduced Levels of PYROXD1 Protein
in Muscle, Fibroblasts, or Myoblasts
Western blot analysis of PYROXD1 protein levels showed a
marked reduction in primary skin fibroblasts of A-II1 andften in clusters; and (vii) fibers show thin filament accumulations
small nemaline bodies. Family C: (viii) Small atrophic fiber with
nd streaming and a minicore-like region with absence of normal
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Figure 3. PYROXD1 Is an Oxidoreductase
(A) A schematic of PYROXD1 with functional domains and identified missense variants created using DOG 2.0.35 Family A, Dexon3 and
p.Gln372His (Q372H, green); families B and D, p.Asn155Ser (N155S); family C, Dexon4 and p.Asn155Ser (N155S, red).
(B) PYROXD1 homology model derived from eight homologous crystal structures (see Subjects and Methods). A co-ordinated FAD co-
factor and the position of each identified variant on the crystal structure of PYROXD1 are highlighted in green (family A, Dexon3 and
Q372H) and pink (family C: Dexon4 and N155S) as in (A).
(C) The identified missense variants p.Asn155Ser and p.Gln372His are evolutionarily conserved to primitive eukaryotes (Uniprot
identifiers): human (Q8WU10), bovine (A7YVH9), chicken (F1NPI8), Xenopus (B1WAU8), Danio rerio (Q6PBT5), Dictyostelium
(Q54H36).
(D) Living wild-type (WT, BY4742) yeast cells expressing human PYROXD1-GFP, PYROXD1-N155S-GFP, or PYROXD1-Q372H-GFP
were observed by fluorescence microscopy with GFP filters and DIC optics. The merge represents the merge between the GFP and
DIC images.
(legend continued on next page)
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Figure 4. Affected Individuals with PYROXD1 Variants Show Reduced or Near-Normal Levels of PYROXD1
(A) Western blot of skin fibroblasts from two controls (42 and 46 years of age) and affected siblings from family A (29 and 26 years) and
family C (6 and 8 years). HEK293 cells transfected with a plasmid encoding human PYROXD1 establishes the apparent molecular weight
of PYROXD1 at ~60 kDa (UT, untransfected; T, transfected). A non-specific (NS) band is indicated by an arrow. Levels of PYROXD1 are
reduced in family A but not different to control levels in family C.
(B) Western blot of A-II1 triceps (11 years) (Abcam cat# ab122458; RRID: AB_11129858) shows reduced levels of PYROXD1 relative to
three age-matched control biopsy specimens (quadriceps 11 years, 10 years, 15 years). Loading controls: b-tubulin and GAPDH control
for overall protein content, with one cytoskeletal and one cytoplasmic marker; emerin controls for the number of nuclei; skeletal a-ac-
tinin controls for myofibrillar content.
(C) Western blot of myoblasts extracts from control subject and B-II3. Extracts from COS-1 cells transfected with the 500 aa human PY-
ROXD1 cDNA (GenBank: NM_024854.3) was used as size control.A-II2 (collected at 29 and 26 years of age) (Figure 4A,
family A: DExon 3 and p.Gln372His), with no significant
change in PYROXD1 levels in skin fibroblasts from C-II1
or C-II2 (8 and 6 years) (family C DExon 4 and
p.Asn155Ser). In-frame deletion of exon 3 or exon 4 is pre-
dicted to remove 4.4 kDa or 4.7 kDa, respectively. Using
two different anti-PYROXD1 antibodies (Abcam cat#
ab122458 or ab204560; RRID: AB_11129858), we were un-
able to detect evidence for a lower molecular weight spe-
cies, even with long exposures. Thus, our results suggest
that in-frame deletions of exon 3 or exon 4 do not produce
a stable protein. Western blot analyses of skeletal muscle
specimens from A-II1 (collected at 11 years of age) similarly
demonstrate reduced levels of PYROXD1 (Figure 4B),
consistent with results in skin fibroblasts. Western blot(E) Cultures of non-transformed wild-type (WT) or glr1D yeast, or glr
N155S-, or Q372H-PYROXD1 were spotted at the indicated concen
3 mM H2O2. Plates were incubated at 30
C and observed after 48 hr
(F)Western blot of non-transformed wild-type (WT) and glr1D, as well
black arrow indicates PYROXD1 and the lower panel shows the prot
The American Jouanalysis of family B (B-II3) cultured myoblasts detected
low levels of PYROXD1 that did not appear altered
compared to control (Figure 4C). Together, our data indi-
cate that the splice variants lead to unstable proteins that
are not detected by western blot, PYROXD1-Asn155Ser ap-
pears to have normal stability and protein levels (family B
and C), whereas PYROXD1-Gln372His is detected at
reduced levels (family A).
PYROXD1 Is a Nuclear-Cytoplasmic Oxidoreductase
Figure 5A demonstrates the localization of PYROXD1 in
control human skeletal muscle longitudinal sections,
lightly stretched (10% passive stretch) prior to fixation to
facilitate resolution of thin and thick filaments. PYROXD1
protein shows a distinct nuclear localization and also1D yeast transformed with expression plasmids bearing wild-type,
tration (OD600nm) on rich (YPD) or on solid medium containing
.
as glr1D yeast transformed with PYROXD1 expression vectors. The
ein-stained membrane used as loading control.
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Figure 5. PYROXD1 Shows Both Nuclear and Striated Immunolocalization in Human Muscle
(A) Control stretched human skeletal (quadriceps) muscle co-stained with a-PYROXD1 (red), myotilin or desmin (green), and DAPI
(blue). PYROXD1 intensely labels peripheral myonuclei, as well as showing two different patterns of striated labeling. Right: In this fiber,
PYROXD1 brightly labels consecutive myonuclei and shows cytoplasmic striated labeling that aligns with desmin (Z-band region) and
interdigitates between Z-bands (M-line region). Left: PYROXD1 does not brightly label myonuclei (asterisks show the position of DAPI-
labeled nuclei) and shows a broader banding of striated labeling spanning the breadth of the I-band.
(B) Control and AII-1 tricep cross-sectioned human skeletal muscle co-stained with a-PYROXD1 (red), a-desmin (green), andDAPI (blue).
The triceps muscle from AII-1 bears large inclusions that positively label for desmin, split fibers, and multiple internalized nuclei that
brightly label for PYROXD1. Coverslips were imaged on a Leica SP5 confocal and single Z-planes are presented.striated labeling (Figure 5A). PYROXD1 labels some periph-
eral nuclei more intensely than other nuclei (Figure 5A,
left, asterisks show nuclei negative for PYROXD1). The
sarcomeric compartment labeled by anti-PYROXD1 anti-
bodies varied in different muscle specimens. Images pre-1098 The American Journal of Human Genetics 99, 1086–1105, Novesented show the two main types of striated labeling
observed. The right panel of Figure 5A shows striations
aligning both with the Z-band and interdigitating between
Z-lines (near the M-band). The left panel shows a broader
band of PYROXD1 labeling spanning the breadth of thember 3, 2016
Figure 6. PYROXD1 Shows Nuclear
Localization in Human Skin Fibroblasts
and Transfected Cos-7 Cells
(A) Untransfected Cos-7 cells (top row)
and Cos-7 cells transfected with human
wild-type, p.Asn155Ser (N155S)-, or
p.Gln372His (Q372H)-PYROXD1 expres-
sion constructs co-stained for PYROXD1
(green) and lamin A/C (red) shows en-
riched labeling for PYROXD1 within the
nucleus, as well as labeling of cytoplasmic
networks. For transfected Cos-7 cells (bot-
tom three rows), asterisks demark untrans-
fected cells within the field, with much
lower levels of PyroxD1, that show very
weak labeling under optimum capture
conditions for transfected cells.
(B) Nuclear-cytoplasmic labeling is ob-
served for endogenous PYROXD1 in pri-
mary human fibroblasts.I-band. These data establish that PYROXD1 localizes to the
nucleus and to sarcomeric/sarcoplasmic compartments.
Immunohistochemistry of control human skeletalmuscle
in cross section similarly shows dual localization of
PYROXD1 inperipheralmyonuclei aswell as intramyofibril-
lar labeling throughout the contractile apparatus (Figure5B).
Levels of PYROXD1 in the triceps of A-II1were lower relative
to control muscle, and higher capture conditions are pre-
sented in order to portray key findings. As observed in the
quadriceps of A-II1 (Figure 2A, i), the tricepsmuscle has large
inclusions that label positively for desmin (Figure 5B, des-
min, green) and multiple internalized nuclei (Figure 5B,The American Journal of Human GeneticsDAPI, blue) that label positively
for PYROXD1-Gln372His (Figure 5B,
PYROXD1, red). Levels of cytoplasmic
PYROXD1 appear brighter in myofib-
ers without myofibrillar aggregates
(Figure 5B, PYROXD1, red, enlarged
inset). Thus, our results suggest that
the equilibrium of cytoplasmic versus
nuclear PYROXD1 is shifted to more
predominant nuclear localization in
muscle fibers burdened with myofi-
brillar aggregates.
Dual nuclear-cytoplasmic localiza-
tion of PYROXD1 is supported by
immunostaining of untransfected
and transfected Cos-7 fibroblasts and
primary human fibroblasts (Fig-
ure 6). Heterologous transfection of
expression constructs encoding wild-
type, p.Asn155Ser, or p.Gln372His
PYROXD1 into Cos-7 fibroblasts
showed a similar distribution of nu-
clear and cytoplasmic localization
(Figure 6); similar patterns of staining
for wild-type and PYROXD1 missense
variants were also observed in trans-fected C2C12 myoblasts and immortalized human myo-
blasts (not shown).Moreover,noovert changes inPYROXD1
localization were observed in primary fibroblasts from two
siblings from family A or two siblings from family C relative
to fibroblasts from two age-matched controls (not shown).
PYROXD1 Shows Nuclear-Cytoplasmic Localization in Mature
Zebrafish Myofibers, with Evidence for Aggregates Induced by
Expression of p.Asn155Ser and p.Gln372His Mutant Constructs
To determine the localization of PYROXD1 within the skel-
etal muscle, we overexpressed eGFP-tagged wild-type and
mutant (p.Asn155Ser and p.Gln372His) human PYROXD1
within zebrafish muscle using the muscle-specific actc1b99, 1086–1105, November 3, 2016 1099
Figure 7. PYROXD1 Shows Nuclear-
Cytoplasmic Localization in Zebrafish My-
ofibers, with Aggregates Induced by
Expression of Asn155Ser and Gln372His
Variants
(A) In situ hybridization on 24 hpf zebra-
fish shows widespread ryroxd1 expression
including the trunk musculature (M) in
both lateral and dorsal views.
(B–D) Immunolabeling of vibratome-
sectioned embryos 4 days post fertiliza-
tion (dpf) expressing eGFP-conjugated
human PYROXD1, either wild-type (B),
p.Asn155Ser (C; N155S), or p.Gln372His
(D; Q372H) via a muscle-specific actin pro-
moter (actc1b) together with the Z-disk
marker Actinin3-mCherry or nuclear
marker histone H2A-mCherry. PYROXD1
localizes to myonuclei and shows striated
labeling of sarcomeres. Small regions of
thickening and sarcomeric disruption (ar-
rowheads and inset) were observed after
heterologous expression of N155S- or
Q372H-PYROXD1, but not with wild-
type PYROXD1.promoter. All PYROXD1 constructs show dual nuclear and
striated labeling aligning with the Z-disk, as evidenced by
co-localization with actc1b:actinin3-mCherry and actc1b:
H2Av-mCherry (Figure 7B, arrows). We also observed an oc-
casional thickeningof theZ-diskat48hpfwhenp.Asn155Ser
and p.Gln372His PYROXD1 isoforms were overexpressed
(Figures 7C and 7D, actinin3-mCherry arrowheads).
Zebrafish with Knockdown of RyroxD1 Show
Sarcomeric Disorganization, Myofibrillar Aggregates,
and a Defect in Swimming
We identified a single PYROXD1 ortholog in zebrafish,
ryroxd1, which is expressed throughout the developing em-1100 The American Journal of Human Genetics 99, 1086–1105, November 3, 2016bryo, including the skeletal muscle
(Figure 7A). To study the function of
Ryroxd1, we analyzed the effects of
ryroxd1 knockdown during early
embryogenesis (Figure 8). Both quan-
titative PCR (qPCR) and western
blot analyses confirm reduction of
Ryroxd1 when ryroxd1 ATG and
exon2 splice morpholinos were used
singularly and in combination (Fig-
ures 8A–8C).
To determine the effect of Ryroxd1
knockdown, we examined the swim-
ming performance of the morpho-
lino-injected embryos. Ryroxd1 single
(ATG) and double (ATG and splice)
morphants show a significant reduc-
tion in maximum acceleration in a
touch-evoke response assay at 2 dpf
compared to GFP morpholino-in-
jected control zebrafish (Figure 8C).Co-injection of eGFP-tagged human wild-type PYROXD1
mRNA (wtPYROXD1-eGFP) with both Ryroxd1 morpholi-
nos rescued the reduction in swim performance, demon-
strating that the effect was due specifically to reduction
of Ryroxd1 (Figure 9D).
Examination of zebrafishmuscle through antibody label-
ing for Actinin2 and phalloidin shows no obvious defects
in Ryroxd1 splice and ATG single morphants (Figure S1),
but disrupted sarcomeric structure is evident in Ryroxd1
double morphants (Figure 8D). By 96 hpf, Actinin2 and
phalloidin-positive aggregates are observed in Ryroxd1
ATG morphants (Figure S1). However, RyroxD1 double
morphants show severe disruption of the musculature
Figure 8. ZebrafishDeficient forRyroxD1
Show Sarcomeric Disorganization, Myofi-
brillar Aggregates, and a Defect in Swim-
ming
(A) Quantitative PCR for ryroxd1 mRNA
levels in control (uninjected) and Ryroxd1
morpholino-injected (Ryroxd1 ex2 splice
MO) zebrafish at 2 dpf.
(B) Western blot for Ryroxd1 protein and
a-tubulin loading control in control (unin-
jected) and Ryroxd1 morpholino-injected
zebrafish (D ¼ Ryroxd1 double morpho-
lino, ATG ¼ Ryroxd1 ATG morpholino,
and splice ¼ Ryroxd1 splice-site targeting
morpholino) at 48 hpf demonstrates effec-
tive reduction of Ryroxd1.
(C) Ryroxd1 ATG-single and ATG/splice
double morphants show a significant
reduction, of 48% and 73% respectively,
in maximum acceleration in a touch-evoke
response assay at 2 dpf compared to con-
trol zebrafish injected with a GFP targeting
morpholino (Cont).
(D and E) Antibody labeling of Ryroxd1
double morphants at 48 hpf (D) and
96 hpf (E) for Actinin2 and phalloidin
show disruption of muscle structure com-
pared to uninjected controls.
(E) At 96 hpf, Ryroxd1 double morphants
show severe disruption of the musculature
with remnants of fragmented muscle fibers
evident (arrows).
For (A) and (C), error bars represent SEM for
three independent replicate experiments
comprising 15 fish in each, **p < 0.01.with fragmentation of the muscle fibers (Figure 8E) and, in
some cases, loss of fiber integrity and accumulation of actin
at the myosepta (Figure 9A). Consistent with the improve-
ment in muscle performance, the severity of structural
muscle defects was significantly reduced by co-injection
of Ryroxd1 double morphants with wtPYROXD1-eGFP
mRNA (Figure 9A), demonstrating that the phenotype is
due to reduction of Ryroxd1.
To further investigate the muscle phenotype observed
in the morphant embryos, we examined the muscle
structure using electron microscopy. In morphant em-
bryos, but not uninjected controls, we observed disintegra-
tion of the myofibrils with mitochondrial infiltration
of the resulting space, loss of Z-disk structures, and the for-
mation of electron dense, nemaline-like, bodies reminis-
cent of those observed in the human muscle biopsies
(Figure 9E).The American Journal of Human GeneticsDiscussion
This publication describes the oxido-
reductase function of PYROXD1
and identifies recessive variants in
PYROXD1 as a cause of early-onset
myopathy characterized histologi-
cally by a combination of multiple
internalized nuclei, with large zonesof sarcomeric disorganization—often devoid of mitochon-
dria and organelles, accumulations of thin filaments,
thickened Z-bands, and desmin-positive inclusions (Fig-
ure 2). All affected individuals presented in infancy or early
childhood (1–8 years) with slowly progressive symmetrical
weakness affecting both proximal and distal muscles, with
normal to moderately elevated creatine kinase. Mild facial
weakness, a high palate, nasal speech, and swallowing dif-
ficulties were typical features, mild restrictive lung disease
was common, and evidence of cardiac involvement was
present in the eldest individual, now aged 27. Thus, we
emphasize the need for respiratory and cardiac surveil-
lance in individuals with PYROXD1 myopathy. Nerve
conduction studies in family A in the third decade showed
a mild length-dependent axonal sensory neuropathy.
These findings were present only in family A, so the signif-
icance is uncertain, but raises the possibility that different99, 1086–1105, November 3, 2016 1101
Figure 9. Human PYROXD1 Rescues Muscle Pathology and Swimming Defects in Ryroxd1 Morphants and EM of Zebrafish Muscle
Pathology
(A) Representative images depicting the range of severity of muscle defects in Ryroxd1 double morphants. No obvious phenotype
(none), embryos displaying occasional broken fibers and actin accumulation (mild, arrows), severe fragmentation of muscle fibers
(severe, arrowheads), severe loss of fiber integrity and accumulation of actin at the myosepta (severe, arrows).
(B) Quantification of phenotypes (as in A) observed in Ryroxd1 double morphants (Ryroxd1 D MO) injected with either 0.5 ng/mL or
1.0 ng/mL wild-type (wt) wtPYROXD1-eGFP RNA compared to Ryroxd1 double morpholino injection alone (no RNA). 15–20 animals
were scored per condition, *p < 0.05.
(C)Western blot for GFP and a-tubulin in GFPmorpholino-injected control embryos (cont), Ryroxd1 doublemorpholino-injected zebra-
fish (no RNA), and Ryroxd1 double morpholino-injected zebrafish co-injected with either 0.5 ng/mL or 1.0 ng/mL wtPYROXD1-eGFP
RNA, demonstrating translation of the injected mRNA.
(D) Ryroxd1 double morphants injected with human wtPYROXD1-eGFP mRNA show dose-dependent rescue in a touch-evoke response
assay at 2 dpf. Ryroxd1 double morphants injected with 1.0 ng/mL human wtPYROXD1-eGFP show a 61% increase in maximum accel-
eration compared to Ryroxd1 double morphants (no RNA), achieving similar levels of maximum acceleration to wild-type embryos
injected with a control GFP targeting morpholino (GFP MO).
(E) Electron micrograph of muscle (i) in a wild-type uninjected 96 hpf zebrafish embryo; examination of Ryroxd1 double morphant
embryos (ii–iv) demonstrates myofibrillar fragmentation (ii, arrows) with mitochondrial infiltration, small nemaline-like bodies
(iii, black arrowheads), and Z-disk fragmentation and loss (iii–iv; black arrowheads).
Scale bar represents 1 mm. Error bars represent SEM for three independent replicate experiments comprising 15 animals in each replicate
experiment, *p < 0.05, **p < 0.01.PYROXD1 variants may eventually predispose to the devel-
opment of a neuropathy with increasing age.
All families identified in this study for which muscle,
myoblasts, or fibroblasts were available exhibited either
normal levels or reduced levels of PYROXD1; no individual1102 The American Journal of Human Genetics 99, 1086–1105, Noveshowed absence of PYROXD1. Analysis of splice variants
identified in PYROXD1 in family A and family C revealed
a subset of transcripts with in-frame deletion of amino
acid sequences encoded by exon 3 (family A) or exon 4
(family C). However, we could not find evidence formber 3, 2016
expression of truncated proteins, suggesting that the re-
sulting protein products are unstable and degraded. The
two substitutions p.Asn155Ser and p.Gln372His strongly
impair the oxidoreductase activity of PYROXD1 in a
yeast heterologous expression system. Importantly, no
affected individuals described to date possess two predicted
loss-of-function variants or exhibited complete loss of
PYROXD1 in skin fibroblasts or skeletal muscle specimens.
Thus, our findings suggest that myopathy results from par-
tial loss of PYROXD1 function. Of note, targeted deletion
of PYROXD1 in murine models results in embryonic
lethality (our own studies and confirmed by the Interna-
tional Mouse Phenotyping Consortium). This suggests
that recessive loss-of-function variants in PYROXD1 may
result in a severe-lethal presentation in humans. Our
current studies are defining the tissue-specific and develop-
mental expression of PYROXD1, together with determina-
tion of the consequences of PYROXD1 deficiency, using
a PYROXD1 conditional knock-out and LacZ reporter
mouse-model.
PYROXD1 mRNA is ubiquitously expressed at low levels
(GTex Portal). PYROXD1 is highly evolutionarily con-
served to unicellular eukaryotes, with functional FAD-
dependent oxidoreductase and NADH-dependent nitrile
reductase domains present in prokaryotic enzymes. Thus,
PYROXD1 has an ancient biology not yet understood. In
contrast to PYROXD1, the five other class I PNDRs are
well characterized and play significant roles in regulation
of cellular redox: glutathione reductase (GSR), thioredoxin
reductases 1, 2, and 3 (TXNRD1, TXNRD2, and TXNRD3),
and mitochondrial dihydrolipoyl dehydrogenase (DLD).6
Recessive variants in DLD cause dihydrolipoamide dehy-
drogenase deficiency (DLDD [MIM: 246900]), a metabolic
disorder characterized by lactic acidosis and neurological
dysfunction. Dihydrolipoamide dehydrogenase is the E3
component of several vital mitochondrial enzyme com-
plexes, including pyruvate dehydrogenase and ketogluta-
rate dehydrogenase, affecting oxidative metabolism via
both the citric acid cycle and fatty acid biosynthesis.6
In addition to the reducing capabilities of their enzyme
co-factors (FAD and NAD), PNDRs typically bear an
intrinsic ‘‘redox active site’’ that catalyzes the final step
to reduce their substrate, most commonly a conserved
redox-reactive disulphide motif. Many PNDRs form enzy-
matic homodimers via a C-terminal conserved motif and
are grouped into two classes (class 1 and class 2), according
to characteristics related to nucleotide and flavin binding
sites, the type of non-flavin redox active site, and the
structural features of their dimer interface.34 Although
PYROXD1 is classified as a class 1 PNDR, it does not
contain a conserved redox active disulphide within the
oxidoreductase domain, nor a classical C-terminal dimer-
ization motif, and thus appears a divergent member of
the class I PNDR family.
Importantly, using a heterologous complementation
assay in yeast, we showed that human PYROXD1 exhibits
a reductase activity that can rescue the H2O2 sensitivity ofThe American Jouyeast cells lacking the glutathione reductase glr1. As the
two missense variants impair this activity, it supports
that the myopathy observed in affected individuals arises,
at least in part, from a defect in oxidoreductase activity.
Future work will need to identify what are the substrate(s)
of PYROXD1 to better understand the pathophysiology.
Immunolocalization studies in human skeletal muscle,
skin fibroblasts, and zebrafish myofibers show that
PYROXD1 localizes to both the nucleus and cytoplasmic/
sarcomeric compartments. Knockdown of the zebrafish
ortholog Ryroxd1 produced embryos with abnormal
musculature and marked sarcomeric disorganization
within individual myofibrils, including Z-disk loss and
fragmentation and the presence of electron-dense bodies,
reminiscent of findings observed in human muscle bi-
opsies. In addition to the pathological features observed,
Ryroxd1 morphants also performed poorly in a touch-
evoked swim assay, consistent with impaired muscle
function.
In summary, we describe PYROXD1 as a nuclear-cyto-
plasmic oxidoreductase conserved through evolution and
important for human skeletal muscle biology. Recessive
variants in PYROXD1 cause an early-onset myopathy char-
acterized by slowly progressive limb and facial weakness,
nasal speech, and swallowing difficulties. PYROXD1
myopathy histopathology is distinctive in that it combines
multiple pathological hallmarks characteristic of different
myopathies: central core and minicore disease, centronu-
clear, myofibrillar, and nemaline myopathies. Although
one or two of these histopathological features can often
exist in combination, it is rare to observe core-like zones,
multiple internal nuclei, extensive myofibrillar disorgani-
zation, myofibrillar accumulations, and small nemaline-
like bodies all within a single biopsy specimen. Thus, our
discovery of PYROXD1myopathy introduces altered redox
regulation as a primary disease mechanism in congenital
myopathy and raises the provocative possibility that
several pathological endpoints in the myopathies may be
linked ultimately to altered cellular redox.Supplemental Data
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4.2 Part B: Characterisation of the oxidoreductase PYROXD1 in 
health and disease  
4.2.1 Results 
4.2.1.1 Establishing molecular biology tools to study PYROXD1 
The Pyridine nucleotide disulphide reductase (PNDR) family of redox enzymes have 
previously been studied with several members having a plethora of literature available on their 
characterisation, such as glutathione (Couto, Wood, & Barber, 2016) and thioredoxin 
(Mustacich & Powis, 2000) reductases. However, PYROXD1 was previously undescribed in 
the published literature, and thus no validated molecular biology tools were available to enable 
investigations into the possible pathogenicity of PYROXD1 variants.  
Thus, we optimised three commercially available antibodies against PYROXD1, each raised 
using immunogens representing a different region of the PYROXD1 protein sequence (Figure 
4.1). In combination, these antibodies would enable detection of each patient variant, taking 
into consideration the deletion of amino acids 56-95 (∆exon 3, Family A, c.285+1G>A) and 
amino acids 96-138 (∆exon 4, Family C, c.414+1G>A) from one allele, and the positions of 
the missense variants on the second allele, Q372H (c.1116G>C, Family A) and N155S 
(c.464A>G, Family C).  
To test these antibodies for the desired experimental applications (western blotting, 
immunocytochemistry and immunohistochemistry) we generated expression constructs of 
wildtype human PYROXD1, and two patient missense variants, N155S and Q372H. We 
generated constructs without epitope tags to optimise western blotting, as well as GFP-
PYROXD1 fusion constructs to optimise immunocytochemistry. 
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Figure 4.1: PYROXD1 antibody immunogen regions and predicted changes to patient 
protein indicated on the PYROXD1 protein. To-scale schematic representing the 500 amino 
acid human PYROXD1 (NM_024854) protein. Immunogens used to generate three 
commercial antibodies against human PYROXD1 are annotated with the respective antibody 
and amino acid span in brackets. Protein changes within Pyroxd1 patients from Family A and 
C are annotated. 
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Optimisation of Pyroxd1 antibodies for western blot 
To allow optimal protein extraction we tested two solubilisation methods: Extraction with (1) 
RIPA buffer (RadioImmunoPrecipitation Assay) and (2) Sodium dodecyl sulphate (SDS) lysis 
buffer. The lysis buffer used for protein solubilisation prior to separation by SDS 
polyacrylamide gel electrophoresis (PAGE) is dependent on the localisation and biochemical 
properties of the protein. Mild extraction with RIPA is commonly used for cell and tissue 
protein extractions. Whereas more harsh extraction by SDS lysis buffer is required when the 
protein in question is a structural protein or binds to the cytoskeleton. As PYROXD1 had not 
been previously studied, the ideal extraction method was unknown.  
We carried out protein extraction on human control skeletal muscle and primary human 
fibroblasts with RIPA or SDS lysis buffer (Figure 4.2). We found a light extraction with RIPA 
resulted in no detectable PYROXD1 from skeletal muscle and very low levels of PYROXD1 
from primary human fibroblasts by western blot. Extraction with SDS better enabled detection 
of PYROXD1. Based on PYROXD1 mRNA levels in GTEx (Figure 4.3), we had expected 
similar protein levels in fibroblasts and skeletal muscle. However, we detected higher levels of 
PYROXD1 in primary human fibroblasts compared to skeletal muscle despite the skeletal 
muscle manifestation of PYROXD1 mutations (Figure 4.3).  
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Figure 4.2: SDS lysis results in the best extraction of PYROXD1 protein from skeletal 
muscle and fibroblast samples. Western blot of 20 µg control human skeletal muscle (SkM), 
control primary human fibroblast (PHF) and 5 µg Cos-7 cell lysates with protein extracted with 
RIPA or SDS lysis buffer probed for PYROXD1 and GAPDH. Cos-7 cells transfected (T) with 
wild type human PYROXD1 extracted with SDS were used as a positive control where a 
protein band immunoreactive to an anti-PYROXD1 antibody (AB122458) runs at ~65 kDa and 
is stronger than that seen in untransfected (UT) Cos-7 cells. Skeletal muscle protein extracted 
with RIPA does not contain enough PYROXD1 to be detected by western blot and PYROXD1 
is weakly detected in primary human fibroblasts. Skeletal muscle protein extracted with SDS 
lysis buffer contains enough PYROXD1 to be detected by western blot with a stronger 
PYROXD1 band observed in primary human fibroblasts. Coomassie of myosin and actin were 
used as positive controls for SDS extraction of skeletal muscle. M- Molecular weight marker. 
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Figure 4.3: PYROXD1 RNA is expressed ubiquitously and at low levels. PYROXD1 RNA 
expression in 53 human tissues from 544 donors. PYROXD1 RNA is detected in all 53 tissues. 
RPKM – Reads per kilobase per million. These images were adapted from the GTEx portal 
(https://www.gtexportal.org/home/). 
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Optimisation of Pyroxd1 antibodies for immunocytochemistry and immunohistochemistry  
We utilised the GFP-fused PYROXD1 expression construct (GFP-PYROXD1) to determine 
localisation of PYROXD1 in transfected cells and optimise PYROXD1 antibodies for 
immunocytochemistry by comparing the predicted staining pattern. As PYROXD1 is predicted 
to be a soluble enzyme present at low levels, we were mindful that harsh permeabilisation 
techniques such as high concentrations of triton and saponin as well as alcohol permeabilisation 
might extract PYROXD1 from fixed cells, so we tested a number of permeabilisation 
techniques and compared the results. 
Light permeabilisation: Cos-7 cells were transfected with GFP-PYROXD1, permeabilised 
with 0.015% saponin and stained separately with two PYROXD1 antibodies, AB122458 and 
SAB1104648 (Figure 4.4). GFP staining was dominantly nuclear, with lower levels of staining 
evident within the cytoplasm. We observed a lack of correlation between GFP fluorescence 
and staining from the AB122458 PYROXD1 antibody (Left panel, green arrows). Furthermore, 
staining of endogenous PYROXD1 (negative for GFP fluorescence) differed for each antibody. 
The AB122458 PYROXD1 antibody showed an intense signal in a cluster to the periphery of 
the nucleus (left panel, red arrow). Whereas the SAB1104648 PYROXD1 antibody showed 
weak cytoplasmic staining, with intense signal observed within the nucleus (Right panel, 
yellow arrow) and in a cluster to the periphery of the nucleus (Right panel, red arrow). While 
weak GFP fluorescence was observed to the periphery of the nucleus, the intensity of the signal 
was inconsistent with the staining intensities observed with the PYROXD1 antibodies. 
Permeabilisation with 0.01% triton, 0.1% triton and 0.15% saponin showed similar staining 
patterns (data not shown).  
The lack of correlation between GFP fluorescence and PYROXD1 antibody staining seen with 
saponin or triton permeabilisation suggested detergent was unlikely to provide optimal 
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permeabilisation conditions for detection of PYROXD1. Therefore, we next tried alcohol 
permeabilisation.  
Alcohol permeabilisation: We permeabilised Cos-7 cells transfected with GFP-PYROXD1 
with methanol, acetone or methanol:acetone v:v and stained with anti-PYROXD1 AB122458 
(Figure 4.5). Each condition showed good correlation between GFP-PYROXD1 fluorescence, 
and fluorescent labelling with anti-PYROXD1 AB122458 (and also for anti-PYROXD1 
AB204560 and SAB1104648, not shown). Thus, alcohol extraction was determined to provide 
the best revelation of PYROXD1 immunogens for labelling. Our data also suggest, anecdotally, 
that PYROXD1 may not exist as a freely diffusable soluble enzyme in the nucleoplasm or 
cytoplasm, but is bound to other proteins or tethered to the cytoskeleton, and thus resistant to 
alcohol extraction. 
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Figure 4.4: Localisation of GFP-PYROXD1 and antibody labelling differ when 
permeabilised with saponin. Cos-7 cells transfected with GFP-PYROXD1 stained with anti-
PYROXD1 AB122458 (left panel) or SAB1104648 (right panel) and DAPI. GFP-PYROXD1 
is predominately localised to the nucleus with lower levels detected in the cytoplasm. 
AB122458 inconsistently stains the GFP-PYROXD1 construct (Green arrows) with staining 
of endogenous PYROXD1 seen in cytoplasmic clusters (red arrow). SAB1104648 consistently 
stains the GFP-PYROXD1 construct with staining of endogenous PYROXD1 predominately 
localised to the nucleus (yellow arrow) and additionally, to cytoplasmic clusters (red arrow). 
PYROXD1 – red, GFP – green, DAPI – blue. 
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Figure 4.5: Alcohol permeabilisation results in consistent and specific detection of 
PYROXD1 by immunocytochemistry. Cos-7 cells transfected with GFP-PYROXD1 
permeabilised with methanol (left panel), acetone (centre panel), or methanol:acetone v:v (right 
panel) and stained with anti-PYROXD1 AB122458. In each permeabilisation condition the 
PYROXD1 antibody consistently and specifically stains the GFP-PYROXD1 construct. 
PYROXD1 – red, GFP – green, Dapi – blue.   
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4.2.1.2 Cell & molecular biology and biochemistry of PYROXD1 
Nuclear localisation and export signals within Pyroxd1 
In Figures 5A and 6 of Part A, we established PYROXD1 as a nuclear-cytoplasmic 
oxidoreductase. Observing that PYROXD1 localised to the nucleus in some cells, but not in all 
cells; results suggest PYROXD1 may dynamically shuttle between the nucleus and cytoplasm. 
PYROXD1-patient skeletal muscle showed increased PYROXD1 expression within 
internalised nuclei coupled with reduced cytoplasmic expression in fibres burdened with 
aggregates, fibre splitting and internalised nuclei (Figure 5B), in comparison to staining 
intensities observed in control skeletal muscle.  
We used predictive programs to determine whether PYROXD1 contained nuclear localisation 
sequences (NLS) and nuclear export sequences (NES) (Figure 4.6). cNLS mapper (http://nls-
mapper.iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi) discovered 8 sequences within 
PYROXD1 predicted to target PYROXD1 to both the nucleus and the cytoplasm (Figure 4.6A). 
NetNes 1.1 (http://www.cbs.dtu.dk/services/NetNES/) predicted a nuclear export sequence 
inclusive of leucine 476 as the hydrophobic residue. Collectively, these results support the 
hypothesis that PYROXD1 is a dynamic enzyme capable of translocating between the nucleus 
and cytoplasm. This has led to further investigations into the translocation of PYROXD1 under 
oxidative distress, beyond the scope of this thesis – and now the topic of investigation for 
another PhD student within our group.          
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Figure 4.6: PYROXD1 contains predicted NLS and NES.  
(A) Predicted NLS within human PYROXD1 predicted by cNLS Mapper and marked on the 
PYROXD1 (NM_024854) sequence. Scoring: The localisation of a GUS-GFP protein fused to 
a sequence with a score of: 1-2, cytoplasm; 3-5, nucleus and cytoplasm; 7-8 nucleus partially; 
8-10, nucleus (B) DeepView/Swiss-Pdb viewer (v 4.1.0, http://www.expasy.org/spdbv/) was 
used for molecular modelling of the PYROXD1 homology model generated by A/Prof Roger 
Bryan Sutton. Left panel - NLS from (A) highlighted in: orange, green, pink, red, cyan, lilac, 
black and white from N- to C- terminal; Right panel – NES predicted by NetNes 1.1 indicated 
by leucine 476 highlighted in pink.   
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PYROXD1 protein levels within human skeletal muscle and mouse tissues 
To determine PYROXD1 protein levels within skeletal muscle during development, we 
performed western blot of human skeletal muscle samples from a cross-section of ages. We 
detected a ~55 kDa PYROXD1 protein in all tested ages (14/40 weeks gestation to 58 years; 
Figure 4.7). We then explored PYROXD1 protein levels during in vitro myogenic 
differentiation of primary human myoblasts into myotubes. Western blot detected a ~55 kDa 
PYROXD1 protein in myoblasts and myotubes (day 0 - day 8 of differentiation; Figure 4.8). 
We also observed additional bands with the PYROXD1 AB122458 antibody which do not 
correspond to known isoforms. From the late perinatal period we consistently see a 32 kDa 
band (Figure 4.7) and in differentiating myoblasts we see an 80 kDa band (Figure 4.8) band. 
These bands may be isoforms, degradation products, posttranslational modification or non-
specific binding of the antibody.  
The GTEx database suggested ubiquitous expression of PYROXD1 mRNA (refer to Figure 
4.2). To explore protein levels of PYROXD1, we performed western blot on mouse tissues and 
myoblasts, probing membranes with the AB122458 PYROXD1 antibody. We observed a ~55 
kDa Pyroxd1 protein in mouse brain, bladder, kidney, testis, uterus, skeletal muscle (Figure 
4.9, left blot, red arrow) and differentiating mouse myoblasts (right blot, red arrow). 
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Figure 4.7: PYROXD1 is expressed throughout skeletal muscle development.  
Western blot of whole human skeletal muscle lysates through development probed with an 
anti-PYROXD1 antibody (AB122458). PYROXD1 (55 kDa) is detected in all ages tested 
(14/40 weeks gestation to 58 years of age). A 32 kDa band is detected consistently from the 
late perinatal period, the relevance of this band is unknown. Cardiac actin was used as a control 
for pre-natal skeletal muscle; GAPDH was used as a loading control; sarcomeric actin and 
myosin were used as loading controls for skeletal muscle. W - weeks of gestation, D - days, M 
- months, Y – years, X-empty lane. 
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Figure 4.8: PYROXD1 is expressed consistently throughout differentiating primary 
human myoblasts. Western blot on whole cell lysates of primary human myoblasts 
differentiated for 8 days and probed for PYROXD1 (AB122458). Cell lysate from HEK293T 
cells transfected with EGFP-CI human PYROXD1 (untagged) was used as a positive control 
(55 kDa). PYROXD1 is detected consistently from day 0 to day 8 of myoblast differentiation, 
in comparison to the muscle protein alpha-actinin which is detected weakly from differentiation 
day 1 with expression increasing with differentiation age. An 80 kDa band is consistently 
detected in all samples, the relevance of this band is unknown. GAPDH and β-tubulin were 
used as loading controls. X- empty lane. 
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Figure 4.9: Pyroxd1 protein is detected in adult mouse tissues and differentiating mouse 
myoblasts. Western blot of: Left blot - whole tissue lysates from C57BL/6J wild type mouse 
brain, bladder, kidney, testis, uterus and skeletal muscle (SkM); and human skeletal muscle, 
primary human fibroblasts (PHF); Right blot – whole cell lysates from mouse and human 
primary myoblasts differentiated for 0, 3 and 6 days. Membranes were probed with an antibody 
against PYROXD1 (AB122458). Red arrow – mouse Pyroxd1/human PYROXD1.  
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Investigating disulphide bond formation within PYROXD1 
Evolutionary analysis identifies PYROXD1 within a class of oxidoreductases (Class I PNDRs) 
which have the characteristic feature of  a redox-active disulphide bond, utilised in the first 
electron transfer step of substrate reduction (Argyrou & Blanchard, 2004). We carried out 
reducing and non-reducing western blots on HEK293T cells transfected with GFP-PYROXD1 
and PYROXD1 constructs. Formation of one or more intramolecular disulphide bridges 
between the 11 cysteines within PYROXD1 should result in a more globular secondary 
structure, enabling progression through the polyacrylamide gel at an apparent lower molecular 
weight.  
GFP-PYROXD1-WT, GFP-PYROXD1-N155S and GFP-PYROXD1-Q372H constructs ran at 
80 kDa (Figure 4.10B, green arrow). PYROXD1-WT, PYROXD1-N155S & PYROXD1-
Q372H ran at 55 kDa (Red arrow). A non-specific band was evident at 80 kDa in all samples, 
and endogenous PYROXD1 at 55 kDa. When these samples were separated on a non-reducing 
gel (Figure 4.10B, right blot), we observe an additional lower molecular weight band at 70 kDa 
(green asterisks), only in samples transfected with GFP-PYROXD1. This suggests PYROXD1 
forms an intramolecular disulphide bond with GFP. GFP contains two cysteines - at amino 
acids 49 and 71. There are two amino acids between PYROXD1 and GFP - serine and glycine. 
This places GFP within close proximity to PYROXD1, making a disulphide bond with one of 
the 11 cysteines within PYROXD1 a possibility. However, we could find no evidence 
supporting the existence of a covalent intramolecular disulphide within PYROXD1 itself. 
We also carried out reducing and non-reducing western blots on primary human fibroblasts 
from controls and patients of Family A & C, and skeletal muscle from Family A. We observed 
no difference in banding patterns between reducing and non-reducing western blots (Figure 
4.11B). This suggests PYROXD1 does not form intramolecular disulphide bonds with 
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cysteines within PYROXD1 that differ between patients and controls, detectable by this 
technique.     
 
 
 
 
Figure 4.10: Exogenous PYROXD1 forms an intramolecular disulphide bond with N-
terminally fused GFP. HEK293T cells were transfected with PYROXD1-WT, N155S or 
Q372H with (+) or without (-) an N-terminally fused GFP tag. Reducing (left) and non-
reducing (right) western blots were carried out on cell lysates solubilised in the presence of N-
Ethylmaleimide to quench free thiols and probed for PYROXD1 (AB122458). GFP-
PYROXD1 constructs run at 80 kDa (green arrow) with a non-specific band at the same 
molecular weight seen in all remaining samples. Non-GFP fused constructs run at 55 kDa (red 
arrow). In the non-reducing western blot we observe a 70 kDa band (green asterisks) only in 
samples transfected with GFP-fused PYROXD1. 
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Figure 4.11 Endogenous wildtype and patient PYROXD1 do not show evidence of 
intramolecular disulphide bond formation. (A) Cysteines within PYROXD1 are highlighted 
in pink. Patient variants from Family A (upper panel) and Family C (lower panel) are 
highlighted in yellow with the missense variants denoted with the wild type amino acid in the 
left model and the missense variant in the right model. DeepView/Swiss-Pdb viewer (v 4.1.0, 
http://www.expasy.org/spdbv/) was used for molecular modelling of the PYROXD1 homology 
model generated by A/Prof Roger Bryan Sutton; (B) Reducing (left) and non-reducing (right) 
western blots were carried out on lysates solubilised in the presence of N-Ethylmaleimide to 
quench free thiols and probed for PYROXD1 (AB122458). HEK293T cells were transfected 
(T) with PYROXD1-WT untagged which runs at approximately 65 kDa with a weaker band 
evident in untransfected (UT) HEK293T cells at the same molecular weight (red arrow, 
endogenous PYROXD1). PYROXD1 is detected in primary skin fibroblasts from controls (42 
and 46 years), Family A (29 and 26 years) and Family C (6 and 8 years) at 65 kDa with a non-
specific band at 85 kDa (top blue arrow). PYROXD1 is detected in skeletal muscle (SkM) from 
a healthy control (C – age 11 years) and Family AII-1 (11 years) at 65 kDa with a non-specific 
band at 25 KDa (lower blue arrow). No additional bands were observed on the non-reducing 
gel. Sarcomeric actinin was used as loading control for skeletal muscle and GAPDH as a 
loading control for HEK293T cells and primary human fibroblasts.  
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4.2.1.3 Patient PYROXD1 variants and PYROXD1 in muscle disease 
Protein levels of patient splice site variants 
PYROXD1-patients showed normal or reduced levels of PYROXD1 protein (Part A, Figure 4A 
and B). The anti-PYROXD1 antibody AB122458 recognises an immunogen encoded by amino 
acids 28-125 of PYROXD1 (NM_024854). Western blot using AB122458 did not reveal 
evidence for truncated protein products resulting from the splice site variants identified in 
Family A and C – shown previously to cause in-frame skipping of exon 3 (Family A) or exon 
4 (Family C) (Part A, Figure 1D). However, deletion of exon 3 (corresponding to amino acids 
56-95) or exon 4 (corresponding to amino acids 96-138) may remove the antibody binding site. 
 To confirm the observed results were not due to removal of the antibody binding site, we 
probed the same samples with a second PYROXD1 antibody, AB204560. AB204560 
recognises an immunogen encoded by amino acids 260-357 (NM_024854). Therefore, the 
antigen recognised by PYROXD1 AB204560 antibody could not be removed by the patient 
splice-site variants. (Refer to Figure 4.1 for antibody immunogen schematics). 
 A duplicate western blot probed with AB204560 (Figure 4.12, upper panel) showed results 
consistent with AB122458 (Figure 4.12, lower panel). The Q372H missense variant harboured 
by Family A was expressed at reduced levels, and the N155S missense variant carried by 
Family C was expressed at normal levels, compared to controls. Thus, collective results suggest 
the in-frame deletion of residues encoded by exon 3 (Family A) or exon 4 (Family C) does not 
produce a stable protein detectable by western blot. 
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Figure 4.12: Patient splice site variants causing in-frame exon deletions do not produce a 
protein detectable by western blot. Cos-7 or HEK cells were transfected (T) with 
PYROXD1-WT as a positive control. PYROXD1-WT runs at approximately 60 kDa, with a 
weak band present at the same molecular weight in untransfected Cos-7 or HEK cells (UT). 
PYROXD1 is detected in primary skin fibroblasts from controls (42 and 46 years), Family A 
(29 and 26 years) and Family C (6 and 8 years) at 55 kDa (red arrow). Lower levels of 
PYROXD1 are detected in Family A with no lower molecular weight bands seen uniquely in 
patients corresponding to expression of PYROXD1 absent of exon 3 (Family A, 4.4 kDa) and 
exon 4 (Family C, 4.7 kDa). Upper blot – probed with anti-PYROXD1 AB204560; Lower blot 
re-presented from Figure 4 Part A – probed with anti-PYROXD1 AB122458. Beta-tubulin, 
GAPDH and emerin were used as loading controls. X – lane containing the molecular weight 
ladder. 
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Intron retention within PYROXD1 
Essential splice site variants identified within Family A and Family C caused in-frame skipping 
of exon 3 and 4 respectively (refer to Figure 1D & E, Part A). These transcripts do not contain 
a premature termination codon (PTC), and therefore should not activate nonsense-mediated 
decay (NMD). Interestingly, we cannot detect protein product of patient splice site variants by 
western blot (refer to Figure 4.12). However, intron retention was also a plausible outcome 
from the essential splice site variants. Intron retention would generate a premature stop codon, 
triggering nonsense-mediated decay - possibly explaining the absence of protein on western 
blot.  We designed additional PCRs to test for relative levels of intron-3 or intron-4 retention 
in Family A or Family C (respectively), versus controls.   
I extracted mRNA from control and patient primary skin fibroblasts and synthesised cDNA. I 
carried out PCR amplification of the cDNA using primer pairs to detect intron 3 and intron 4 
retention (Figure 4.13). Unexpectedly, I found evidence for exon-3 extension in fibroblast 
cDNA from controls (C1 and C2), both siblings from Family A (who bear the intron 3 variant), 
and Family C (who bear the intron 4 variant) (Figure 4.13A). This data suggests a level of 
innate leakiness at this splice site in controls. I also found evidence for intron-4 retention in 
fibroblast cDNA from controls, both siblings from Family A and both siblings from Family C. 
This data suggests, as with Exon 3, that there is an innate leakiness at this splice site in controls. 
Collectively, these data suggest intron retention and subsequent NMD does not explain the 
absence of truncated PYROXD1 proteins encoded by patient splice-site variants. 
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Figure 4.13: Extension of exon 3 and exon 4 of PYROXD1 is evident in controls. mRNA 
was extracted from skin fibroblasts of controls (C1, C2), Family A (blue - AII-1, AII-2) and 
Family C (pink- CII-2, CII-1). cDNA was synthesised using random PdN(6) (P) or OligoDT20 
(O) primers. Control gDNA was used as the negative DNA control (-ve) and water (W) as a 
negative control. E – Exon, I – Intron, X – blank lane. (A) PCR was carried out with primers 
within exon 1 (F, green arrow) and intron 3 (3R, red arrow) to detect extension of exon 3. Low 
levels of exon 3 extension were detected as a 327 bp band in controls and Family A with higher 
levels detected in Family C. Family A splice site variant - blue asterisks, Family C splice site 
variant - pink asterisks. (B) PCR was carried out with primers within exon 1 (F, green arrow) 
and intron 4 (4R, red arrow) to detect extension of exon 4. Exon 4 extension was detected in 
all samples as a 487 bp band. The 367 bp band detected within Family A is consistent with the 
deletion of exon 3 caused by their splice site variant (blue, ∆exon3). Family C splice site variant 
-pink asterisks.  
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Proteasome degradation of PYROXD1 patient variants 
Next, we hypothesised the variant forms of PYROXD1 (namely, lacking residues encoded by 
exon 3 or exon 4) were unstable and were being targeted for ubiquitin-mediated proteasomal 
degradation. To investigate this hypothesis, we treated control and patient primary skin 
fibroblasts with the proteasome inhibitor MG132, and determined protein levels by western 
blot. We did not observe a lower molecular weight band corresponding with the in-frame 
deletion of exon 3 (reduction by 4.4 kDa) in Family A, nor a noticeable difference in expression 
of PYROXD1 Q372H (Figure 4.14A). Thus, we were unable to confirm active degradation of 
misfolded protein products by the proteasome, and these experiments were not further pursued.  
Similarly, treatment of fibroblast cultures from Family C siblings with MG132 showed no 
significant difference in levels of PYROXD1 expression. This result suggests N155S is not 
influenced by the proteasome. A weak lower molecular weight band corresponding to protein 
product from c.414+G>A (reduction by 4.7 kDa) was observed with MG132 treatment (Figure 
4.14B, red asterisk). This result suggests, PYROXD1 protein harbouring the c.414+G>A 
variant, causing in-frame deletion of exon 4, is made at very low levels and degraded by the 
proteasome. Collectively, these results are consistent with the equal levels of cDNA expression 
observed from each allele in Family A, and a biased towards N155S in Family C (Figure 1E, 
Part A).   
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Figure 4.14: MG132 treatment mildly rescues the protein expression of splice site variant 
within Family C but not Family A. Cos-7 cells were transfected (T) with PYROXD1-WT as 
a positive control running at approximately 60 kDa (red arrow) with a weaker band present at 
the same molecular weight in untransfected Cos-7 cells (UT, endogenous PYROXD1). Primary 
skin fibroblasts were treated with the proteasome inhibitor MG132 (+) or vehicle control 
DMSO (-) and run on a reducing western blot. PYROXD1 is detected in all primary skin 
fibroblasts at 60 kDa. (A) Family A shows a lower level of PYROXD1 expression with no 
lower molecular weight bands detected unique to patient samples; (B) Family C shows a 
normal level of PYROXD1 expression with a faint lower molecular weight band in MG132 
treated samples (red asterisks) corresponding to the molecular weight of PYROXD1 containing 
the patient’s splice site variant and absence of exon 4 (decrease of 4.7 kDa). A non-specific 
band is detected at 80 kDa (blue arrow). 
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PYROXD1 levels in dystrophic muscle 
The Australian index case (Family A) had an initial clinical diagnosis of muscular dystrophy, 
due to dystrophic features observed in patient muscle. To determine whether PYROXD1 
protein was also involved in the pathogenesis of other types of dystrophies we investigated 
PYROXD1 protein levels in: (1) Duchenne muscular dystrophy (DMD) (2) Limb girdle 
muscular dystrophy type 2B (DYSF); and (3) Limb girdle muscular dystrophy type 2A 
(CAPN3), caused by variants within calpain 3.  
Skeletal muscle lysates were loaded so total actin levels were equal between samples. 
Dystrophic muscle contains an increased number of nuclei (Dubowitz, Sewry, & Oldfors, 
2013). We rationalised PYROXD1 levels should be analysed in comparison to a nuclear 
marker, due to PYROXD1 predominantly localising within the nucleus (Part A, Figure 6). 
When PYROXD1 levels were normalised to emerin, PYROXD1 protein levels did not differ 
between dystrophic and healthy muscle (Figure 4.15). 
148 
 
 
Figure 4.15: Skeletal muscle PYROXD1 expression in muscular dystrophy patients does 
not differ to controls. Western blot of whole muscle lysates from healthy controls (5 and 21 
years), duchenne muscular dystrophy caused by variants within dystrophin (8 and 5 years), 
limb girdle muscular dystrophy type 2B caused by variants within dysferlin (22 and 20 years) 
and limb girdle muscular dystrophy type 2A caused by variants within calpain 3 (18 and 17 
years). Actin & myosin coomassie and α-actinin probe were used as loading controls for 
skeletal muscle. GAPDH and β-tubulin were used as markers for fat and connective tissue 
infiltration in diseased muscle. Emerin was used as a nuclei marker. PYROXD1 expression 
levels match those of emerin and when this is taken into account, PYROXD1 expression within 
dystrophic muscle does not differ to that within controls. 
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Localisation of PYROXD1 in patient fibroblasts 
Protein localisation studies showed exogenous PYROXD1 missense variants did not alter the 
localisation of PYROXD1 (refer to Figure 6, Part A). Here, we investigated the localisation of 
endogenous PYROXD1 in primary human fibroblasts. Figure 4.16 shows consistent 
localisation patterns between patients of Family A & C and controls - predominant nuclear 
localisation with diffuse cytoplasmic staining.  
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Figure 4.16: PYROXD1 localisation in patient primary skin fibroblasts does not differ to 
controls. Primary human fibroblasts were co-stained with PYROXD1 (AB122458) and DAPI. 
PYROXD1-patient fibroblasts from Family A (AII-1 & AII-2) and Family C (CII-1 & CII-2) 
show predominant PYROXD1 staining within the nucleus and diffuse cytoplasmic staining 
coupled with stronger staining to the periphery of the nucleus. Control primary human 
fibroblasts match the staining patterns observed in our patients. PYROXD1 – red, DAPI – blue. 
Note: Exposure times were higher for patient compared to control fibroblasts to observe 
perinuclear staining.  
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Parallels between PYROXD1-myopathy and neurodegeneration 
Collectively, our data suggests oxidative distress caused by perturbed PYROXD1 activity is 
only evident within long lived cells. The dominant clinical presentations of our patients are 
muscular. In addition, our eldest PYROXD1-patient (AII-1), is beginning to present with a 
peripheral neuropathy. The pathological features of PYROXD1-myopathy share similarities 
with neurodegenerative disease – mitochondrial dysfunction, cellular atrophy and cellular 
aggregates (Rothstein, 2009). Variants within TDP-43 cause motor neuron disease, as well as 
being a component of skeletal muscle aggregates in myofibrillar myopathy (Olive et al., 2009; 
Rothstein, 2009). We have shown a link between PYROXD1-myopathy and myofibrillar 
myopathy. Therefore, we wanted to investigate the link between PYROXD1 and 
neurodegeneration. 
We stained PYROXD1-patient muscle for the neuronal aggregate markers αβ-crystalin and 
TDP-43. We found aggregates within PYROXD1- patient muscle stained for αβ-crystalin and 
TDP-43 (Figure 4.17). Furthermore, when we stained myofibrillar myopathy skeletal muscle, 
we found skeletal muscle aggregates also stained for PYROXD1 (Figure 4.18). These results 
draw a parallel between PYROXD1-myopathy and neurodegeneration. Further studies need to 
be carried out, to determine if similar pathways are involved in the pathogenesis and if similar 
mechanistic therapies may be successful. 
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Figure 4.17: Neuronal aggregate markers αβ-crystalin and TDP-43 stain aggregates 
within PYROXD1 patient muscle. Sequential sections of skeletal muscle (quadricep) from 
PYROXD1-patient AII-1 (15 years), a myofibrillar myopathy patient (45 years) and a healthy 
control (38 years) stained for DAPI (blue) and the neuronal aggregate markers αβ-crystalin 
(yellow) & TDP-43 (green). In healthy control muscle αβ-crystalin stains the centre of the 
myofibre and TDP43 stains the peripheral nuclei. In myofibrillar myopathy control and 
PYROXD1-patient AII-1 muscle αβ-crystalin and TDP-43 stain myofibril aggregates.  
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Figure 4.18: PYROXD1 labels aggregates within myofibrillar myopathy patient muscle. 
Sequential sections of skeletal muscle (quadricep) from PYROXD1-patient AII-1 (15 years), a 
myofibrillar myopathy patient (45 years) and a healthy control (38 years) stained for myotilin 
(cyan) and co-stained for desmin (purple) and Pyroxd1 (red – AB122458). In healthy control 
muscle myotilin stains the centre of the myofibre, desmin stains the periphery of the myofibre 
and PYROXD1 predominantly stains the peripheral nuclei with lower levels of staining seen 
within the centre of the myofibre. In PYROXD1-patient AII-1 and myofibrillar myopathy 
control muscle myotilin, desmin and PYROXD1 stain myofibril aggregates.   
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4.3 PART C: Generating mouse models to gain insight into 
PYROXD1 biology and disease  
4.3.1 Introduction 
4.3.1.1 The international Knockout Mouse Consortium 
The International Knockout Mouse Consortium (IKMC) formed in 2006, aims to generate a 
null-reporter mouse for each protein-encoding gene, and make these available to the scientific 
community to study gene function (Collins, Finnell, Rossant, & Wurst, 2007). The IKMC is 
made up of three knock-out programs: (1) KnockOut Mouse Project (KOMP), (2) European 
Conditional Mouse Mutagenesis Program (EUCOMM), and (3) North American Conditional 
Mouse Mutagenesis Project (NorCOMM) ("A Mouse for All Reasons," 2007). The IKMC 
chose to use the C57BL/6 mouse strain as the background mouse strain for the generation of 
mutant alleles ("A Mouse for All Reasons," 2007). The C57BL/6 is one of the best 
characterised mouse strains, applicable to many fields of research, and C57BL/6J was the 
reference strain used to first sequence the mouse genome (Mouse Genome Sequencing et al., 
2002). A C57BL/6 embryonic stem cell line with robust germline transmission was established 
for the international mouse knockout program - JM8 from the C57BL/6N mouse strain (Pettitt 
et al., 2009). A combination of gene-trapping and gene-targeting technologies were used in 
C57BL/6N embryonic stem (ES) cells to generate a conditional knockout resource for the 
scientific community (Skarnes, Auerbach, & Joyner, 1992; Skarnes et al., 2011; Testa et al., 
2004). 
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4.3.1.2 Aims of this project 
In Parts A and B we established PYROXD1 as a new player in muscle disease and oxidative 
biology. The next goal was to establish an appropriate mouse model as a tool to study: (1) the 
role of PYROXD1 in fundamental biology; and (2) the role of PYROXD1 in disease 
pathogenesis.  
More specifically, the aims for this project were: 
Aim 1: To define the tissue-specific and developmental expression of murine Pyroxd1. 
Aim 2: To develop a skeletal muscle knock-out of murine Pyroxd1. 
4.3.1.3 Background 
We utilised the knockout-first conditional Pyroxd1 Tm1a mouse strain from KOMP, available 
through the KOMP repository (https://www.komp.org/). While this strain had been generated 
by KOMP, no characteristaion had been carried out on this strain at time of purchase. The 
Pyroxd1 Tm1a allele (Figure 4.19A) is a knock-out-first conditional allele and serves three 
purposes: (1) β-galactosidase reports on the expression of Pyroxd1; (2) the genetrap knocks-
out Pyroxd1 expression at the transcript level; and (3) the FRT and loxP sites enable generation 
of a conditional Pyroxd1 knock-out allele.  
Components of the gene trap enable reporting of Pyroxd1 expression by β-galactosidase. FRT 
sites flank the genetrap (Figure 4.19A). The FRT sites allow FLP-mediated excision of the gene 
trap, re-establishing wild type Pyroxd1 expression. Exon 5 of Pyroxd1 lies outside of the 
genetrap, and is flanked by loxP sites. The loxP sites flanking exon 5 of Pyroxd1 allow cre-
mediated excision of exon 5. Removal of exon 5 generates a frameshift predicted to induce 
nonsense mediated decay of the mRNA transcript. Cre-mediated excision of exon 5 of Pyroxd1 
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allows conditional temporal and spatial knock-out of Pyroxd1 by ustilising cre-expressing 
mouse strains (http://www.mousephenotype.org/data/order/creline). 
The Tm1a genetrap cassette is inserted within introns 4 and 5 of Pyroxd1 and driven by the 
endogenous Pyroxd1 promotor (Figure 4.19A). The En2 splice acceptor (En2 SA) and SV40 
polyadenylation sequence (pA) allows incorportion of lacZ into the Pyroxd1 mRNA transcript 
(Figure 4.19B). There are two translation start sites from the Pyroxd1 Tm1a mRNA (Figure 
4.19B, red arrows). The first is the endogenous translation start site within exon 1 of Pyroxd1. 
The second translation start site, mediated by the internal ribosome entry site (IRES), is at the 
ATG of lacZ. Two protein products are predicted to be generated from the one Pyroxd1 Tm1a 
mRNA transcript (Figure 4.19C). The first is Pyroxd1 exons 1-4 plus 11 amino acids of the 
En2 SA sequence prior to the premature stop codon (PTC). The PTC is predicted to trigger 
nonsense-mediated decay, resulting in no Pyroxd1 protein generated from the Pyroxd1 Tm1a 
allele. The second predicted protein product is β-galactosidase. β-galactosidase reports on the 
expression of endogenous Pyroxd1. The presence of the Tm1a allele within endogenous 
Pyroxd1 is predicted to generate a Pyroxd1 knock-out allele at the mRNA level.     
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Figure 4.19: Pyroxd1 Tm1a conditional reporter mouse cassette. To scale schematic of (A) Pyroxd1 Tm1a KOMP cassette and points 
of insertion within the Pyroxd1 locus; (B) Predicted messenger RNA of the Pyroxd1 Tm1a allele, translation initiation sites marked with 
red arrows; and (C) Predicted protein primary structure of Pyroxd1 Tm1a. Two protein products are predicted: (1) Pyroxd1 exons 1-4 
with a premature stop codon 11 amino acids into the En2 sequence. This product would only be made if nonsense mediated decay did 
not degrade the mRNA transcript; and (2) Beta-galactosidase. FRT – flippase recognition target, En2 SA – En2 splice acceptor, IRES – 
internal ribosomal entry site, pA – SV40 polyadenylation sequence, loxP – lox sequence, hBactP – human beta actin promoter, neo – 
neomycin resistance gene, E – exon. The intron between FRT and En2 SA (876 bp) is not to scale.  
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4.3.2 Results 
4.3.2.1 Pyroxd1 null-reporter mouse strain 
Lethality of homozygous Pyroxd1Tm1a/Tm1a mice  
Upon receiving Pyroxd1 Tm1a mice from KOMP, we carried out genotyping to confirm the gene 
trap cassette was inserted within the Pyroxd1 locus, using two PCR reactions: (1) to identify the 
Pyroxd1 Tm1a allele (Figure 4.20A); and (2) to identify the endogenous Pyroxd1 allele (Figure 
4.20B).  
We received five mice from KOMP, for which genotyping confirmed heterozygosity for the 
Pyroxd1Tm1a allele (Pyroxd1Tm1a/WT), as expected (Figure 4.20). The genotyping strategy of the 
original embryonic stem cells was carried out across the 3’ homology arm (Skarnes et al., 2011). 
This leaves the possibility of a non-homologous insertion event having taken place. We confirmed 
correct insertion of the 5’ end of the Pyroxd1 Tm1a allele by Sanger sequencing (results not 
shown).  
Interestingly, we observed no Pyroxd1Tm1a/Tm1a mice in nine litters of Pyroxd1Tm1a/WT crosses. We 
expected 50% Pyroxd1Tm1a/WT, 25% Pyroxd1WT/WT and 25% Pyroxd1Tm1a/Tm1a. I observed 77% 
Pyroxd1Tm1a/WT and 23% Pyroxd1WT/WT mice (Chi-squared p-value = 1.1x10-5). Entertaining the 
possibility that global knock-out of Pyroxd1 in Pyroxd1Tm1a/Tm1a embryos is embryonic lethal, the 
expected genotype ratios would become 67% heterozygous and 33% wild-type. When 
homozygous embryos are excluded from expected ratios, the chi-squared value is then not 
significant at 2.5% (chi-squared, p-value = 0.026 > 0.025).  
159 
 
In 165 offspring from Pyroxd1Tm1a/WT crosses I observed 0/41 expected Pyroxd1Tm1a/Tm1a, based on 
Mendelian ratios.  This data provided compelling evidence that Pyroxd1Tm1a/Tm1a mice did not 
survive to weaning (3 weeks of age). Consistent with our observations, KOMP released data 
indicating that homozygous knock-out of Pyroxd1 results in pre-weaning lethality (based on 0 
homozygotes among 87 neonates from heterozygous crosses, 
http://www.mousephenotype.org/data/genes/MGI:2676395).  Further, global gene knock-out 
studies in human cell lines identified PYROXD1 as a gene essential for cell survival (Blomen et 
al., 2015; Hart et al., 2015; T. Wang et al., 2015). Therefore, the next question became: When does 
embryonic lethality of Pyroxd1Tm1a/Tm1a mice occur?  
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Figure 4.20: Genotyping of the Pyroxd1 Tm1a and endogenous Pyroxd1 alleles. 
(A) Screening of the Pyroxd1 Tm1a allele. Upper: To scale schematic of the Pyroxd1 Tm1a 
allele. Primer locations are indicated by black arrows (the start of each arrow marks the primer’s 
start location, remainder of arrow is not to scale) and PCR product size above. Lower:  Agarose 
gel of PCR products from Pyroxd1 (F0) screening for the Pyroxd1 Tm1a allele.; (B) Screening of 
the endogenous Pyroxd1 allele. Upper: To scale schematic of the endogenous Pyroxd1 allele with 
primer locations indicated by black arrows (the start of each arrow marks the primer’s start 
location, remainder of arrow is not to scale) and PCR product size above. Lower: Agarose gel of 
PCR products from Pyroxd1 (F0) screening for the endogenous Pyroxd1 allele. MQ – MilliQ 
water, horizontal filled lines – indicate introns, horizontal dashed lines – not to scale, numbering 
– indicate an exon, FRT – flippase recognition target, En2 SA – En2 splice acceptor, IRES – 
internal ribosomal entry site, pA – SV40 polyadenylation sequence, loxP – lox sequence, hBactP 
– human beta actin promoter, neo – neomycin resistance gene. The primers and PCR conditions 
utilised to screen for the endogenous Pyroxd1 allele were designed such that the Pyroxd1 Tm1a 
allele would not be detected (PCR product is 7556 bp – too long to be efficiently amplified with a 
40 second extension at 72°C). 
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We investigated whether Pyroxd1Tm1/Tm1a embryos were formed, but were reabsorbed prior to birth 
(ie, death was post-implantation). To address this question, we performed timed-mating of 
Pyroxd1Tm1a/WT mice, and genotyped two litters at embryonic day 10 (E10), approximately half 
gestation. The first dam carried 8 embryonic sacs, 4 of which were reabsorbed. The second dam 
carried 9 embryonic sacs, 3 of which did not contain an embryo. We expected 25% 
Pyroxd1Tm1a/Tm1a mice. Reabsorption of greater than 25% of embryos (50% and 33% respectively) 
meant it was possible Pyroxd1Tm1a/Tm1a embryos were formed, but reabsorbed by E10.  
We collected a tail clip of each embryo and a portion of the amniotic sac of reabsorbed embryos 
for genotyping. The amniotic sac consists of embryonic tissue (Dobreva et al., 2012; Pereira et al., 
2011). I did not observe any Pyroxd1Tm1a/Tm1a embryos or amniotic sacs at E10 (Figure 4.21). 
Absence of Pyroxd1Tm1a/Tm1a mice from two litters at E10 suggested Pyroxd1Tm1a/Tm1a embryos do 
not survive to E10.  
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Figure 4.21: Homozygous Pyroxd1 Tm1a embryos were not observed at ED10.  
(A) Screening of the Pyroxd1 Tm1a allele. Upper: To scale schematic of the Pyroxd1 Tm1a 
allele. Primer locations are indicated by black arrows and the PCR product size is specified above. 
Lower:  Representative agarose gel of PCR products from Pyroxd1 E10 screening for the Pyroxd1 
Tm1a allele.; (B) Screening of the endogenous Pyroxd1 allele. Upper: To scale schematic of the 
endogenous Pyroxd1 allele with primer locations indicated by black arrows  and the PCR product 
size is specified above. Lower: Representative agarose gel of PCR products from Pyroxd1 E10 
screening for the endogenous Pyroxd1 allele. MQ – MilliQ water, horizontal filled lines – indicate 
introns, horizontal dashed lines – not to scale, numbering – indicate an exon, FRT – flippase 
recognition target, En2 SA – En2 splice acceptor, IRES – internal ribosomal entry site, pA – SV40 
polyadenylation sequence, loxP – lox sequence, hBactP – human beta actin promoter, neo – 
neomycin resistance gene. The start of each arrow marks the primer’s start location, the remainder 
of arrow is not to scale. 
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We assessed whether the lack of Pyroxd1Tm1a/Tm1a mice at E10 is due to the inability of 
Pyroxd1Tm1a/Tm1a embryos to implant within the uterus. C57BL/6 mouse embryos implant within 
the uterus between E4.5 and 5.5 (Bedzhov, Leung, Bialecka, & Zernicka-Goetz, 2014). We 
harvested embryos soon after fertilisation and cultured the embryos ex vivo until the late blastocyst 
stage. The late blastocyst stage should provide an adequate number of cells for genotyping, while 
avoiding the challenges associated with in-vitro culture of post-implantation embryos (Bedzhov et 
al., 2014).  
To maximise the number of embryos per pregnancy and reduce the number of litters required to 
reach statistically significant numbers, we superovulated the dams prior to mating. Ovaries of 
pregnant dams were harvested at the zygote stage, E0.5 (Figure 4.22A). Pronuclei were cultured 
ex vivo and individually collected at E4.5 and genotyped as described above (Figure 4.22A). 
Pyroxd1Tm1a/Tm1a embryos were present at  E4.5 (Figure 4.22B – embryos 6 & 7) indicating 
Pyroxd1Tm1a/Tm1a embryos are made, and survive to pre-implantation age. This narrowed the 
window of embryonic lethality to between E4.5 and E9.5. 
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Figure 4.22: Homozygous Pyroxd1 Tm1a embryos are present at E4. (A) Images taken on a 
Leica MIR microscope demonstrate the process of embryo collection: Three week old 
Pyroxd1Tm1a/WT females were superovulated and mated with Pyroxd1Tm1a/WT males. Ovaries were 
harvested at E0.5 with the oviduct showing distention (white arrow) from over-production of eggs. 
Fertilised eggs were collected and grown ex vivo to E4. Each embryo was collected into a separate 
PCR tube. The process of embryo collection was carried out by Dr Frances Lemckert; (B) 
Representative agarose gel of Pyroxd1 E4 embryos screened for the endogenous Pyroxd1 and 
Pyroxd1 Tm1a alleles. Heterozygous Pyroxd1 gDNA was used as the positive control (+ve), MQ 
– MilliQ water. Embryos 6 and 7 are homozygous - A PCR band corresponding to endogenous 
Pyroxd1 is not detected (upper gel) and a PCR band corresponding to Pyroxd1 Tm1a is detected 
(lower gel).  
 
168 
 
β-galactosidase reporting of Pyroxd1 expression 
To define the tissue-specific and developmental expression of murine Pyroxd1 we utilised the lacZ 
reporter within the Pyroxd1 Tm1a allele of the Pyroxd1 Tm1a mouse strain. LacZ is controlled by 
the endogenous Pyroxd1 promoter. Therefore, lacZ is expressed when and where endogenous 
Pyroxd1 is expressed (refer to Figure 4.19). LacZ encodes β-galactosidase which can be detected 
with X-gal staining.  
We carried out X-gal staining on whole-mount E9.5 Pyroxd1 Tm1a embryos and preliminary 
results indicate X-gal staining in the developing brain (Figure 4.23). Of note, X-gal staining was 
not observed in all Pyroxd1Tm1a/WT embryos, nor consistently in sequential sections of the same 
embryo. We harvested E15.5 and E18.5 Pyroxd1 Tm1a embryos and brain, heart, lung, quad, 
ovaries/testis, stomach, spleen, kidney, bladder and liver of 3 and 12 month-old Pyroxd1 Tm1a 
mice. Unfortunately, X-gal staining was unsuccessful on cryo-sections despite trying a number of 
conditions. We performed western blot of Pyroxd1Tm1a/WT tissue to determine protein levels of β-
galactosidase, which was inconclusive (Appendix, Figure A.3). These results suggest very low 
levels of Pyroxd1 expression, too low to be detected consistently with this technique.  
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Figure 4.23: X-gal staining of the developing brain at E9.5 in the Pyroxd1Tm1a/WT mouse. X-
gal staining was performed on E9.5 embryos from a Pyroxd1Tm1a/WT intercross. Embryos were 
wax-embedded and sectioned at 8µm. They were subsequently dewaxed, stained with nuclear fast 
red and imaged with a Scanscope microscope. X-gal staining was detected in the developing brain 
(black arrows) at E9.5 in the Pyroxd1Tm1a/WT which was absent from a littermate control. 
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4.3.2.2 Generation of a murine model with skeletal muscle knock-out of Pyroxd1 
To further understand the role of Pyroxd1 in muscle biology and disease, we initiated a 
breeding program to derive a skeletal muscle knock-out of Pyroxd1. We anticipated a mouse 
model lacking Pyroxd1 protein within skeletal muscle would provide: (1) A Pyroxd1-
myopathy disease model to study disease pathogenesis of Pyroxd1-myopathy; (2) A Pyroxd1-
myopathy disease model to test treatments for Pyroxd1-myopathy; and (3) A system to study 
the biochemistry of Pyroxd1, by comparing Pyroxd1 wild type and Pyroxd1 knock-out tissue.  
The breeding regime to generate a Pyroxd1 skeletal muscle knock-out mouse line involved two 
breeding strategies, with multiple breeding steps. The first breeding strategy, designed to 
remove the gene trap, utilised the FLP-FRT system. The second breeding strategy, designed to 
knock-out both Pyroxd1 alleles within skeletal muscle, utilised the Cre-loxP system controlled 
by MyoD.  
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Breeding strategy one: Gene trap removal 
Background 
A global Pyroxd1 knock-out allele is induced by the gene trap within the Pyroxd1 Tm1a 
cassette (Figure 4.24). The gene trap cassette within the Pyroxd1 Tm1a allele is designed to be 
removed with the FLP-FRT system. FRT sites - 
5’GAAGTTCCTATTCTCTAGAAAGTATAGGAACTTC3’ – flank the gene trap cassette. 
The recombinase FLP (flippase) from Saccharomyces cerevisiae cuts at FRT sites removing 
the intervening sequence, regenerates one FRT site and maintains two loxP sites flanking exon 
5 – the PFLP allele. To remove the gene trap cassette, we crossed the Pyroxd1 Tm1a mouse 
line with a global FLP expressing mouse line, FLPe, (Rodriguez et al., 2000) (Figure 4.24, 
kindly donated to The Kids Research Institute by The Victor Chang Cardiac Research 
Institute). The human beta-actin promoter regulates global FLPe expression with flippase 
activity seen by mouse E10.5 (Rodriguez et al., 2000).  
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Figure 4.24: Predicted allele modification at the Pyroxd1 locus to re-establish a wild type 
allele. Crossing the Pyroxd1 mouse line - carrying the Pyroxd1 Tm1a allele, with a FLP mouse 
line – carrying the FLP transgene, is predicted to remove the gene trap cassette. The 
recombinase FLP cuts at the two FRT sites flanking the gene trap, removing the intervening 
sequence. The allele generated – PFLP - contains one regenerated FRT site and two loxP sites 
flanking exon 5 within intronic sequence. The PFLP allele expresses wild-type Pyroxd1 
mRNA translated into wild-type Pyroxd1 protein. The resulting line – PFLP – is expected to 
carrying the PFLP allele in a global fashion. FRT – flippase recognition target, loxP – lox 
sequence, SA – splice acceptor, pA – SV40 polyadenylation sequence, neo – promoter driven 
neomycin resistance gene, numbering in grey indicate exons, horizontal filled lines indicate 
introns.  
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Breeding step one 
The first breeding strategy involved two breeding steps: (1) Remove the gene trap cassette; and 
(2) breed the flippase transgene away and generate homozygous mice. The parental lines were 
Pyroxd1Tm1a/WT and homozygous FLPe mice (FLPFLP/FLP). We were unable to use 
Pyroxd1Tm1a/Tm1a mice due to their embryonic lethality. We crossed Pyroxd1Tm1a/WT and 
FLPFLP/FLP  which generated a new line – PFLP (Figure 4.25). We confirmed genotypes as 
depicted in Figure 4.26. FLP-mediated modification of the Pyroxd1 Tm1a allele generated the 
PFLP allele which was confirmed by Sanger sequencing (results not shown) and the 
unmodified Pyroxd1 Tm1a allele could not be detected by PCR (results not shown). Absence 
of the Pyroxd1 Tm1a allele suggests FLP recombinase excises the gene trap cassette in all 
nuclei 
Breeding step two 
The FLP cassette was then outbreed to avoid potential off target effects due to random insertion 
of the FLP transgene. PFLPPFLP/WT, FLP/WT (F1) were intercrossed (Figure 4.27) to generate the 
desired homozygous genotype, PFLPPFLP/PFLP,WT/WT. From here onwards, the FLP genotype is 
not depicted in breeding schematics or explanations 
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Figure 4.25: Breeding schematic to remove the gene trap from the Pyroxd1 Tm1a allele. 
Heterozygous Pyroxd1 mice were crossed with homozygous FLP mice. Flippase removes the 
genetrap cassette reverting the Pyroxd1 Tm1a allele to wild-type. A new mouse line is 
generated - PFLP. Predicted litter genotype proportions are marked as percentages and the 
desired genotype indicated with an asterisk. FRT – flippase recognition target, blue – LacZ, 
red – loxP site, cyan – promotor driven neomycin resistance gene, F1 – generation one, 
numbering in grey indicate exons, horizontal filled lines indicate introns. 
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Figure 4.26 Genotyping of the FLP and PFLP alleles. (A) Screening of the FLP allele. 
Upper: To scale schematic of the FLP allele. Primer locations are indicated in green arrows 
(the start of each arrow marks the primer’s start location, remainder of arrow is not to scale) 
and PCR product size above. Lower:  Representative agarose gel of PCR products from PFLP 
(F1) screening for the FLP transgene. MQ – MilliQ water; (B) Screening of the PFLP and 
endogenous Pyroxd1 alleles. Upper: To scale schematic of the PFLP and endogenous Pyroxd1 
alleles with primer locations indicated by blue arrows (the start of each arrow marks the 
primer’s start location, remainder of arrow is not to scale) and PCR product sizes indicated 
above respective alleles. Dashed  lines – not to scale,  FRT – flippase recognition site, loxP – 
loxP sequence, grey numbering indicate exons, horizontal filled lines indicate introns. Lower: 
Representative agarose gel of PCR products from PFLP (F1) – lanes 1-10; controls – lanes 11-
13: Pyroxd1 wild type (WT), Pyroxd1 heterozygous (het) and MilliQ (MQ); base pair ladder – 
lane 14.  The upper band indicates the PFLP allele and the lower band indicates the endogenous 
Pyroxd1 allele. The primers and PCR conditions utilised to screen for PFLP and endogenous 
Pyroxd1 alelles were designed such that the Pyroxd1 Tm1a allele would not be detected (PCR 
amplicon is 7885bp – too long to be amplified effectively with a 60 second extension at 72oC). 
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Figure 4.27: Breeding schematic to remove the FLP transgene and generate homozygous 
PFLP mice. PFLP (F1) heterozygous for PFLP and heterozygous for FLP were intercrossed 
to generate homozygous PFLP mice lacking the FLP allele. The progeny of this cross - PFLP 
(F2) have predicted litter genotype proportions marked as fractions and the desired genotype 
indicated with an asterisk. Green triangle – FRT site, red triangle – loxP site, numbering in 
grey indicate exons, F1 – generation 1, F2 – generation 2. 
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Second breeding strategy: Knock-out of Pyroxd1 in skeletal muscle 
Background 
The first breeding strategy was successful in generating the parental line – PFLP, where exon 
5 of PFLP is flanked by LoxP sites. The second breeding strategy was designed to generate a 
Pyroxd1 skeletal-muscle knock-out mouse model, utilising the Cre-loxP system controlled by 
MyoD.  
The Cre-loxP system makes use of the cre enzyme which originates from bacteriophage P1 and 
cuts loxP sites – 5’ATAACTTCGTATAGCATACATTATACGAAGTTAT3’, removing the 
intervening sequence (Sauer & Henderson, 1988). Exposure of the PFLP allele to cre 
recombinase results in cre cutting the loxP sites flanking exon 5 of Pyroxd1, removing the 
intervening sequence inclusive of exon 5. Removing exon 5 of Pyroxd1 generates a frameshift 
with a premature stop codon within exon 6 at base pair 409. The premature stop codon is 
predicted to trigger nonsense-mediated decay of the Pyroxd1 mRNA transcript. Degradation 
of Pyroxd1 mRNA by nonsense-mediated decay would result in no Pyroxd1 protein generated 
from that allele. If nonsense-mediated decay is not triggered the, predicted, truncated Pyroxd1 
protein formed would be p.Gln135fsValX (Figure 4.28); lacking oxidoreductase and nitrile 
reductase domains, and likely non-functional. 
To allow skeletal muscle specific knock-out of Pyroxd1 we chose to cross the PFLP mouse 
with a MyoD-cre transgenic mouse line (MDC) generated by J. C. Chen, Mortimer, Marley, 
and Goldhamer (2005). The MDC mouse line expresses Cre under the control of the human 
MyoD promotor and core enhancer (J. C. Chen et al., 2005) (Figure 4.30). MyoD encodes 
myoblast determination protein 1 (MyoD), a muscle-specific transcription factor that plays an 
important role directing skeletal muscle differentation. Transcription of skeletal-muscle 
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specific genes is activated by MyoD (Davis, Weintraub, & Lassar, 1987). Cre enzyme activity 
from MDC is first detected at E9.5, in the branchial arches (J. C. Chen et al., 2005). The 
branchial arches contain muscle progenitors, from which facial muscles develop (J. C. Chen et 
al., 2005). By E12.5, cre enzyme activity from MDC is seen extensively in limb and trunk 
muscles (J. C. Chen et al., 2005).  
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Figure 4.28: Predicted allele modification to establish a Pyroxd1 knock-out allele in 
skeletal muscle.  Crossing the PFLP mouse line - expressing the PFLP allele, with the MDC 
mouse line - expressing cre recominase under the control of skeletal-muscle specific promotor 
MyoD (black arrow), is predicted to generate a Pyroxd1 knock-out allele in skeletal muscle - 
PFLPMDC. Cre cuts the loxP sites flanking exon 5 of Pyroxd1, removing exon 5. Removal of 
exon 5 - base pairs 406-479 - is out of frame. The premature stop codon within exon 6 (base 
pair 409) is predicted to induce nonsense-mediated decay of the Pyroxd1 mRNA transcript. If 
nonsense mediated decay is not activated, a truncated Pyroxd1 protein would be produced of 
136 amino acids – p.Gln135fsValX. The resulting line – PFLPMDC - is expected to carry the 
PFLPMDC allele only within skeletal muscle. PFLPMDC is expected to carry the PFLP allele 
in all tissues other than skeletal muscle. FRT – flippase recognition target, loxP – lox sequence, 
numbering in grey indicate exons, horizontal filled lines indicate introns. 
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Breeding step one: Introducing MyoD-Cre into the PFLP line 
The first breeding step of the second breeding strategy required crossing of mice homozygous 
for PFLP (PFLPPFLP/PFLP, WT/WT), with mice heterozygous for MyoD-Cre (MDC+/-) (Figure 
4.29). We chose to breed with MDC+/- mice as we did not know the integration site of the MDC 
transgene. We therefore reasoned that one copy of the MDC allele would limit off-target 
effects, and cre activity from one MDC allele would be sufficient for modification of the PFLP 
allele. The resulting progeny were a new line, PFLPMDC. Predicted genotype ratios of 
PFLPMDC (F1) were 50% PFLPMDCPFLP/WT, MDC/WT and 50% PFLPMDCPFLP/WT, WT/WT. We 
wished to use PFLPMDCPFLP/WT, MDC/WT in the next breeding step. We expected 
PFLPMDCPFLP/WT, MDC/WT mice to have a MyoD-Cre modified knock-out PFLPMDC allele 
only in skeletal muscle. 
Genotyping of PFLPMDC F1 progeny (Figure 4.30) required three PCRs to determine the 
presence of: (1) PFLP and endogenous Pyroxd1 alleles (as before, Figure 4.30A); (2) the MDC 
allele (using intragenic primers, Figure 4.30B); and (3) the cre-modified knock-out allele 
PFLPMDC allele. Expected Mendelian ratios were observed among F1 PFLPMDC, progeny, 
50% PFLPMDCPFLP/WT, MDC/WT. PFLPMDCPFLP/WT, WT/WT, (chi-squared, p-value = 1).  
The gDNA used for genotyping originated from the earclip of 4 week old mice. If MyoD tightly 
restricted cre expression to the skeletal muscle, we would not expect any cre-mediated 
modification to the PFLP allele in the earclip. We investigated this by screening for the 
modified knock-out PFLPMDC allele (Figure 4.30C) utilising a forward primer within the FRT 
site and a reverse primer within the 3’ loxP site.  
In gDNA isolated from ear-clips, we detected the PFLPMDC allele. We observed the presence 
of a weak PFLPMDC PCR product (Figure 4.30C, lower band), which was confirmed by 
183 
 
Sanger sequencing (results not shown). Presence of the PFLPMDC allele was observed in ear 
clips from each mouse positive for MDC. The presence of detectable levels of the PFLPMDC 
allele was observed irrespective of which parent donated the MDC allele – dam or sire. The 
PCR reaction produced two products: a 904 bp band corresponding to the unmodified PFLP 
allele; and a 144 bp band corresponding to the knockout PFLPMDC allele. We observed a 
weak PFLPMDC band, suggesting a small subset of PFLP alleles had been modified by cre. 
The presence of low levels of cre-recombination within the earclip, suggests cre recombinase 
activity is not restricted to skeletal muscle.  
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Figure 4.29: Breeding schematic to generate PFLPMDC F1. Homozygous PFLP – 
homozygous for the PFLP allele and wild-type homozygous for MDC, were crossed with 
heterozygous MDC – homozygous for endogenous Pyroxd1 and heterozygous for MDC. MDC 
expresses cre under the control of skeletal muscle specific promotor MyoD. A new mouse line 
is generated – PFLPMDC generation one (F1). Predicted litter genotype proportions are 
marked as percentages and the desired genotype indicated with an asterisks. PFLP/WT, 
MDC/WT, mice are predicted to have cre activity only in the skeletal muscle. Cre cuts the loxP 
sites flanking exon 5 of Pyroxd1, removing exon 5 and inducing a knock-out allele– 
PFLPMDC. Green triangle - FRT site, red triangle – loxP site, numbering in grey indicate 
exons, horizontal filled lines indicate introns. 
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Figure 4.30: Cre recombinase activity is not restricted to skeletal muscle. (A) Screening 
for PFLP and endgoneous Pyroxd1 - Upper: To scale schematic of the PFLP and endogenous 
Pyroxd1 alleles with primer locations indicated by blue arrows (the start of each arrow marks 
the primer’s start location, the remainder of the arrow is not to scale) and the PCR product sizes 
are indicated above the respective alleles. Lower: Representative agarose gel of PCR products 
from PFLPMDC generation one (F1). Lanes 1-8 – heterozygous PFLPMDC; Lanes 9 & 13 – 
base pair ladder; Lanes 10-12 - controls: Pyroxd1 heterozygous (Het), PFLP homozygous 
(hom) and MilliQ (MQ); The upper band indicates the PFLP allele and the lower band indicates 
the endogenous Pyroxd1 allele. 
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(B) Screening for MDC - Upper: To scale schematic of the MDC allele. Primer locations are 
indicated in red arrows (the start of each arrow marks the primer’s start location, the remainder 
of the arrow is not to scale) and the PCR product size is indicated above. Lower:  
Representative agarose gel of PCR products from PFLPMDC (F1) screening for the MDC; 
Lanes 1-2 – PFLPMDC negative for MDC; Lanes 3-8 – PFLPMDC positive for MDC; Lanes 
9 & 13 – base pair ladders; Lanes 10-12 – controls. (C) Screening for PFLPMDC - Upper: 
To scale schematic of the PFLP and PFLPMDC alleles with primer locations indicated by 
purple arrows and PCR product sizes indicated above respective alleles. Lower: Representative 
colour-inverted agarose gel of PCR products from PFLPMDC (F1). The upper band indicates 
the PFLP allele and the lower band indicates the PFLPMDC allele. Red asterisks indicate 
samples positive for MDC. Lanes 1-2 – negative for PFLPMDC; Lanes 3-8 – positive for 
PFLPMDC; Lane 9 & 13 – base pair ladder; Lanes 10-12 – controls. Horizontal lines indicate 
introns, dashed  lines – not to scale, grey boxes indicate exons, green triangle – FRT site, red 
triangle – loxP site. 
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Breeding step two: Generating PFLPMDCPFLP/PFLP, MDC/WT mice  
The next breeding step aimed to generate PFLPMDCPFLP/PFLP, MDC/WT mice. We crossed 
PFLPMDCPFLP*/WT, MDC/WT with PFLPPFLP/PFLP, where PFLP* refers to mice with low levels of 
the PFLPMDC allele in their earclip (Figure 4.31). As modification of the PFLP allele knocks-
out Pyroxd1, we were anticipating low levels of modification in the earclip (see Figure 3.30) 
represented only low levels of modification to the PFLP allele in non-skeletal muscle tissue. 
Litters from this cross were expected to contain 25% of the desired experimental genotype, 
PFLPMDCPFLP/PFLP, MDC/WT - homozygous for PFLP, carrying one copy of MDC which is 
expected to induce skeletal muscle knock-out of Pyroxd1.  
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Figure 4.31: Breeding schematic to generate PFLPMDC F2. Homozygous PFLP – 
homozygous for the PFLP allele and wild-type homozygous for MDC, were crossed with 
PFLPMDC (F1) - heterozygous for PFLP and heterozygous for MDC. MDC expresses cre 
under the control of skeletal muscle specific promotor MyoD. PFLPMDC generation two (F2) 
progeny have predicted litter genotype proportions marked as percentages and the desired 
genotype indicated with an asterisks. PFLP/PFLP, MDC/WT and PFLP/WT, MDC/WT mice 
are predicted to have 100% of the PFLP allele modified to the PFLPMDC knock-out allele 
within skeletal muscle. Cre cuts the loxP sites flanking exon 5 of Pyroxd1, removing exon 5 
and inducing a knock-out allele – PFLPMDC. Green triangle - FRT site, red triangle – loxP 
site, numbering in grey indicate exons, horizontal filled lines indicate introns. 
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Embryonic litters 
We established in section 4.3.2.1 that global knock-out of Pyroxd1 is embryonic lethal and we 
now had evidence that cre acted outside of skeletal muscle. The leakiness of cre was confirmed 
by a second study in our laboratory (Capns1, Frances Lemckert unpublished results).  
The MyoD-Cre mouse strain has previously been used, with success, while showing cre activity 
in tissues other than skeletal muscle, including in female gametes (J. C. Chen et al., 2005). 
Thus we proceeded with care, electing to harvest embryonic animals for genotyping, as mice 
born unwell can be cannibalised by their mothers.  
We crossed female PFLPPFLP/PFLP with male PFLPMDCPFLP*/WT, MDC/WT , genotyping 
PFLPMDC (F2) progeny at E10. If homozygous PFLPMDC mice positive for MDC are 
observed at E10 – before the developmental time-point when widespread muscle-specific cre 
expression occurs (ED12.5 (J. C. Chen et al., 2005)) – this would indicate either: (1) MDC-
mediated cre activity was not evident by E10; or (2) MDC-mediated cre activity prior to E10 
was compatible with life.  
Our results indicate cre is active outside of skeletal muscle by E10. We did not observe a 
PFLPMDCPFLP/PFLP, MDC/WT at E10 (Figure 4.32A & B) (non-mendelian inheritance, χ-squared, 
p-value = 0.04< 0.05) and the MDC allele was inherited in non-mendelian ratios (χ-squared, p-
value = 0.007<0.01). Only 1 out of 11 mice (9%) were positive for MDC  (Figure 4.32B, red 
asterisk indicates MDC-carrying mouse). We observed mendelian inheritance of the PFLP 
allele (χ-squared, p-value = 0.38) (Figure 4.32A, blue asterisks indicate homozygous mice). 
These results suggest: (1) PFLPMDCPFLP/PFLP, MDC/WT are not viable at E10; and (2) Cre activity 
in the early embryo or gamete(s) may be knocking-out Pyroxd1 expression. 
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Activity from the MDC allele was not observed in the tail at E10. We did not observe MDC-
mediated modification to the PFLP allele within the sole mouse positive for MDC (mouse 3) 
(Figure 4.32C, red asterisks). Mouse 3 was heterozygous for the PFLP allele (Figure 4.32A) 
and therefore inherited the PFLP allele from the  PFLPPFLP/PFLP, WT/WT dam. This result makes 
it unlikely that cre activity in the early embryo knocks out Pyroxd1 expression and is the cause 
of homozygous lethalities. 
Genotyping results of the PFLPMDC allele support the hypothesis that cre is active within 
gametes of the dam or sire, and a null allele is transmitted to the progeny. Evidence supporting 
cre-activity in gametes is provided through detection of a recombined PFLP allele 
(PFLPMDC) in the tail of PFLPMDCPFLP/PFLP, WT/WT mice (Figure 4.32C, blue asterisks) that 
do not have cre. PFLPMDCPFLP/PFLP, WT/WT mice must have inherited one recombined PFLP 
allele from the PFLPMDCPFLP*/WT,MDC/WT sire. The presence of PFLPMDC in all mice who 
have inherited a PFLP allele from the PFLPMDCPFLP*/WT,MDC/WT sire, ie. all mice genotyping 
homozygous for PFLP, suggests all PFLP alleles within male gametes have been modified to 
the PFLPMDC knock-out allele. Therefore, the inheritable genotype of male (F1) 
PFLPMDCPFLP*/WT,MDC/WT mice in reality is PFLPMDCPFLPMDC/WT, MDC/WT (Figure 4.33).  
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Figure 4.32: PFLPMDC is present in male gametes. (A) Screening for PFLP and 
endogenous Pyroxd1 - Upper: To scale schematic of the PFLP and endogenous Pyroxd1 
alleles with primer locations indicated by blue arrows and the PCR product sizes indicated 
above respective alleles. Lower: Agarose gel of PCR products from PFLPMDC generation two 
(F2) at  E10): Lanes 2-12 – PFLPMDC (F2); Lane 12-16 – controls: Mother (Dam), Pyroxd1 
heterozygous (Het), PFLP homozygous (Hom) and MilliQ (MQ); Lanes 1 & 17 – base pair 
ladder; The upper band indicates the PFLP allele and the lower band indicates the endogenous 
Pyroxd1 allele. Blue asterisks indicate PFLP homozygotes. (B) Screening for MDC - Upper: 
To scale schematic of the MDC allele. Primer locations are indicated in red arrows and PCR 
product size above. Lower:  Agarose gel of PCR products from PFLPMDC generation two 
(F2) at E10: Lanes 1-11 –  PFLPMDC (F2); Lanes 12-15 – controls; Lane 16 – base pair ladder. 
(C) Screening for PFLPMDC - Upper: To scale schematic of the PFLP and PFLPMDC 
alleles with primer locations indicated by purple arrows and PCR product sizes indicated above 
respective alleles. Lower: Agarose gel of PCR products from PFLPMDC generation two (F2) 
at E10. The upper band indicates the PFLP allele and the lower band indicates the PFLPMDC 
allele. Red asterisks indicate samples positive for MDC. Blue asterisks indicate samples absent 
for MDC and positive for PFLPMDC. Lanes 1-11 –  PFLPMDC (F2); Lanes 12-15 – controls; 
Lane 16 – base pair ladder. Horizontal lines indicate introns, dashed  lines – not to scale, grey 
boxes indicate exons, green triangle – FRT site, red triangle – loxP site. The start of each arrow 
marks the primer’s start location, remainder of arrow is not to scale. 
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Figure 4.33: Breeding schematic of actual PFLPMDC (F2). Parental lines: Homozygous 
female PFLP (F4) – homozygous for the PFLP allele and wild-type homozygous for MDC; 
based on genotyping results, male PFLPMDC (F1) - heterozygous for PFLPMDC and 
heterozygous for MDC. The PFLPMDC allele inherited from the sire is tracked in purple. 
Homozygous PFLPMDC progeny inherited a PFLP allele from the dam and a PFLPMDC 
allele from the sire. We expect cre-mediated modification of the PFLP allele inherited from 
the dam to  a PFLPMDC allele in the skeletal muscle of MDC carrying mice. Heterozygous 
PFLPMDC mice who have inherited a PFLP allele from the dam are expected to be modified 
to PFLPMDC only in MDC carrying mice. PFLPMDC (F2) litter genotypes are marked as 
fractions and the desired genotype indicated with an asterisk. Green triangle - FRT site, red 
triangle – loxP site, numbering in grey indicate exons, horizontal filled lines indicate introns. 
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We then reversed the cross. We crossed a male PFLPPFLP/PFLP, WT/WT with a female (F1) 
PFLPMDCPFLP*/WT, MDC/WT , genotyping PFLPMDC (F2) progeny at E10. This procedure 
involved a terminal caesarian. The sacrificed PFLPMDC (F1) female carried eight embryonic 
sacs at E10 (Figure 4.34A). Five embryos were evident. Two embryos had completely 
reabsorbed by E10 (Figure 4.34A, embryos 2 and 5, white asterisks) and one embryo had been 
reabsorbed with the aminotic sac remaining (Figure 4.34B, embryo 6). A tail clip was taken for 
genotyping purposes from all embryos, and from the remaining amniotic sac of embryo 6 
(Figure 4.34A, genotyping tissue indicated by schematics). From here-in the amniotic sac of 
embryo 6 is stated as an embryo and indicated in Figure 4.34 with a dashed white circle.  
We observed two PFLPMDCPFLP/PFLP, MDC/WT mice at E10 - embryos 3 and 6 (Figure 4.34A 
and B, blue and red asterisks respectively). We had generated the experimental genotype. 
Embryo 6 had been reabsorbed by E10. This result indicates that when the MDC allele is 
inherited from the dam, PFLPMDCPFLP/PFLP, MDC/WT mice are viable at E10. We observed 
mendelian inheritance. The MDC locus was inherited in a mendelian fashion (Chi-squared, p-
value = 0.41). We observed four embryos positive for MDC (Figure 4.34C, red asterisks) – 
embryos 3, 4, 6 and 7. The Pyroxd1 locus was also inherited in a mendelian fashion (Chi-
squared, p-value = 0.41). We observed four embryos homozygous for the PFLP allele (Figure 
4.34B, blue asterisks) – embryos 1, 3, 6 and 8. Activity from the MDC allele was detected 
outside of skeletal muscle. However, cre activity from the MDC allele was not consistent 
between embryos. We observed MDC activity within the tail of E10 embryo 4. Embryo 4 is 
PFLPMDCPFLP/WT, MDC/WT (Figure 4.34A and B). The PFLP allele can only have been inherited 
by the PFLPPFLP/PFLP, WT/WT . We observed a weak PFLPMDC band in embryo 4 (Figure 4.35C). 
This raises the possibility that MDC-mediated cre is active in all mouse tissues, at low levels. 
The PFLPMDC allele could not have been present in the gametes forming mouse 4. The 
presence of a strong PFLP PCR product in mouse 4 (Figure 4.34B) suggests modification to 
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the PFLP allele is mosaic – MDC-mediated cre activity is not evident in all nuclei. Importantly, 
we did not detect the PFLPMDC allele in mouse 7 (Figure 4.34C) which is PFLPMDCPFLP/WT, 
MDC/WT.  
Our results suggest the MyoD-cre reporter mouse is confounded by ‘leaky’ expression that can 
include the gametes of both sire and dam. These preliminary results suggest female gametes 
are ‘less leaky’.  
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Figure 4.34: Mice homozygous for PFLP and positive for MDC survive to E10. (A) 
Embryonic sacs of E10 litter indicating reabsorbed embryos – white asterisks, and schematics 
indicating genotyping tissues. (B) Screening for PFLP and endogenous Pyroxd1 - Upper: 
To scale schematic of the PFLP and endogenous Pyroxd1 alleles with primer locations 
indicated by blue arrows (the start of each arrow marks the primer’s start location, remainder 
of arrow is not to scale) and PCR product sizes indicated above respective alleles. Lower: 
Agarose gel of PCR products from PFLPMDC generation two (F2) at E10: Lane 1 – Mother 
(Dam); Lanes 2-7 – PFLPMDC (F2); Lanes 8-12 – controls: PFLPMDC heterozygoute (Het),  
Pyroxd1 Het, PFLP Het, PFLP homozygous (Hom) and MilliQ (MQ); Lane 13 – base pair 
ladder. The upper band indicates the PFLP allele and the lower band indicates the endogenous 
Pyroxd1 allele. Blue asterisks indicate PFLP homozygotes. (C) Screening for MDC - Upper: 
To scale schematic of the MDC allele. Primer locations are indicated in red arrows (the start of 
each arrow marks the primer’s start location, remainder of arrow is not to scale) and PCR  
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product size above. Lower:  Agarose gel of PCR products from PFLPMDC generation two 
(F2) at embryonic day 10 (E10): Lane 1 – Mother (Dam); Lanes 2-7 – PFLPMDC (F2); Lanes 
8-12– controls: PFLPMDC heterozygote (Het), Pyroxd1 Het, PFLP Het, PFLP homozygous 
(Hom) and MilliQ (MQ); Lane 13 – base pair ladder. Red asterisks indicate MDC positive 
mice; (D) Screening for PFLPMDC - Upper: To scale schematic of the PFLP and PFLPMDC 
alleles with primer locations indicated by purple arrows (the start of each arrow marks the 
primer’s start location, remainder of arrow is not to scale) and PCR product sizes indicated 
above respective alleles. Lower: Agarose gel of PCR products from PFLPMDC generation two 
(F2) at embryonic day 10 (E10): Lane 1 – Mother (Dam); Lanes 2-7 – PFLPMDC (F2); Lanes 
8-12 – controls: PFLPMDC heterozygoute (Het),  Pyroxd1 Het, PFLP Het, PFLP homozygous 
(Hom) and MilliQ (MQ); Lane 13 – base pair ladder. The upper band indicates the PFLP allele 
and the lower band indicates the PFLPMDC allele. Purple asterisks indicate mice homozygous 
for PFLP positive for MDC. Green triangle – FRT site, red triangle – loxP site, dashed  lines – 
not to scale, grey boxes indicate exons, horizontal lines indicate introns. 
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Neonatal litters 
The next step was to determine if the experimental genotype was viable at birth. We crossed a 
male PFLPPFLP/PFLP, WT/WT with a female (F1) PFLPMDCPFLPMDC/WT, MDC/WT, genotyping two 
litters of PFLPMDC (F2) progeny at day 1 from gDNA extracted from tail clips (Figure 4.35). 
We anticipated a severe, potentially prenatally lethal, phenotype in mice lacking Pyroxd1 
within skeletal muscle. Three independent studies have identified PYROXD1 as a gene essential 
for cell viability (Blomen et al., 2015; Hart et al., 2015; T. Wang et al., 2015). Therefore, we 
chose to genotype as soon after birth as possible, inkeeping with ethical guidelines of GMO 
monitoring.  
We successfully derived mice with conditional knock-out of PYROXD1 in skeletal muscle that 
survive to birth (though likely succumb a few days of age) (Figure 4.35A, blue asterisks 
indicate homozygous PFLP mice and Figure 4.35B, red asterisks indicates MDC positive 
homozygous PFLP mice). Two litters were genotyped with 5 and 8 live pups, respectively. 
The later litter contained 2 of the experimental genotype, PFLPMDCPFLPMDC/PFLP, MDC/WT. 
Unfortunately, the two mice of the experimental genotype did not survive past day 2. White 
milk spots were observed indicating these mice were able to suckle. It is unclear if this is 
stochastic, environmental or genotype-related. We speculate that death was due to weakness of 
the diaphragm causing respiratory failure as the mice appeared runty, but no further defining 
features were observed. (Note: since preparation of this thesis, further skeletal muscle KO mice 
have been born, with similar results, suggesting survival to birth followed by neonatal 
lethality).  
Across the two litters we observed mendelian inheritance. Mendelian inheritance of the 
Pyroxd1 locus (chi-squared, p-value = 0.78) and the MDC locus (chi-squared, p-value = 0.63) 
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suggested we were not loosing any PFLPMDCPFLP/PFLPMDC, MDC/WT mice between E10 and day 
1.  
As observed in E10 litters, we detected the PFLPMDC knock-out allele outside of skeletal 
muscle and in the absence of MDC. We observed the PFLPMDC allele in the tail clips of all 
mice homozygous for PFLP (Figure 4.35A and C – mice 4, 5 and 8), where only mouse 8 
carries MDC (Figure 4.35B red asterisks and Figure 4.35C purple asterisks). This result 
confirms that the PFLPMDC allele is present within female gametes.  
We achieved the generation of mouse lines that can be used for future study of Pyroxd1 in 
fundamental biology and disease. Tissues from this skeletal muscle conditional knock-out of 
Pyroxd1 will provide an extremely valuble resource to determine the role and potential 
substrates of Pyroxd1.  
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Figure 4.35: Mice homozygous for PFLP and positive for MDC survive to birth. (A) 
Screening for PFLP and endogenous Pyroxd1 - Upper: To scale schematic of the PFLP and 
endogenous Pyroxd1 alleles with primer locations indicated by blue arrows (the start of each 
arrow marks the primer’s start location, remainder of arrow is not to scale) and PCR product 
sizes indicated above respective alleles. Lower: Agarose gel of PCR products from PFLPMDC 
generation two (F2) at embryonic day 10 (E10): Lane 1 –base pair ladder; Lanes 2-9 – 
PFLPMDC (F2); Lanes 10-14 – controls: PFLPMDC heterozygote (Het),  Pyroxd1 Het, PFLP 
Het, PFLP homozygous (Hom) and MilliQ (MQ). The upper band indicates the PFLP allele 
and the lower band indicates the endogenous Pyroxd1 allele. Blue asterisks indicate PFLP 
homozygotes. 
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 (B) Screening for MDC - Upper: To scale schematic of the MDC allele. Primer locations are 
indicated by red arrows (the start of each arrow marks the primer’s start location, remainder of 
arrow is not to scale) and PCR product size above. Lower:  Agarose gel of PCR products from 
PFLPMDC generation two (F2) at embryonic day 10 (E10): Lanes 1-8 – PFLPMDC (F2); 
Lanes 9-13 – controls: PFLPMDC heterozygote (Het),  Pyroxd1 Het, PFLP Het, PFLP 
homozygous (Hom) and MilliQ (MQ); Lane 14 – base pair ladder. Red asterisks indicate MDC 
positive mice; (C) Screening for PFLPMDC - Upper: To scale schematic of the PFLP and 
PFLPMDC alleles with primer locations indicated by purple arrows (the start of each arrow 
marks the primer’s start location, remainder of arrow is not to scale) and PCR product sizes 
indicated above respective alleles. Lower: Agarose gel of PCR products from PFLPMDC 
generation two (F2) at embryonic day 10 (E10): Lanes 1-8 – PFLPMDC (F2); Lanes 9-13 – 
controls: PFLPMDC heterozygote (Het),  Pyroxd1 Het, PFLP Het, PFLP homozygous (Hom) 
and MilliQ (MQ); Lane 14 – base pair ladder. The upper band indicates the PFLP allele and 
the lower band indicates the PFLPMDC allele. Purple asterisks indicate mice homozygous for 
PFLP positive for MDC. Green triangle – FRT site, red triangle – loxP site, dashed  lines – not 
to scale, grey boxes indicate exons, horizontal lines indicate introns. 
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4.4 Discussion, conclusions and future directions 
Through an international collaboration, we identified variants within PYROXD1 as a new 
genetic cause of early-onset congenital myopathy. We provide the first characterisation of 
PYROXD1 as a nuclear-cytoplasmic oxidoreductase. Collectively, this study highlights 
oxidative distress as a core mechanistic pathway in the myopathies. We derived a mouse model 
of Pyroxd1 deficiency and determined that global loss of Pyroxd1 is embryonic lethal in mice. 
We subsequently developed a murine model with skeletal muscle knock-out of Pyroxd1 as a 
means to elucidate the role of PYROXD1 in biology and disease. The phenotypic 
characterisation of this mouse model is currently in progress in our laboratory and exceeds the 
scope of this PhD thesis. 
4.4.1 Cell biology and biochemistry of PYROXD1 
Localisation of PYROXD1 in skeletal muscle 
We have carried out preliminary studies on the localisation of PYROXD1 within skeletal 
muscle. By confocal microscopy we observe striated patterning of PYROXD1 co-staining with 
desmin and myotilin. At this resolution it is unclear if PYROXD1 is within the sarcomere, or 
lies above the sarcomere in the sarcoplasmic reticulum. Super-resolution microscopy would 
allow more specific localisation of PYROXD1 within skeletal muscle. This could then help to 
identify possible proteins which PYROXD1 reduces.  
We observed an increase in nuclear-PYROXD1 staining within patient skeletal muscle, 
coupled with reduced cytoplasmic-PYROXD1 staining compared to controls. This raises the 
question whether PYROXD1 translocates to the nucleus under oxidative distress. It will be 
important to test this hypothesis and define the nuclear localisation signal within PYROXD1 
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that mediates nuclear translocation. This may also help to identify possible substrates 
PYROXD1 reduces within the nucleus. 
Identifying PYROXD1 substrates 
Identifying the essential substrates PYROXD1 reduces will lend insight into the development 
of each of the pathological hallmarks in PYROXD1 related myopathy. Skeletal muscle from 
the skeletal muscle knockout, PFLPMDCPFLPMDC/PFLP, MDC/WT, mouse can be used to 
experimentally determine the substrates of mouse Pyroxd1. Mass spectrometry can be carried 
out on PFLPMDCPFLPMDC/PFLP, MDC/WT and PFLPMDCPFLPMDC/PFLP, WT/WT skeletal muscle to 
look for substrates that Pyroxd1 reduces, utilising such methods as ICAT (isotope coded 
affinity tag) (Baez, Reisz, & Furdui, 2015). However, considering the dominant nuclear 
localisation of PYROXD1, PYROXD1 may also, or instead, modify DNA or RNA.  
4.4.2 Mouse models 
Embryonic lethality of Pyroxd1Tm1a/Tm1a mice 
We found Pyroxd1Tm1a/Tm1a embryos were formed upon genotyping embryos at E4.5 and absent 
at E9.5. This refined embryonic lethality to between E4.5 and E9.5. Presence of the 
Pyroxd1Tm1a/Tm1a global knock-out genotype does not necessarily mean these embryos are 
absent, and therefore surviving in the absence of Pyroxd1 protein. It is important to note that 
up to ~E4.5, the fertilised embryo undergoes cell division, but without an overall increase in 
size. Thus, cytoplasmic components are subdivided into each daughter cell. Perhaps it is only 
when the mass of the embryo expands, and levels of Pyroxd1 present in the gamete from the 
Pyroxd1Tm1a/WT parent are sufficiently diluted, when lethality occurs.  It is also important to 
consider the half-life of Pyroxd1 (currently known) and the role it would play in the length of 
time Pyroxd1 protein from the Pyroxd1Tm1a/WT parent may be active within the gamete.  
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X-gal staining of Pyroxd1Tm1a/WT mice 
Preliminary experiments with wax embedded and sectioned embryos showed X-gal staining of 
the developing brain of E9.5 Pyroxd1Tm1a/WT embryos. We were unsuccessful when X-gal 
staining was carried out after cryo-preservation and cryo-sectioning of samples. We 
hypothesised that Pyroxd1 expression was low, as observed with human PYROXD1 mRNA 
(refer to Figure 4.3), resulting in low β-galactosidase levels, as observed with human 
PYROXD1 levels (refer to Figure 4.3), which was washed out through tissue-processing and 
wash steps during X-gal staining. X-gal staining pre-sectioning has been shown to produce 
better results compared to X-gal staining post-sectioning in a past study (Shimada, Komatsu, 
Nakashima, Poschl, & Nifuji, 2012). 
One option would be to carry out X-gal staining and subsequent wax-embedding on late 
gestation embryos and adult mouse tissues to determine developmental and tissue-specific 
expression of Pyroxd1. A second, to carry out conventional immunohistochemistry using an 
antibody raised against mouse Pyroxd1. Both of which were beyond the scope of this thesis. 
An alternative would be to take advantage of recent methodological advances such as CUBIC 
(Clear, Unobstructed Brain/Body Imaging Cocktails and Computational analysis, (Susaki et 
al., 2015)). Tissues are cleared of lipids and can be subsequently stained with antibodies and 
3D imaging performed (Susaki et al., 2014). CUBIC would enable high resolution imaging of 
the expression of Pyroxd1 protein throughout development and tissues. 
Successful generation of the experimental genotype 
We were successful in generating the desired experimental genotype – PFLPDMCPFLPMDC/PFLP, 
MDC/WT - which should induce skeletal muscle knock-out of Pyroxd1. The important next steps 
are to: (1) Characterise the extent to which the PFLP allele is modified to the knock-out 
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PFLPMDC allele within skeletal muscle; and (2) determine the extent of Pyroxd1 protein 
knock-out within skeletal muscle. 
The ethical way forward 
The experimental genotype survives to birth when the PFLPMDCPFLPMDC/WT, MDC/WT parent is 
the dam. However, initial progeny of this genotype do not survive past two days. 
Experimentation on embryonic litters may be necessary to obtain high quality skeletal muscle 
tissue, and to minimise impact to the mice. We do not have certain evidence that lack of 
survival is genotype-related or indeed the cause of death. However, respiratory failure due to 
weak diaphragm muscles is one explanation to why a Pyroxd1 skeletal muscle knock-out 
mouse may survive in the womb, but not after birth. Prior to generating an experimental cohort, 
it would need to be determined if: (1) the experimental genotype can survive to birth when the 
PFLPMDCPFLPMDC/PFLP parent is the sire; and (2) the experimental genotype can survive past 
day two. An alternative approach, experimentation on embryonic litters, would inkeep with 
ethical guidelines of reducing the number of mice used and the impact to animals.  
Characterising the effects of ‘leaky’ cre 
Our results indicate cre activity outside of skeletal muscle, inclusive of gametes. These results 
suggest that PFLPMDCPFLPMDC/PFLP, MDC/WT carry one knock-out, PFLPMDC, allele in all 
tissues. Additionally, cre activity observed outside of skeletal muscle may reduce Pyroxd1 
expression to levels inducing a phenotype. It will be important to determine: (1) The extent to 
which PFLP has been modified to the knock-out PFLPMDC allele in tissues outside of skeletal 
muscle; and (2) the extent of Pyroxd1 protein knock-out in tissues outside of skeletal muscle. 
This characterisation will become vital when interpreting the phenotype of the PFLPMDC 
mouse. 
Limitations of transgenic mice 
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We show that cre is not under tight regulation by MyoD in the MyoD-cre mouse line. We 
observe cre activity outside of skeletal muscle. This highlights the importance of characterising 
mouse strains generated by crossing temporal and/or spatial cre-expressing mouse strains with 
mouse strains carrying the conditional knock-out allele of interest. This limitation is important 
to characterise for phenotype interpretation and ethical production of genetically modified 
mouse lines. 
The integration site of the transgenes used in this study were unknown at the time of this 
project. The integration site of a transgene may be within an endogenous gene, disrupting gene 
function and possibly result in the display of a phenotype. In one line of c-myc transgenic mice, 
the c-myc transgene deletes exon 1 of Gtf2ird1 resulting in reduced mRNA expression of 
Gtf2ird1 (Durkin, Keck-Waggoner, Popescu, & Thorgeirsson, 2001). Loss of one copy of the 
human homologue, GTF2IRD1, is associated with Williams-Beuren syndrome. Alternatively, 
the transgene may lie on the same chromosome as the conditional-allele to be targeted, 
interfering with mendelian inheritance. We chose to outbred the FLP transgene due to its 
unknown influence on mouse phenotype. It is also interesting to note that using the MyoD-Cre 
mouse line to target loxP sites within the Pyroxd1 locus (chromosome 6) was successful, whilst 
targeting loxP sites within the Capsn1 locus (chromosome 7) was unsuccessful. One 
explanation to this, is that the location of the MDC locus is on chromosome 7 in close proximity 
to Capsn1, interfering with gene function and/or mendelian inheritance. This highlights the 
possible ethical benefit of mapping the location of transgenes prior to crossing, to reduce the 
number of mice required to generate the experimental genotype. The integration site of 
transgenes within seven mouse lines has been carried out using targeted locus amplification 
(Cain-Hom et al., 2017). Furthermore, gene insertion had resulted in structural rearrangements 
which could be identified with this technique. Knowledge of the integration site and structural 
rearrangements at the integration site aids not only planning of crosses, but phenotype 
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interpretation. Mapping of the MDC transgene with targeted locus amplification will be 
important to understand the limitations of the Pyroxd1 skeletal muscle knock-out, 
PFLPMDCPFLPMDC/PFLP, MDC/WT, mouse which can be applied to phenotype interpretation.   
4.4.3 PYROXD1-myopathy therapies 
Using CRISPR/Cas-9 technology to generate an inducible Pyroxd1N155S/N155S mouse, the 
common mis-sense patient variant, would allow testing of potential treatments of PYROXD1-
myopathy on a mouse model that more closely mimics PYROXD1-patients. The inducibility of 
the strain would enable further testing on whether Pyroxd1-myopathy can be reversed, or if 
treatment needs to be effective prior to end-stage muscle. An inducible Pyroxd1 global knock-
out mouse would allow further investigations into why Pyroxd1 is essential for life. The 
combination of these mouse models with our Pyroxd1-skeletal muscle KO mouse model will 
be important to further understand the link between Pyroxd1-myopathy, myofibrillar myopathy 
and neurodegeneration; and to determine whether any oxidative treatments targeting 
neurodegenerative diseases could also target the myopathies. 
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Chapter 5 - Materials and methods 
5.1 Ethics approval 
Ethics approval was obtained from The Human Research Ethics Committes of the Children’s 
Hospital of Westmead (10/CHW/45) for all human aspects within this thesis. Ethics approval 
from the Children’s Medical Research Institute and The Children’s Hopsital at Westmead’s 
Animal Ethics Committee was obtained for the generation of (K342) and experimentation on 
(K348) mouse strains in this thesis.  
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5.2 Immunolabelling 
Antibodies 
All antibodies and conditions used in this thesis are stated in Table 5.1 and Table 5.2 
Table 5.1 Primary antibodies 
Protein (clone) Antibody type Dilution Supplier (Catalogue number) 
α-skeletal actin 
Polyclonal 
rabbit, IgG WB: 1:2000 
Sophie Clement, Univeristy of 
Geneva 
Sarcomeric actin (5C5) 
Monoclonal 
mouse, IgM WB 1:20,000 Sigma (A2172) 
Desmin* (DE-R-11) 
Monoclonal 
mouse, IgG 
WB 1:1000; 
 IHC 1:50 (Fix:3% PFA 15 mins and cold methanol 10 mins; 
Block: 2%BSA/PBS) Novocastra (NCL-L-DES-DERII) 
Filamin 
Polyclonal, 
rabbit IgG 
WB 1:2500; 
IHC 1:250 (Fix: 3% PFA 3 mins and cold methanol 5 mins; 
Block: 2% BSA/PBS) 
Gift from Isin Dalkilic, Harvard 
Medical School, Boston 
αβ-crystalin (G2JF) 
Monoclonal 
mouse, IgG 
WB 1:100;  
IHC 1:25 (Fix: 3% PFA 3 mins; Block: 2% BSA/PBS) Novocastra (NCL-ABCrys-512) 
α-actinin-2 (4B2) 
Monoclonal 
rabbit, IgG WB: 100,000 
Gift from Alan Beggs Harvard 
Medical School, Boston 
GAPDH (6C5) 
Monoclonal 
mouse, IgG WB 1:10,000 Millipore (MAB374) 
Myotilin (RSO34) 
Monoclonal 
mouse, IgG 
WB 1:2000; 
 IHC 1:20 (Fix:3% PFA 15 mins and cold methanol 10 mins; 
Block 2%BSA/PBS) Novocastra (NCL-MYOTILIN) 
Leiomodin-1 
Polyclonal 
rabbit, IgG WB 1:1000 Abcam (Ab104858) 
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Leiomodin-2 
Polyclonal 
rabbit, IgG WB 1:1000 
Santa Cruz Biotechnology, Inc (sc-
135493) 
Leiomodin-3 
Polyclonal, 
rabbit IgG WB 1:10,000 Proteintech (14948-1-AP) 
KLHL40 (KBTBD5) 
Polyclonal 
rabbit, IgG WB 1:10,000 Sigma Aldrich (HPA024463) 
Smooth muscle actin 
(asm-1) 
Monoclonal 
mouse, IgM WB 1:1000 
Leica Biosystems, Novocastra Ltd 
(NCL-SMA)  
Cardiac actin 
Monoclonal 
mouse, IgG WB 1:1500 
American Research Products Inc, 
USA 
Beta-tubulin 
Polyclonal 
rabbit, IgG  WB 1:2,000 
Developmental studies hybridoma 
bank, The univeristy of Iowa, USA 
(E7-C 8H4) 
Slow Myosin 
Monoclonal 
mouse, IgG WB 1:7000 Chemicon (MAB1628) 
Fast Myosin (MY32) 
Monoclonal 
mouse, IgG WB 1:10,000  Sigma Aldrich (M4276) 
FLAG (M2) 
Monoclonal 
mouse, IgG WB 1:5000 Sigma Aldrich (F1804) 
eIF2-α 
Monoclonal 
mouse, IgG WB 1:1000 
Cell signalling technology 
(L57A5) 
P- eIF2-α# 
Monoclonal 
rabbit, IgG WB 1:1000 
Cell signalling technology 
(119A11) 
PYROXD1 
Polyclonal 
rabbit, IgG  
WB 1:1,000 (tissues and fibroblasts 20 µg, transfected cells 
5µg, incubation O/N);  
IHC 1:50 (Fix:3% PFA 15 mins and cold methanol 10 mins; 
Block 2%BSA/PBS, incubation O/N) 
Abcam (ab122458); Abcam 
(ab204560); Sigma Aldrich (504-
260) 
α-actinin (EA-53) 
Monoclonal 
mouse, IgG WB 1:2500 Sigma Aldrich (A7811) 
Emerin 
Monoclonal 
mouse, IgG WB 1:300 Novocasta (NCL-Emerin) 
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TDP-43 (2E2-D3) 
Monoclonal 
mouse, IgG IHC 1:750 (Block: 10% FBS/PBS) Abcam (ab57105) 
β-galactosiadse 
Polyclonal 
rabbit, IgG WB 1:1000 Molecular probes (A-11132) 
*Secondary antibody 1:4500; # PPI 1:50 used in lysis buffer; WB – Western blot; IHC – Immunohistochemistry  
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Table 5.2: Secondary antibodies 
Secondary antibody Dilution Supplier (Catalogue number) 
HRP congugated anti-rabbit 
WB 
1:2000 
GE Healthcare Biosciences (NA934-
1ML) 
HRP congugated anti-mouse 
WB 
1:2000 
GE Healthcare Biosciences (NA931-
1ML) 
Alexa Fluor 488 congugated anti-
rabbit  IHC 1:200 Life technologies  (A21260) 
Alexa Fluor 488 congugated anti-
mouse IHC 1:200 Life technologies (A21202) 
Alexa Fluor 555 congugated anti-
rabbit IHC 1:200 Life technologies (A21428) 
Alexa Fluor 555 congugated anti-
mouse IHC 1:200 Life technologies (A21424) 
DAPI - 405 
IHC 
1:5000  Life technologies (D1306) 
 
Immunohistochemistry  
8 µm tissue cryosections were cut on a Leica CM 1950 cryostat, collected onto glass slides 
(HD Scientific supplies Ptd Ltd) and circled with a Liquid Blocker Super Pap Pen (Sigma 
Aldrich, Z377821-1EA). Sections were fixed (as stated in Table 5.1), washed three times 10 
dips in phosphate buffered saline (PBS, Amresco, E703-1L) and blocked for 10 minutes (as 
stated in Table 5.1). 50 µl of Primary antibody (Table 5.1), diluted in block, was applied to the 
tissue section and incubated at room temperature (RT) for 2 hours, or overnight (O/N) in a 
humidified chamber at 4⁰C. Tissues were washed 5 times ten dips in PBS, blocked for 10 
minutes and 50 µl of secondary antibody (Table 5.2), diluted in block, was incubated at RT for 
1 hour. Sections were washed 3 times ten dips and mounted in Prolong Gold with DAPI 
(molecular probes, life technologies, P36941) or ImmunoMount (Thermo Scientific, 9990402). 
Where two fixation conditions are stated, one wash step was performed after the first fixation 
condition. 
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Immunocytochemistry 
Cos-7 cells and primary human fibroblasts were seeded onto glass coverslips (No. 1 thickness, 
TAAB Laboratory Equipment LTD) in 24-well plates (In vitro technologies, FAL353047) and 
immunocytochemistry was carried out when cells were 65% confluent. Coverslips were 
washed three times 10 dips in Hanks Balanced Salt Solution (HBSS, Life Technologies, 14025-
092) and then inverted onto a 50 µl droplet of 3% paraformaldyhyde (PFA, Sigma-Aldrich, 
P6148) on a parafilm-covered glass plate. Slides were washed three times 10 dips in HBSS and 
inverted onto a droplet of cold methanol for ten minutes. Slides were washed three times ten 
dips in HBSS, blocked for 10 minutes in 2% bovine serum albumin (BSA, Sigma-Aldrich, 
A7906)/HBSS and inverted onto 50 µl of primary antibody (Table 5.1), diluted in 2% 
BSA/HBSS, O/N in a humidified chamber at 4⁰C. Slides were washed five times in HBSS, 
blocked for ten minutes in 2% BSA/HBSS and inverted onto a 50 µl droplet of secondary 
antibody (Table 5.2) diluted in 2% BSA/HBSS for one hour at RT. Slides were washed three 
times in HBSS and mounted using Prolong Gold with DAPI (molecular probes, life 
technologies, P36941).  
Zenon labelling 
Zenon labelling allows co-staining with two or more antibodies raised in the same species. 
Zenon Mouse IgG1 labelling kits were used to co-label skeletal muscle sections with cardiac 
actin and slow myosin, neonatal myosin or developmental myosin – all of which are 
monoclonal mouse IgG antibodies (Table 5.3). Frozen muscle biopsy sections cut at 8 µm were 
blocked in 2% BSA for 10 minutes. During the incubation, cardiac actin was tagged with the 
Zenon Alexa Fluor 555 label (Invitrogen, Z25005), and each respective myosin was tagged 
with the Zenon Alexa Fluor 488 (Invitrogen, Z25002) for 5 minutes at room temperature. IgG 
fragments were then added to each reaction (equal volume to Zenon label) for 5 minutes to 
bind unbound label. Antibody/label/block mixtures were combined and added to muscle 
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sections and incubated at room temperature for 2 hours. Muscle sections were then washed 3 
times in 1 x PBS. DAPI (1 µg/ml) was applied for 5 minutes, sections washed 4 times in 1 x 
PBS and mounted with Immunomount (Thermo Scientific, 9990402). 
 
Table 5.3: Antibodies used in Zenon labelling  
Protein Clone Company (Catalogue 
number) 
Ratio (antibody: label)  
Neonatal myosin  WB-MHCn Novocastra (NCL-MHCn) 4:1 
Developmental 
myosin  
RNMy2/9D2 Novocastra (NCL-MHCd) 4:1 
Slow myosin  NOQ7.5 4D Millipore, (MAB1628) 0.6:6 
α-Cardiac actin Ac1-20.4.2 Progen, (61075) 2:1 
 
Imaging 
Imaging was performed on an Olympus BX50 microscope linked to a SPOT digital imaging 
camera (Diagnostics) or a Leica SP5 confocal microscope using LAS AF software. 
Western blotting 
Tissue samples were cryosectioned at 8 µm and solubilised in 100 µl of 2x solubilisation buffer 
with 1:500 protease inhibitors (PI, Sigma-Aldrich P8340) (Table 5.1) per 100 mm2 of 
cryosectioned tissue. Cells were harvested from a 6-well plate. Media was removed and cells 
were washed three times in 2 ml of dPBS –Ca2+/-Mg2+ (ThermoFischer Scientific, 14190250), 
scraped in 1 mL of dPBS –Ca2+/-Mg2+ and spun at 300 RCF for 3 min at 4⁰C. dPBS was 
removed and 150 µl of 2 x solubilisation buffer with 1:500 PI was added to the cell pellet. After 
the addition of solubilising buffer to either tissues or cells the solution was mixed, sonicated 
and left to solubilise for 20 minutes on ice. Samples were then heated for 3 min at 94⁰C, 
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vortexed and spun down. Protein concentrations were determined by bicinchoninic acid assay 
(BCA assay,Thermo Scientific, 23225) as per the manufacturer’s instructions, or a loading gel 
assessing actin and myosin levels when patient skeletal muscle was under examination. 2x or 
4x loading buffer was added to the sample dependent on concentration. Samples were either 
immediately run on western blot or stored at -80⁰C. 
Protein separation was performed on NuPAGE Bis-Tris 10%, 10-well and 12-well gels 
(ThermoFisher Scientific, NP0301BOX and NP030B) or CriterionXT Bis-Tris 10%, 18 well 
(Biorad, 345-0112) gels in MOPS running buffer (Table 5.4) at 150 V for one hour with 5µl of 
PagerulerPlus prestained protein ladder (Thermoscientic, 26620). Proteins were transferred 
onto PVDF membranes (GE Healthcare, 3030-917) in transfer buffer (Table 5.4) at 400 mA 
for 1 hour (Invitrogen gels) or 1.5 hours (Biorad gels). Membranes were blocked in 5% skim 
milk/Phosphate buffer saline – 0.1% Tween 20 (PBST) for 1 hour at room temperature (RT) 
before incubating the membrane in primary antibody (Table 5.1) for 2 hours at room 
temperature or overnight at 4⁰C. Membranes were washed 5 times 5 min in PBST, blocked for 
15 minutes and incubated with the secondary antibody congugated to Horse radish protein 
(HRP) (Table 5.2) for 1 hour at room temperatre. The membrane was washed 5 x 5 mins in 
PBST and developed using ECL chemiluminescent (GE Healthcare, RPN2106) reagents and 
hyperfilm (VWR, 28906837). 
Coomassie was used in some western blot analyses to determine myosin and actin protein 
levels. The membrane was incubated in Coomassie (45% methanol, 45% MilliQ water, 10% 
acetic acid, 0.25 g Brilliant Blue) for 1 hour at RT and destained (60% MilliQ water, 30% 
methanol, 10% acetic acid) until bands were clear. In some cases western blot membranes were 
striped of antibodies before being reprobed with a second primary antibody. Membranes were 
incubated with striping buffer (62.5 mM Tris, 2% SDS, 0.1 M beta-mercaptoethanol [Amresco, 
217 
 
0482-100 mL] for 20 minutes at 55⁰C. The membrane was rinsed of β-mercaptoethanol by 
washing with PBST following by blocking for 30 min.  
 
Single fibre isolation for western blot was carried out on human skeletal muscle kindly donated 
by Dr Neil Street, Children’s Hospital at Westmead. Mechanical dissection was carried out in 
paraffin oil. Single muscle fibres were washed in relax solution (Table 5.4): glycerol v:v with 
1:50 phosphatase inhibitors (PPI, Sigma-Aldrich) and 1:500 PI. Fibres were solubilised in 2 x 
solubilising buffer (Table 5.4) in 1:50 PPI and 1:500 PI and put straight on dry ice. Protein 
concentrations were determined by a BCA assay and 250 ng of protein was run on western blot 
to allow for fibre typing and experimental probes of a single fibre. 
Non-reducing blots were solubilised without DTT, not heated and with N-ethylmaleimide 
(NEM, 5 mM final, Sigma-Aldrich, E3876) in the solubilising and loading buffer to quench 
free thiols. 
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Table 5.4: Solutions used for solubilisation and single fibre dissection 
Solution Reagents 
2x SDS solubilising buffer 125 mM Tris, 4% SDS 
 
2x SDS loading buffer 125 mM Tris, 4% SDS, 20% glycerol, Bromophenol 
blue (BMP); 1:20 DL-Dithiothreitol (DTT, 50 mM 
stock) 
4 x SDS loading buffer 125 mM Tris, 4% SDS, 40% glycerol, BMP, 1:10 
DTT (50 mM stock) 
 
MOPS 50 mM 3-(N-Morpholino)propanesulfonic acid 4- 
morpholinepropanesulfonic acid (MOPS); 50 mM 
Tris; 0.1% SDS; 1 mM EDTA 
Transfer buffer 25 mM Tris; 192 mM glycerol; 0.075% SDS; 15% 
methanol added fresh before use 
Relax solution 40.76 mM Kpropionate, 100 mM BES, 6.97 mM 
EGTA, 6.48 mM MgCl2,6 mM Na2ATP, 1 mM 
DTT,  
14.5 mM creatine phosphate, pH 
7.1 and pCa 9 at 15 °C 
Reagents were obtained from Sigma-Aldrich 
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5.3 Expression constructs, cloning and sequencing 
Details of the source and sub-cloning of expression constructs are in Table 5.5 and sequencing 
primers in Table 5.6. All restriction enzymes were purchased from New England Biolabs. 
Blunting was carried out with Klenow (New England Biolabs, M0210S) and DNA was purified 
with the Jetquick gel extraction kit (Astral, G420050) prior to ligation with T4 DNA ligase 
(Sigma-Aldrich, 10481220001). Transformations were carried out with TOP10 chemically 
competent cells (Thermo Fisher Scientific, C404003) and the HI SPEED Maxi Kit (Qiagen, 
12663) or the Virogene MiniPlus plasmid DNA extraction system (Diagnostic technology, 
GF2002) were used to prepare DNA for sequencing, cloning and transfections. Sequencing 
was carried out at the Australian Genome Research Facility Ltd (Sydney, Australia) and 
analysed using Sequencher 4.8 (Gene Codes Corporation, Michigan, USA). 
To generate the insert for pcDNA3.1 FLAGKozakHumanLMOD3 and TOPO-VA we carried out 
primer annealing with the primers listed in Tables 5.5 and 5.6. 10 µl of 10 µM forward and 
reverse primers were mixed and heated at 94⁰C for 30 seconds, followed by decreasing the 
PCR by 1⁰C per second to 4⁰C.  
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Table 5.5: Expression constructs and cloning  
Construct Vector or source 
Restriction 
enzymes used 
to cut the 
vector Insert 
Restriction 
enzymes used 
to cut the insert 
Sequencing 
primers 
(Sigma 
Aldrich) Accession number 
pcDNA3.1-MouseLmod3MycHis 
Gift from Prof Eric Olsen,  
Department of Molecular Biology, 
University of Texas Southwestern 
Medical Center, Dallas, United States 
(Garg et al 2014)       
T7-F;BGH-R;  
2bF-Lmod3; 
 2aR-Lmod3 NM_001081157.1 
pEGFP-NI-HumanKLHL40 
Gift from Prof Nigel Laing,  
Centre for Medical Research, The 
University of 
Western Australia & the Harry Perkins 
Institute of Medical Research, Perth, 
WA, Australia       
CMV-F; EBV-
R; KLHL40-F; 
KLHL40-R NM_152393 
pcDNA3.1-MouseKlhl40MycHis 
Gift from Prof Eric Olsen,  
Department of Molecular Biology, 
University of Texas Southwestern 
Medical Center, Dallas, United States 
(Garg et al 2014)       T7-F; BGH-R; NM_028202.3 
pcDNA3.1-HumanLMOD1 GenScript USA Inc       N/A NM_012134 
pMT3-FLAGHumanLMOD3 
Generated prior to this study (Yuen et 
al 2014)       N/A BC121019 
pEGFP-NI-Empty 
Generated prior to this study 
(PhD student Natalie Woolger)       N/A N/A 
TOPO-Empty Thermo Fisher (45-0641)       N/A N/A 
pcDNA3.1-HumanLMOD3 pcDNA3.1-MouseLMOD3MycHis 
BamHI, blunt, 
XhoI  pMT3-FLAGHumanLMOD3 NcoI, blunt, SalI 
CMV-F; 
 BGH-R BC121019 
pcDNA3.1-HumanLMOD2 pcDNA3.1-MouseLMOD3MycHis 
BamHI, blunt, 
XhoI  
pMT3-FLAGhumanLMOD2 
(Yuen et al) SmaI/SaI 
CMV-F; 
 BGH-R 
AK300698.1, 
BAG62379.1 
pcDNA3.1-Empty pcDNA3.1-HumanLMOD3 
BamHI/XhoI. 
Blunt. Re-ligate.      BGH-R N/A 
pCMV10(-KanR)-Empty 
pCMV10-3xFLAGMouseKlhl40HA (Gift 
from Prof Eric Olsen, 
 Department of Molecular Biology, 
University of Texas Southwestern 
Medical Center, Dallas, United States 
(Garg et al 2014)) 
HindIII/XbaI. 
Blunt. Re-ligate.      CMV-F N/A 
pMT3HumanLMOD3 delta 1-38 pMT3-FLAGHumanLMOD3 PstI N/A Cut. Re-ligate. pMT2-F 
Modified from 
BC121019 
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pcDNA3.1 
FLAGKozakHumanLMOD3 pcDNA3.1-HumanLMOD3 HindIII/KpnI 
Annealed 
KozakFLAG_F/KozakFLAG_R   
CMV-F; 
 BGH-R BC121019 
TOPO-VA TOPO-Empty XhoI/EcoRI 
Annealed VA-F_Oligo and VA-
R_Oligo   VA-F; VA-R N/A 
pEGFP-C1 -GFP WT human 
PYROXD1 GenScript USA Inc. N/A N/A N/A 
pEGFP-CI;  
EBV-R NM_024854 
pEGFP C1 -GFP N155S human 
PYROXD1 
pEGFP-C1 -GFP WT human 
PYROXD1 EcoR1/EcoR1 
pUC57 mutant PYROXD1 
(GenScript USA Inc) EcoR1/EcoR1 
PYROXD1-F; 
PYROXD1-R; 
pEGFP-c 
term;pEGFP_CI 
Modified from 
NM_024854 
pEGFP C1-GFP Q372H human 
PYROXD1 
pEGFP-C1 -GFP WT human 
PYROXD1 EcoRV/Spe1 
pUC57 mutant PYROXD1 
(GenScript USA Inc) EcoRV/Spe1 
EBV_R; 
PYROXD1-F; 
PYROXD1-R; 
pEGFP-c 
term;pEGFP-C1 
Modified from 
NM_024854 
pEGFP-C1 WT human 
PYROXD1 
pEGFP-C1 -GFP WT human 
PYROXD1 AgeI/BspE1 N/A 
Cut. Blunted. 
Re-ligated. 
PYROXD1-F; 
PYROXD1-R; 
CMV-F; 
pEGFP-c term NM_024854 
pEGFP-C1 N155S human 
PYROXD1 
pEGFP C1 -GFP N155S human 
PYROXD1 AgeI/BspE1 N/A 
Cut. Blunted. 
Re-ligated. 
PYROXD1-F; 
PYROXD1-R; 
CMV-F;  
pEGFP-c term 
Modified from 
NM_024854 
pEGFP-C1 Q372H human 
PYROXD1 
pEGFP C1-GFP Q372H human 
PYROXD1 AgeI/BspE1 N/A 
Cut. Blunted. 
Re-ligated. 
PYROXD1-F; 
PYROXD1-R; 
CMV_F;  
pEGFP-c term 
Modified from 
NM_024854 
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Table 5.6: Sequencing and annealing primers 
Primer name Primer sequence (5'-3') 
2bF_Lmod3 CAATCAGAGGCACATGTTGG 
2aR_Lmod3 GCTGCTGTTTTTGCTCTTCC 
BGH-R TAGAAGGCACAGTCGAGG 
CMV-F CGCAAATGGGCGGTAGGCGTG 
EBV-R GTGGTTTGTCCAAACTCATC 
KLHL40-F TTCCTGGGATCCTCAATGAC 
KLHL40-R TCCTTGGTAACCAGGCTGAC 
KozakFLAG-F 
AGCTTGCCACCATGGATTACAAGGATGACGACGATAAGG
GTAC 
KozakFLAG-R CCTTATCGTCGTCATCCTTGTAATCCATGGTGGCA 
pEGFP-CI CATGGTCCTGCTGGAGTTCGTG 
pEGFP-c term CCATTATAAGCTGCAATAAACAAGTTAAC 
pMT2_F ACAATGACATCCACTTTGC 
PYROXD1-F GCAGGAGCAGCTGAATTCTT 
PYROXD1-R TTCCACATAGACAGGCCACA 
T7-Fwd TAATACGACTCACTATAGGG 
VA-F GAGCCTGTAAGCGGGCACTCTT 
VA-R GAAGCCAAAAGGAGCGCTCCCC 
VA-F_Oligo 
TCGAGCCTGTAAGCGGGCACTCTTCCGTGGTCTGGTGGAT
AAATTCGCAAGGGTATCATGGCGGACGACCGGGGTTCGA
ACCCCGGATCCGGCCGTCCGCCGTGATCCATGCGGTTACC
GCCCGCGTGTCGAACCCAGGTGTGCGACGTCAGACAACG
GGGGAGCGCTCCTTTTGGCTTCCG 
VA-R_Oligo 
AATTCGGAAGCCAAAAGGAGCGCTCCCCCGTTGTCTGACG
TCGCACACCTGGGTTCGACACGCGGGCGGTAACCGCATGG
ATCACGGCGGACGGCCGGATCCGGGGTTCGAACCCCGGTC
GTCCGCCATGATACCCTTGCGAATTTATCCACCAGACCAC
GGAAGAGTGCCCGCTTACAGGC 
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5.4 Cell culture and transfections 
Transfections 
Cell lines and culture media conditions are stated in Table 5.7. Lipofectimine LTX (Thermo 
Fischer Scientific, 94756) was used to transfect COS-7 cells as per manufacturer’s instructions. 
Briefly, 6-well plates were seeded at a cell concentration of 2.5 x 105 and transfected after 16 
hours. A total concentration of 3 µg of plasmid DNA was used, evenly divided in co-
transfections. Plasmid DNA was incubated with optimem and PLUS reagent (Thermo Fischer 
Scientific, 10964-021) for 5 min at RT, and Lipofectamine LTX and optimem were incubated 
for 5 min at RT. Mixtures were combined and incubated at RT for 20 min. The mixture was 
added to cells dropwise. Antibiotic media was used during the transfection and changed to 
antibiotic-containing media four hours post-transfection. HEK293T cells were transfected with 
polyethylenimine (PEI, Poysciences). Cells were seeded on Poly-D-lysine coated plates 
(Incubated for 5 min at RT, washed once with dPBS) at 30% to be transfected at 80% 
confluency.  PEI and NaCl (8.3 µl PEI, 100 µl 0.9% NaCl) were mixed, DNA (3µg) added, 
mixed and incubated for 20 min at RT. The mixture was added to cells dropwise. Co-
transfection studies carried out in Chapter 3 were harvested for western blot 48 hours post-
transfection. Single transfections carried out in Chapter 4 were harvested 24 hours post-
transfection. Transfected cells to be used for immunocytochemistry were re-seeded onto 
coverslips 8 hours post-transfection and stained 24 hours post-transfection.   
 
MG132 treatment 
MG132 (final concentration 10 µM, Sigma-Aldrich C2211) treatment of Cos-7 cells was 
carried out 24 hours post-transfection and harvested after incubation for a further 24 hours. 
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Mouse tail fibroblast outgrowth 
Tail fibroblasts were outgrown from a tail clip of a Pyroxd1Tm1a/WT mouse.  The tail clip was 
wiped with an iodine wipe and immersed in 70% ethanol for 10 seconds before washing 5 times 
in PBS/gentamicin 1:200. A T25 flask was coated with collagen (1:50, 10 min) and scratch 
marks were made on which cut up tissue were placed to assist cell adherence. Enough media 
was added to cover the base of the flask. The flask was incubated undisturbed for two days to 
allow outgrowth. 
Table 5.7: Cell lines and media 
Cell Culture media 
Cos-7 DMEM/ F12 (Gibco 1133-032); 10% Heat 
inactivated Foetal calf serum (HI FCS); 50 
µg/mL Gentamycin (Gibco 15710-072) 
HEK293T DMEM (Gibco 11995-065); 10% HI FCS; 
50 µg/mL Gentamycin;  
Primary human fibroblasts DMEM /F12; 20% HI FCS; 10% aminomax 
(Gibco 11269-016); 20% HI FCS; 50 µg/mL 
Gentamycin  
Primary human myoblasts  Differentiation media: DMEM /F12; 3% 
heat inactivated horse serum; 20%, 1 x 
Insulin-Selenium-Transferrin (51300-044); 
50 µg/mL Gentamycin 
 
Growth media: DMEM /HAMS F12 
(11330-032; 10% aminomax; 20% HI FCS; 
50 µg/mL Gentamycin 
Primary mouse fibroblasts outgrowth media Outgrowth media: DMEM /F12; 10% 
aminomax; 20% HI FCS; 50 µg/mL 
Gentamycin 
 
Growth media: DMEM /F12; 10% HI FCS; 
50 µg/mL Gentamycin 
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5.5 PCR and cDNA synthesis of PHF 
RNA extraction 
Primary human fibroblasts were cultured to 100% confluency in a T75 tissue culture flask (In 
vitro technologies, FAL353136) and lysed with TRIzol reagent (Ambion, 15596018). A 
TissueLyser II (Qiagen) was used at 25hertz for 1 minute bursts, interluded with incubation on 
ice, until cells were homogenised. The homogenised mix was spun at 12,000 g for 10 minutes 
at 4⁰C, the supernatant transferred to a fresh tube and incubated at RT for 5 minutes. 
Chloroform (0.2 ml/1 mL of TRIzol used) was added, mixed, and incubated at RT for 3 
minutes. The mixture was spun at 12,000 g for 15 minutes at 4⁰C and the upper aqueous layer 
transferred to a new tube. Isopropanol (0.5 mL/ 1 mL of TRIzol used) was added to precipitate 
the RNA and incubated at RT for 10 minutes. The mixture was spun at 12,000 x g for 10 
minutes at 4⁰C and the supernatant discarded. The pellet was washed once with 75% ethanol, 
vortexed, spun at 7,500g for 5 minutes at 4⁰C and re-suspended in Diethyl pyrocarbonate 
(DEPC)-treated water (Thermo Fisher Scientific, AM9915G). 
cDNA synthesis 
Immediately after RNA re-suspension cDNA synthesis was performed. 1 µg of RNA was 
mixed with 2 µl of primers (Oligo(dt)20, Invitrogen 55063; or random primers p(dn)6, Roche 
11043921) and made up to 12 µl with DEPC-treated water. The mixture was heated for 5 
minutes at 65⁰C then chilled on ice for 2 minutes. Synthesis reagents (1 x: 4 µl 5X First strand, 
2 µl [DTT,0.1M, Sigma-Aldrich, D9779], 1 µl dNTP [10 mM, Thermo, R1121] and 1 µl 
Superscript III [Thermo fischer scientific, 18080-044]) were added to the mixture and 
incubated for: 5 minutes at 25⁰C, 1.5 hours at 50⁰C, and 15 minutes at 70⁰C). cDNA was diluted 
to 10 ng/µl with DEPC-treated water. 
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Polymerase chain reaction 
To investigate extension of intron 3 and intron 4 we used PYROXD1Splice_F (5’ 
AGGGAAGTTCGTGGTGGTC3’)/PYROXD1-3R (5’TGAAAAGAGGCAGGCAAAAC3’) 
and PYROXD1Splice_F/PYROXD_4R (5’CCCTTCTGCCCTTACAGTTTAG3’) 
respectively. PCR conditions were: 95⁰C for 2 minutes; 35 cycles of 95⁰C for 30 seconds, 62⁰C 
for 30 seconds, 72⁰C for 30 seconds; 72⁰C for 5 minutes. PCR products were run on a 1% Tris-
acetate- Ethylenediaminetetraacetic acid (TAE, Astral Scientific, AM0796) agarose (Astral, 
BIOD0012) gel. 
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5.6 Mouse work 
Source of mouse lines and breeding 
Mouse husbandry was carried out by the Kids Research Institute transgenic facility staff. We 
imported the Pyroxd1 Tm1a line from the KOMP repository (https://www.komp.org/). We 
received heterozygous mice and generated a Pyroxd1 Tm1a colony by crossing with Black/6J 
mice present within the transgenic’s facility. The FLP mouse line (FLPe, 
B6.Cg_Tg(ACTFLPe)9205DYM/J) was kindly donated to The Kids Research Institute by The 
Victor Chang Cardiac Research Institute and originated from The Jackson Laboratory 
(https://www.jax.org/line/005703). Pyroxd1Tm1a/wt mice were crossed with FLPFLP/FLP mice to 
generate first generation heterozygous PFLPPFLP/WT, FLP/WT mice.  PFLPPFLP/WT, FLP/WT mice were 
intercrossed to generate homozygous second generation PFLPPFLP/PFLP,WT/WT mice.  MDC mice 
were kindly shared by Dr Aaron Schindler at the Kids Research Institute and originated from 
the Jackson Laboratory. PFLPPFLP/PFLP, WT/WT were crossed with MDC+/- mice to generate first 
generation PFLPMDCPFLP*/WT, MDC/WT mice, where PFLP* denotes detectable MDC-mediated 
recombination in the earclip. PFLPPFLP/PFLP,WT/WT were crossed with PFLPMDCPFLP*/WT, MDC/WT 
to generate second generation  homozygous mice PFLPMDCPFLPMDC/PFLP, MDC/WT.  The Pyroxd1 
Tm1a colony was maintained by crossing Pyroxd1Tm1a/wt mice with Black/6J mice. The PFLP 
colony was maintained by intercrossing PFLPPFLP/PFLP, WT/WT.  
Mouse genotyping 
Genomic DNA preparation 
Genotyping was carried out on earclips of weaned mice and tail clips of neonates and 
gestational mice. Tissue was digested in 200 µl STE (100 mM Tris [Astral, BIO3094T], pH 
8.5; 5 mM Ethylenediaminetetraacetic acid [EDTA, Sigma-Aldrich E5134]; 0.2% Sodium 
dodecyl sulphate [SDS, Astral, DG093] 200 mM sodium chloride [NaCl, VWR, 
27810.364])/Proteinase K [Final 0.4 µg/µl; Stock 20 µg/µl, Sigma-Aldrich P2308]) at 55⁰C for 
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three hours. To deactivate proteinase K the temperature was raised to 70⁰C for five minutes. 
Samples were quenched on ice, spun for 1 minute and the supernatant was transferred to a fresh 
tube to which 0.1 volumes of 3M Sodium acetate [NaOAc, Sigma-Aldrich S2889] and 2 
volumes of 100% ethanol were added. Samples were inverted to mix and spun at 17,000 RCF 
for 20 minutes at 4⁰C. The supernatant was removed, the pellet washed in 5 volumes of 70% 
ethanol and spun as before. The supernatant was removed and the pellet allowed to air dry 
before re-suspending DNA in 100 µl of MilliQ water. 
PCR reactions 
The primers used to screen for each allele are stated in Table 5.8, primer sequences in Table 
5.9 and PCR conditions in Table 5.10. The 1 x master mix for all mouse genotyping consisted 
of: 2 µl gDNA (20 ng/µl), MilliQ 7.8 µl, 1.25 µl foward primer (10 µM), 1.25 µl reverse primer 
(10 µM), 0.2 µl Taq DNA Polymerase (1 Unit, Life technologies 10342-020), 7.5 µl Buffer D 
(Astral Scientific, M07205D). Primers were purchased from Sigma-Aldrich. 
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Table 5.8: Primers used to screen mouse alleles 
Allele Forward primer Reverse primer Size (bp) 
Cre Cre_F Cre_R 355 
Cre Cre_F2 Cre_R2 992 
FLP FLP_F FLP_R 725 
PFLP PFLPMDC_F PFLPMDC_R 904 
PFLPMDC PFLPMDC_F PFLPMDC_R 144 
PFLP PFLPMDC_F2 PFLPMDC_R2 980 
PFLPMDC PFLPMDC_F2 PFLPMDC_R2 220 
Endogenous Pyroxd1 Pyroxd1_F Pyroxd1_R 519 
Endogenous Pyroxd1 Pyroxd1_F Pyroxd1_E5R 848 
PFLP Pyroxd1_F Pyroxd1_E5R 981 
PFLP Pyroxd1_F2 Pyroxd1_R2 291 
Endogenous Pyroxd1 Pyroxd1_F2 Pyroxd1_R2 158 
Pyroxd1 Tm1a Pyroxd1_Tm1a_F Pyroxd1_R 600 
 
Table 5.9: Genotyping primer sequences 
Primer Primer sequence (5'-3') 
Cre_F CATCGTCGGTCCGGGCTGCC 
Cre_F2 CTGACCGTACACCAAAATTTG 
Cre_R CCCCCAGGCTAAGTGCCTTC 
Cre_R2 CACCAGCTTGCATGATCTCC 
FLP_F CACTGATATTGTAAGTAGTTTGC 
FLP_R CTAGTGCGAAGTAGTGATCAGG 
PFLPMDC_F CCGAACTTCCTATTCCGAAG 
PFLPMDC_F2 CGTTCCCAAAGGCGCATAA 
PFLPMDC_R CACCCTAACCAGCACAACAA 
PFLPMDC_R2 AACACACACCCTAACCAGCA 
Pyroxd1_E5R CAGAGCAATGCCACCATTC 
Pyroxd1_F TGAACTTGATGGCAGGGGTTAGAGG 
Pyroxd1_F2 ATGTACATGGTGTCGTCGTC 
Pyroxd1_R ACCCAGTTATGACTGAACCTGTCCC 
Pyroxd1_R2 CAGGGCACATGGAATAGGAG 
Pyroxd1_Tm1a_F GGGATCTCATGCTGGAGTTCTTCG 
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Table 5.10: Mouse genotyping PCR conditions 
Primer combination PCR conditions 
Cre_F/Cre_R 94⁰C 5 min; 38 cycles of 94⁰C for 30 sec, 61⁰C for 30 sec, 72⁰C for 30 sec; 72⁰C 10 min 
Cre_F2/Cre_R2 94⁰C 5 min; 38 cycles of 94⁰C for 30 sec, 58⁰C for 30 sec, 72⁰C for 30 sec; 72⁰C 10 min 
FLP_F/FLP_R 94⁰C 3 min; 35 cycles of 94⁰C for 30 sec, 58⁰C for 60 sec, 72⁰C for 60 sec; 72⁰C 2 min 
PFLPMDC_F/PFLPMDC_R 94⁰C 2 min; 35 cycles of 95⁰C for 10 sec, 54⁰C for 30 sec, 72⁰C for 90 sec; 72⁰C 8 min 
PFLPMDC_F2/PFLPMDC_R2 95⁰C 2 min; 35 cycles of 95⁰C for 10 sec, 60⁰C for 30 sec, 72⁰C for 65 sec; 72⁰C 8 min 
Pyroxd1_F/Pyroxd1_R 
94⁰C 5 min; 10 cycles decreasing 1⁰C/cycle of 94⁰C for 15 sec, 65⁰C for 30 sec, 72⁰C for 60 sec; 30 
cycles of 94⁰C for 15 sec, 55⁰C for 30 sec, 72⁰C 60 sec; 72⁰C 5 min 
Pyroxd1_F/Pyroxd1_E5R 
94⁰C 5 min; 10 cycles decreasing 1⁰C/cycle of 94⁰C for 15 sec, 65⁰C for 30 sec, 72⁰C for 60 sec; 30 
cycles of 94⁰C for 15 sec, 55⁰C for 30 sec, 72⁰C 60 sec; 72⁰C 5 min 
Pyroxd1_F2/Pyroxd1_R2 95⁰C 2 min; 35 cycles of 95⁰C for 10 sec, 61⁰C for 30 sec, 72⁰C for 60 sec; 72⁰C 8 min 
Pyroxd1_Tm1a_F/Pyroxd1_R 
94⁰C 5 min; 10 cycles decreasing 1⁰C/cycle of 94⁰C for 15 sec, 65⁰C for 30 sec, 72⁰C for 60 sec; 30 
cycles of 94⁰C for 15 sec, 55⁰C for 30 sec, 72⁰C 60 sec; 72⁰C 5 min 
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Super-ovulation, embryo and tissue harvests 
The Kids Research Institute’s transgenics facility staff superovulated 4-week old females with 
5IU pregnant mare serum gonadotropin (PSMG) 2 days prior to mating and 5IU human 
chorionic gonadotropin (HCG) the day of mating. At expected E0.5, females were culled by 
cervical dislocation and Dr Frances Lemckert harvested the ovaries, dissected embryos from 
the oviduct and digested the matrix surrounding the embryos with hyaluronidase. Embryos 
were prepared for ex vivo culture in 3cm petri dishes in a 10µl droplet of EmbryoMax KSOM 
media (Millipore, MR-020P-5D) flooded with filter sterilised mineral oil. Embryos were left 
undisturbed in a 37⁰C, 5% CO2 humidified incubator until E4. At E4 embryos were collected 
into individual PCR tubes. DNA was extracted by adding 5µl Potassium hydroxide (10 mM), 
heating for 10 minutes at 95⁰C, chilling on ice and adding 5 µl 10mM TRIS-HCL to neutralise 
the sample. PCR screening carried out as described above with Pyroxd1_F/Pyroxd1_E5R and 
Pyroxd1_Tm1a_F/Pyroxd1_R primers.   
Mice used for tissue harvesting were culled by cervical dislocation. Tissues were harvested and 
immediately frozen in thawing 2-methylbutane (Sigma-Aldrich, 270343-1L). After allowing 
2-methyl butane to evaporate on dry ice, samples were stored at -80⁰C. 
Beta-galactosidase assay 
E9.5 embryos were harvested from a Pyroxd1Tm1a/WT intercross. Embryos were washed twice 
in PBS, fixed in 4% PFA for 10 minutes, washed three times in PBS and immersed in X-gal 
stain (10 mL PBS, 100 µl potassium ferricyanide [0.5 M, Sigma-Aldrich 702587], 100 µl 
ferrocyanide [0.5 M, Sigma-Aldrich P9387], 20 µl MgCl2 [Sigma-Aldrich, M-8266], 10 µl 
Tween-20 [Biochemicals, BIO0777], 250 µl X-gal [40 mg/mL Thermo-Scientific R0401, in 
Dimethylformamide, Sigma-Aldrich, 227056 ]) overnight at 37⁰C. Embryos were washed 
twice in PBS and stored in 4% PFA until wax embedding. Wax embedding, de-waxing and 
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counterstaining of E9.5 embryos was carried out under the guidance of Vanessa Jones at the 
Children’s Medical Research Institute (CMRI). Embryos were incubated in PBS for 1 hour, 
MilliQ water for 2 hours, washed in 70% ethanol followed by a 10 min incubation in fresh 70% 
ethanol. Sequential 10 minutes washes in 80% ethanol, 90% ethanol followed by three 
sequential 10 minutes washed in 100% ethanol were performed. Embryos were immersed in 
xylene for 5 min and a further 10 min incubation in fresh xylene. Embryos were imbedded in 
wax at 65⁰C for 30 minutes three times and left overnight at room temperature to set. Sections 
were cut at 8 µm with a microtome. Sections were then de-waxed and co-stained as follows: 
Sections were immersed twice in xylene for 1 minute each followed by sequential one minute 
washes in 100% ethanol (twice), 90% ethanol, 70% ethanol, 50% ethanol and 25% ethanol. 
Slides were rinsed for one minute in MilliQ water prior to a 20 sec emersion in Nuclear fast 
red (Sigma-Aldrich, N3020) followed by a one minute rinse in MilliQ and a dip in 70% ethanol, 
90% ethanol and one minute incubations in 90% ethanol and two in 100% ethanol. Slides were 
emersed twice in histolene, the first for 3 minutes, the second for 2 min, and immediately 
mounted with Immunomount. Sections were imaged on an Aperio Leica scanner ready 
Scanscope and analysed with Aperio ImageScope v12.1.0.5029. 
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Chapter 7 - Appendix 
 
 
 
 
Figure A.1: Detection of IgG within tissue samples by anti-rabbit secondary antibody 
does not explain the banding pattern we see in mouse tissues with leiomodin antibodies. 
Western blot of tissues harvested from a wild type C57BL/6J mouse (lanes 1-14), human 
skeletal muscle (lane 15) and human heart (lane 16). Membranes were probed with the anti-
rabbit secondary only. The upper blot shows no IgG detection. The lower blot is an 
overexposure showing a 65 kDa band only within the kidney sample. 
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Figure A.2: The leiomodin-2 antibody cross-reacts with tropomodulin-4. Western blot of 
four human heart samples (10 µg), four human skeletal muscle samples (10 µg) and 
recombinant human tropomodulin-4 (1µg) probed for leiomodin-2 (LMOD2). The upper blot 
is an overexposure showing the canonical leiomodin-2 isoform (red arrow). A weak band at 45 
kDa in cardiac and skeletal muscle samples aligns with recombinant tropomodulin-4 (green 
arrow). The position of the recombinant tropomodulin-4 is shown with a 1 second exposure 
(lower blot, green arrow). Human cardiac samples – ventricle; Human skeletal muscle – 5 
years, 15-year quadriceps male, 31-year male, 57-year female. 
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Figure A.3: Membranes probed with an antibody against β-galactosidase detects a band 
in negative-control mouse tissue. Western blot of tissues from Pyroxd1Tm1a/WT and Black/6 
mice probed with an antiboday against β-galatosidase (A-11132, Molecular probes, 116 kDa). 
A weak band at 116 kDa is detected in Pyroxd1Tm1a/WT and Black/6 mouse tissues.  
 
